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Abstract 
Loss of skeletal muscle mass and function with ageing is a major public health 
concern with substantial financial implications. This thesis aims to examine the risk 
factors for age-related muscle changes over 10 years and the impact that these 
changes have on falls risk, fracture, mortality, and health-related quality of life 
(HRQoL) in community-dwelling older adults.  
Data from a population-based sample of older adults aged 50–80 years (51% women; 
mean age 63±7.4 years) studied at baseline, 2.5, 5, and 10 years were analysed. 
Appendicular lean mass (ALM) and bone mineral density (BMD) were assessed by 
Dual-energy X-ray Absorptiometry (DXA). Handgrip strength (HGS) and lower-limb 
muscle strength (LMS) were measured using dynamometer, and muscle quality was 
calculated (muscle strength/muscle mass). Physical activity [steps/day] was assessed 
using a pedometer and the intensity of physical activity was measured using an 
accelerometer. Falls risk was measured using the Physiological Profile Assessment, 
fractures were self-reported and mortality was ascertained from the death registry. 
Serum 25-hydroxyvitamin D [25(OH)D] was assessed by radioimmunoassay, and 
HRQoL, knee pain and dysfunction were assessed using standardised questionnaires.  
Traditionally, analysis has focused on examining how loss of muscle mass, strength 
and muscle quality differ between individuals (between-person comparison). Less 
well recognised is how variability in risk factors over time within the same individual 
(within-person comparison) are associated with muscle loss. The first study of this 
thesis described the longitudinal associations of between-person and a dynamic 
within-person variability in serum 25(OH)D, physical activity and knee pain and 
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dysfunction with muscle mass, strength and muscle quality over 10 years. Both 
between-person and within-person increases in physical activity were associated with 
a higher muscle mass, strength and muscle quality. Within-person and between-
person increases in knee pain and dysfunction were associated with a lower muscle 
strength and quality but not muscle mass. Between-person effects showed that higher 
average 25(OH)D was associated with higher 10-year average muscle mass, strength 
and muscle quality; whereas, within person increases in 25(OH)D was associated with 
a higher muscle strength and quality but not muscle mass.  
The second study compared the performance of low muscle mass, muscle strength 
and muscle quality assessed at baseline with falls risk, incident fracture and mortality 
over 10 years. All baseline muscle strength and muscle quality measures were 
significantly associated with higher falls risk score at 10 years. Low handgrip and 
ALM/body mass index (BMI) were the only significant predictors of fracture and 
mortality respectively. 
The third study described the longitudinal association of between-person and within-
person variability in serum 25(OH)D, physical activity, knee pain and dysfunction 
with falls risk over 10 years. Knee pain and dysfunction above an individual’s usual 
level of pain increases the risk of falling, whereas, increasing one’s own moderate-to-
vigorous physical activity level further reduced their risk of falling. Between-person 
but not within-person associations were observed between 25(OH)D and falls risk. 
The fourth study examined the associations between low muscle mass, upper- and 
lower-limb muscle strength with HRQoL over 10 years. Participants with low LMS 
and low HGS (in women only) at baseline had a clinically meaningful difference in 
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10-year HRQoL compared to those with normal strength. There was a weaker but still 
significant association between low muscle mass and 10-year HRQoL. 
The final study described the relationship between low muscle mass or strength, in the 
presence of osteopenia, with fracture and mortality risk. Incident fracture risk was 
significantly higher in participants with both osteopenia and dynapenia 
(osteodynapenia) compared to those without dynapenia or osteopenia. Mortality risk 
was significantly higher in participants with both osteopenia and sarcopenia 
(osteosarcopenia) compared to those without sarcopenia or osteopenia. However, 
osteosarcopenia and osteodynapenia did not lead to a significantly greater fracture or 
mortality risk compared to having these conditions on their own. 
In conclusions, in addition to traditional between-person associations, variability in 
physical activity, 25(OH)D, knee pain and dysfunction within an individual over time 
relate to muscle changes and falls risk. Within-person effects were generally weaker 
compared to between-person estimates. Furthermore, muscle strength, which can be 
easily measured in clinical practice, appears more important than muscle mass for 
identifying individuals with a higher falls risk, fractures and poorer quality of life. 
However, muscle mass appears to be a better predictor of mortality risk. Low BMD 
combined with low muscle mass or strength does not significantly increase the risk of 
fracture or mortality compared to having low BMD or low muscle mass/strength 
alone, suggesting that combined assessments may not add additional risk for fracture 
and mortality. 
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1.1 Background 
The global population is ageing and this is due to an increase in life expectancy and a 
decline in fertility [1]. In Australia, the number of older people is projected to 
increase from 3.8 million in 2016 to 6.3 million in 2036 [2]. Ageing is characterised 
by a decline in physiological function and an increase in chronic musculoskeletal 
conditions such as osteoporosis, osteoarthritis and rheumatoid arthritis [3]. Therefore, 
promoting a healthy and high quality of life among the growing proportion of older 
people is a major public health priority. Loss of muscle mass with ageing is perhaps 
the most dramatic decline in structure and function [4]. These changes have a 
detrimental impact on multiple health outcomes in older people and could 
substantially increase healthcare costs [5, 6]. Although there are currently no direct 
cost estimates attributed to the health consequences of muscle loss in Australia, the 
financial implication is likely to be substantial [7]. The most recent estimates from the 
United States show that direct costs attributable to muscle loss with ageing 
(sarcopenia) was 18.5 billion in 2000, accounting for 1.5% of the total healthcare 
expenditure at that time [5]. Studies from European countries also show that 
irrespective of the underlying medical condition, low muscle mass or strength at 
hospital admission independently increases hospital costs by 34% or more [8, 9]. 
Despite the health and financial implications of sarcopenia, limited long-term 
prospective studies have examined the risk factors for, and the impact of muscle 
changes on health outcomes such as falls, fracture and mortality among community-
dwelling older adults. Longer-term studies are crucial as it would broaden our 
understanding of changes in skeletal muscle and may help predict and identify 
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individuals at risk of greater muscle loss over a long-term period. Furthermore, such 
studies may also help in the design of interventions aimed at minimising muscle loss. 
Therefore, this thesis aims to examine the risk factors for age-related muscle changes 
over 10 years and the impact that these changes have on falls risk, fracture, mortality, 
and health-related quality of life (HRQoL) in community-dwelling older adults.  
1.2 Age-Related Skeletal Muscle Loss: Assessments and Diagnostic 
Criteria  
Muscle loss with ageing received considerable research attention when, in 1989, 
Irwin Rosenberg first used the word ‘sarcopenia’ (Greek ‘sarx’ or flesh + ‘penia’ or 
loss) to describe the age-related decline in lean muscle mass [10]. Since then there has 
been substantial research into the association between sarcopenia and various health 
outcomes in older people. For instance, a search in Medline (1990 – 2016) yielded 19 
studies in 1995, 39 studies in 2000 and 903 in 2016.  
Muscle mass and strength increase in the early years of life until about 30 years after 
which there is a progressive decline, resulting in the loss of 20 – 40% of muscle mass 
and strength by the seventh and eighth decade of life in both men and women (Figure 
1.1) [11, 12]. The loss of muscle mass with ageing has been attributed to a reduction 
in the size and number of type 1 (slow-twitch) and type 2 (fast-twitch) muscle fibres 
[11, 13]. However, a more recent study showed that smaller fibre size, particularly 
type 2 muscle fibres largely explained the differences in the muscle mass of young 
(mean age ±SD: 23 ± 1 year) and older people (mean age ±SD: 71 ± 1years) [14]. 
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This finding suggests that reduced muscle mass with ageing may be mainly attributed 
to a reduction in size rather than a loss in the number of muscle fibres [14].  
The loss of muscle mass is associated with a concomitant fat infiltration 
(myosteatosis) [Figure 1.2]. Fat infiltration within and around skeletal muscle impairs 
the physiological function of the muscle and it is associated with reduced muscle 
function and poor physical performance [15-17]. An area of contention is whether 
age-related muscle loss is a pathological or biological process, in part because of the 
progressive decline in muscle mass and function even in relatively healthy older 
adults [11]. Terminologies such as ‘secondary sarcopenia’, ‘myopenia’ and ‘muscle-
wasting disease’ have been proposed to distinguish decline in muscle mass or strength 
associated with a known aetiology from ‘primary sarcopenia’ which is solely due to 
ageing [18-20]. Given the increase in co-morbidities with age, distinguishing between 
primary and secondary sarcopenia may be challenging [21]. Indeed, chronic 
conditions such as diabetes, obesity, and hyperthyroidism would accelerate the loss of 
muscle mass and strength [22, 23].  
In the last decade there has been extensive efforts to identify the threshold with which 
loss of muscle mass and function becomes clinically relevant [24, 25]. An important 
advancement in this regard is some level of convergence in the proposed diagnostic 
criteria for sarcopenia [26], leading to the recognition of sarcopenia with the code 
M62.84 in the International Classification of Diseases, tenth revision, clinical 
modification (ICD-10-CM) [27]. An implication of this is that sarcopenia can now be 
diagnosed as a disease state.  
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Table 1.1 outlines the numerous proposed diagnostic criteria for sarcopenia. The 
earliest diagnostic criteria proposed by Baumgartner and colleagues only included 
muscle mass [28]. The authors defined low muscle mass as appendicular lean mass 
(ALM) divided by height squared (HH) of two standard deviations below the mean 
values found in healthy young adults [28]. However, subsequent definitions 
incorporated a decline in muscle function (low muscle strength or physical 
performance). Depending on the operational definitions considered, the prevalence of 
sarcopenia among older adults in Australia ranges from 0% to 45.5% [29, 30]. 
Nonetheless, the proportion of older people with sarcopenia increases with age, 
irrespective of the operational definitions considered [29, 31]. 
Men typically have a higher muscle mass compared to women (Figure 1.3). Hence, 
the cut-points for sarcopenia are sex-specific in order to capture the differences 
between men and women [32, 33]. Besides, men experience a greater age-related 
decline in skeletal muscle mass compared to women, although the mechanism 
underlying the greater loss of muscle in men is not entirely clear [34]. Hormonal 
factors such as growth hormone, testosterone and insulin-like growth factors have 
been postulated as possible contributing factors to higher muscle loss in men [34].  
Cut-points have been developed to classify older adults as having clinically relevant 
low muscle mass and function using reference data from young populations. Due to 
the ethnic and geographic variations in anthropometric measures, reference data from 
young adults should be of the same ethnic background as the older adults [35]. In the 
absence of appropriate reference data for our older Australian adult cohort, the older 
adults studied in this thesis were classified as having low muscle mass and function 
Chapter 1 – Introduction 
31 
 
based on the lowest quintile of the sex-specific distribution of muscle mass or 
strength measures [36]. This is another validated method to define clinically relevant 
low muscle mass and function [36, 37]  
 
 
 
 
 
Figure 1.1 Loss of muscle mass and strength over the life course [12] 
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Figure 1.2 Images of CT scans of the mid-thigh of a young (A) and older adult (B). 
Quadriceps (blue) and whole thigh muscle area (blue and red) in the young (C) and 
older adult (D) are illustrated[14]. 
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1.2.1 Limitation of some of the proposed definitions of sarcopenia 
The first diagnostic criteria proposed by Baumgartner and colleagues has received 
wide acceptance as a valid measure of muscle mass. However, because height 
decreases with advancing age, ALM/HH may not be suitable for determining the 
changes in the prevalence of sarcopenia as it could result in an artifactual increase in 
the proportion of individuals with sarcopenia [38, 39]. For instance, an artifactual 
increase of 2.6kg/m2 in BMI, a similar measure to ALM/HH (substitute weight for 
ALM) has been documented for women aged 80 years [39]. A similar increase of 
1.4kg/m2 was observed in men of the same age [39]. Furthermore, ALM/HH 
classified fewer obese or overweight individuals as having sarcopenia [36]. For 
example, in the Health Aging and Body Composition (Health ABC) Study, no 
participant was identified as having sarcopenia using the ALM/HH criteria [36]. In 
contrast, the prevalence of sarcopenia ranges from 11.5% (in men) to 21.0% (in 
women) when sarcopenia was defined as the residual of the regression of ALM on 
height and body fat mass [36]. ALM/HH was also found to underestimate the 
prevalence of sarcopenia among obese women in the São Paulo Ageing and Health 
Study (SPAH) [40]. Obese or overweight individuals with both high lean mass and fat 
mass may not be classified as having sarcopenia by ALM/HH criteria even though 
these individuals have muscle mass that is inadequate for their size and their physical 
performance [36].  
More recently, the Foundation for National Institute of Health (FNIH) Sarcopenia 
Project recommends ALM normalised to BMI as a measure of low lean mass [41]. 
The FNIH Sarcopenia Project asserts that low muscle mass is of importance only 
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when it is associated with a clinically relevant functional state. Consequently, the cut-
points for ALM/BMI that identify individuals with clinically relevant weakness were 
derived based on the presence of mobility impairment (gait speed of ≤0.8m/s) [41]. 
Prior studies suggest that ALM/BMI but not ALM/HH was more closely associated 
with poor health outcomes including mobility limitation and metabolic syndrome [42, 
43]. However, because ALM/BMI is closely related to higher adiposity, it is possible 
that the association between ALM/BMI and poor health outcomes in older people 
may be related to obesity rather than low lean mass. Due to the increase in fat mass 
with age, individuals could still maintain or increase their total body weight. 
However, relative muscle mass (lean mass/weight) proposed by Janssen et al can be 
seen to decline with age [44]. 
Another limitation of the proposed definitions of sarcopenia is the measurement error 
introduced by DXA [45]. DXA is a commonly used tool to measure ALM, however, 
the inability of DXA to distinguish fat infiltration within the skeletal muscle can 
inflate muscle mass by one to eight percent [46]. This measurement error can result in 
the misclassification of an individual as sarcopenic [45]. The magnetic resonance 
imaging (MRI) is an advance imaging technique that can distinguish intramuscular fat 
infiltration. Nevertheless, MRI is expensive and often inaccessible [45]. Reassuringly, 
a strong correlation (>0.94) has been reported between MRI and DXA measures of 
muscle mass, suggesting that the error in the misclassification of an individual as 
sarcopenic is likely to be minimal [45-47]. 
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Table 1.1 Proposed diagnostic criteria for sarcopenia  
Reference  Low muscle mass Low muscle strength Poor physical performance 
Baumgartner criteria [28] ALM/height2 > 2 SD below young healthy 
mean 
– – 
European Society for Clinical Nutrition and 
Metabolism Special Interest Groups (ESPEN-
SIG) [48] 
Percentage of muscle mass ≥2 SD below 
mean in young adults of the same sex and 
ethnic background 
(individuals aged 18–39 years in the 
NHANES III cohort) 
– 
Gait speed: <0.8 m/s or reduced 
performance in any functional test 
used for comprehensive geriatric 
assessment 
European Working Group on Sarcopenia in 
Older People (EWGSOP) [20] 
ALM/height2 Handgrip strength  OR Gait speed: <0.8 m/s 
 Men: ≤7.23 kg/m2 Men: <30 kg;  
 Women: ≤5.67 kg/m2 Women: <20 kg  AND  
International Working Group on Sarcopenia 
(IWGS) [49] 
ALM/height2 
– 
Gait speed: <1.0 m/s 
 Men: ≤7.23 kg/m2   
 Women: ≤5.67 kg/m2   
Society of Sarcopenia, Cachexia and Wasting 
Disorders [50] 
ALM/height2 > of 2 SD below the mean of 
healthy persons aged 20–30 years of the 
same ethnic group 
– 
Gait speed: ≤1.0 m/s or walking 
distance < 400 m during a 6-min 
walk 
Foundation of NIH Sarcopenia Project [51] ALM/BMI Handgrip strength – 
 Men: <0.789 Men: <26 kg  
 Women: <0.512 Women: <16 kg  AND Gait speed: ≤0.8 m/s 
Delmonico et al [37] Sex-specific lowest 20% of the distribution 
of ALM/height2 
  
Newman et al [36] Sex-specific lowest 20% of the distribution 
of the residuals of linear regression of 
ALM on height and fat mass 
  
Janssen et al [44] ALM/W˟100 1– 2 SD below reference 
population is class I sarcopenia >2 SD 
below reference population is class II 
Sarcopenia 
  
ALM/ht2 = ratio of appendicular lean mass over height squared; ALM/BMI = ratio of appendicular lean mass to body mass index; SD standard deviation 
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A 
 
B 
 
Figure 1.3 Age-related decline in upper and lower body skeletal muscle mass 
for men (A) and women (B) [34] 
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1.2.2 Discordance between age-related decline in muscle mass and muscle 
strength 
Historically, declines in muscle strength with age has been largely attributed to the 
loss of muscle mass [11, 33]. However, recent studies suggest that, although both 
muscle mass and strength decrease with age, the two processes involve different 
pathophysiological processes and declines in muscle mass explain less than five 
percent of the variance in the loss of muscle strength [52]. After 6 weeks of resistance 
exercise training in one of the upper-limbs (trained arm), there was 7% increase in the 
strength of the untrained contralateral upper limb suggesting that changes in muscle 
strength are partly influenced by neural control [53, 54]. Besides, substantial loss of 
muscle strength may or may not be accompanied by significant loss of muscle mass, 
demonstrating that muscle strength (characterised by reduced muscle activation) is 
mostly affected in the early period of immobilisation [55, 56]. Muscle mass is a 
reflection of the total number of sarcomeres present in a muscle, whereas, the amount 
of force produced by each sarcomere together with the quality of this contractile 
protein and connective tissue determines the strength of the muscle [30, 32]. Hence, 
preserving muscle mass may not necessarily result in maintenance of muscle strength 
as the quality but not the quantity of sarcomeres determines muscle strength [30, 52, 
57]. 
Indeed both muscle mass and strength decline with age, however, muscle strength 
declines at a faster rate than muscle mass [33, 58]. For instance, in the Health ABC 
study, the rate of muscle strength loss was 3.6% in men and 2.8% in women 
compared to 1% decline in muscle mass (for both men and women) [57]. Although 
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age-associated loss of muscle strength was higher compared to muscle mass, 
discrepancies also exist in the decline in muscle mass and strength within different 
regions of the body [34, 59]. For instance, the size of the quadriceps femoris muscle 
declines more rapidly with age compared to the biceps, anterior tibial or forearm 
flexor muscles (Figure 1.4) [60]. Generally, for both men and women, the rate of 
muscle loss in the lower-limbs is twice the rate of decline seen in the upper-limbs 
[34]. Although the mechanism underlying this discrepancy is not entirely clear, the 
decrease in mobility-related physical activity with advancing age is likely to 
contribute to a greater decline in lower-limb muscle [34]. However, whether the 
discrepancy in the decline of upper- and lower-limb muscle have a differing impact 
on the health of older people is not entirely clear. The long-term impact of upper and 
lower-limb muscle strength on falls risk, fracture, mortality (Chapter 5) and health-
related quality of life (Chapter 7) are discussed in subsequent chapters.  
The term ‘dynapenia’ has been proposed to distinguish loss of muscle strength from 
mass and to facilitate research into the mechanism underpinning age-associated 
decline in muscle strength [61]. However, ‘dynapenia’ has not achieved widespread 
usage like sarcopenia; in part, because the use of two nomenclatures to describe such 
a closely related concept may create some confusion [20]. Sarcopenia is commonly 
used to describe decline in both muscle mass and strength [20]. Nevertheless, because 
of the discordance between muscle mass and strength, declines in muscle mass and 
strength could have a differing impact on health outcomes in older people. Many but 
not all of the previous studies have provided evidence for the superiority of muscle 
strength in predicting health outcomes such as poor mobility, physical disability, 
hospitalisation and mortality risk over 6 years [62-64].  
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In addition to the loss of muscle mass and strength, muscle quality, a measure of 
functional properties of the muscle also reduces with age [65, 66]. Underpinning the 
decline in muscle quality is the increase in fat infiltration and reduction in neural 
activation and muscle aerobic capacity [66]. There is currently no consensus 
definition for muscle quality, however, it is typically defined as muscle strength per 
unit of muscle mass [65].  
Limited long-term prospective studies have compared the association of muscle mass, 
strength and muscle quality with important health outcomes such as falls, fracture and 
mortality in community-dwelling older people. Understanding these associations is 
crucial in identifying the most valid clinically relevant indicators of age-related 
muscle loss and may also help in the design of intervention trials. The comparison of 
the association between low muscle mass, strength and muscle quality with falls risk, 
fracture and mortality over 10 years is discussed in Chapter 5 of the thesis. 
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Figure 1.4 Age-related muscle changes (muscle thickness) for the biceps 
brachii, forearm flexor, quadriceps, and anterior tibial muscles [60]. 
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1.3 Risk factors for age-related muscle loss: Interindividual 
(between-person) versus intraindividual (within-person) processes 
The mechanism underlying the loss of skeletal muscle mass and strength is not 
entirely clear but is likely to be multi-factorial. Several modifiable risks including 
poor nutrition (particularly protein intake) [67], low levels of physical activity [68], 
low vitamin D [69], higher knee pain [70] as well as non-modifiable risk factor such 
as genetic makeup have been proposed [12, 32]. Non-modifiable risk factors (such as 
genetic makeup and ethnic background) do not change over time. Hence, these 
variables are referred to as time-invariant predictor variables and they contribute 
primarily to interindividual (between-person) differences in muscle loss. However, 
modifiable risk factors such as protein intake and physical activity participation 
change over time. Hence, these variables are referred to as time-varying predictor 
variables and they contribute to both interindividual (between-person) and 
intraindividual (within-person) differences in muscle loss. For example, physical 
activity differs between different individuals (between-person differences) and it also 
varies from time to time within the same individual (within-person variability). 
Previous studies have only examined between-person differences in risk factors for 
muscle loss [68, 71, 72]. There are no published studies describing within-person 
variability in risk factors for muscle loss. This is important to investigate because the 
inferences we make from the between-person effects (for example the magnitude and 
direction of effects) may not align with those we would make from the within-person 
effects [73].  
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For instance, among 245 older people undergoing post-acute rehabilitation, Rodriquez 
et al observed a significant within-person association between pain and functional 
independence such that, at time-points when participants had more pain than their 
average level of pain, they had a significantly less functional independence at the 
same time (within-person effect) [74]. Interestingly, there was no significant 
association between persistent pain and functional independence (between-person 
effect). This finding demonstrates that between-person and within-person effect can 
lead to different conclusions, confirming the importance of examining within-person 
relationships. Studies describing the association of between-person differences in 
physical activity, vitamin D, knee pain and muscle loss are highlighted below.  
1.3.1 Physical activity and age-related muscle loss 
Physical inactivity is one of the most significant contributing factors to accelerated 
loss of skeletal muscle mass, strength and muscle quality [22]. Epidemiological 
studies from different ethnic groups (Korea, Japan, France, USA, China, Switzerland 
and Australia) consistently report an inverse association between physical activity and 
muscle loss, such that muscle loss is lower in older adults who engage in higher light 
or moderate-to-vigorous activity [68, 71, 75-80]. Inactivity, with or without 
hospitalisation, has been shown to compromise muscle metabolic homeostasis and 
contribute to substantial loss of muscle mass and function [81-83]. For example, 10 
days of continuous bed rest among healthy older adults (mean age: 67 years; 50% 
women) resulted in the loss of 0.95kg of DXA-derived lower extremity lean mass and 
a 19 Nm/s decrease in isokinetic knee extension muscle strength [84]. The apparent 
loss of muscle mass and strength in these healthy older people demonstrates the 
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detrimental impact that inactivity has on muscle mass and function in older people 
who are hospitalised. Interestingly, the benefits of exercise on the muscle is palpable 
even for a short duration. For instance, three minutes of intense exercise per week 
performed over six weeks was associated with physiological changes including an 
increase in skeletal muscle oxidative capacity [85]. Taken together, these findings 
underscore the significance of physical activity in maintaining muscle mass and 
function in older people, irrespective of the duration of the activity. 
Whilst physical activity–induced benefits on muscle mass and function has been well 
documented, the mechanisms by which physical activity prevents muscle loss are not 
entirely clear. Skeletal muscle responds to a prolonged period of physical inactivity 
by decreasing muscle protein content and muscle fibre size, particularly type II 
muscle fibres [82, 86]. The loss of muscle protein content is as a result of disruption 
in the rate of new muscle protein synthesis (MPS) and proteolysis or muscle protein 
breakdown (MPB) [87]. Although MPS and MPB jointly contribute to skeletal muscle 
atrophy, there are controversies regarding the magnitude of the contribution of each 
of the two processes, with some authors suggesting inactivity-induced muscle loss is 
caused largely by a decrease in MPS and that MPB plays a minimal role [88, 89]. 
Others suggested that elevated proteolysis or MPB is the dominant mechanism 
responsible for inactivity-induced muscle loss [82, 90]. Regardless of the mechanism, 
muscle loss occurs when MPB exceeds MPS and physical inactivity contributes to 
this process [82, 90].  
In addition to disruption in skeletal muscle homeostasis, pro-inflammatory markers 
which have been shown to trigger muscle loss are elevated in physically inactive 
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older adults [81, 91]. Specifically, toll-like receptor 4 (TLR4) and interleukin-6 (IL-6) 
were significantly increased in healthy older adults who were on bed rest for seven 
consecutive days [81]. The increase in these inflammatory markers was accompanied 
with a 4% loss of lower-limb lean mass. This finding demonstrates the deleterious 
systemic effect of physical inactivity – even for a short duration of seven days – on 
skeletal muscle function. Physical activity participation varies over time within the 
same individual [92]. However, whether variability in physical activity over time 
within the same individual relates to muscle changes has not been previously 
examined. The first longitudinal study describing the relationship of within-person 
variability in physical activity, in addition to traditional between-person associations, 
with muscle mass, strength and muscle quality is presented in Chapter 4 of the thesis. 
1.3.2 Nutrition (vitamin D) and age-related muscle changes 
Ageing is associated with a progressive decline in food intake (anorexia of ageing), 
predisposing older people to inadequate nutrient intakes and energy-protein 
malnutrition [93]. There is increasing evidence of a relationship between poor diet, 
particularly protein (1.0 to 1.2 g/kg BW/day) [94], antioxidant nutrients and vitamin 
D [95], and loss of muscle mass and function. Dietary protein is crucial for skeletal 
muscle as it provides amino acids for muscle protein synthesis. Among 2066 older 
people (mean age: 75 years, women: 53%) followed prospectively for over three 
years in the Health ABC study, individuals in the lowest quintile of energy-adjusted 
total protein intake lost about 40% of total and appendicular lean mass compared to 
those in the highest quintile [96]. Furthermore, older people who consumed more 
protein than the recommended dietary allowance of 0.8g/kg/day had the smallest loss 
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of lean mass, whereas, those who consumed at or below the recommended dietary 
allowance experienced the most significant loss of lean muscle mass [96]. This 
finding suggests that the currently recommended dietary allowance of protein may not 
be optimal for maintaining skeletal muscle in older people [97]. This may be because 
dietary protein requirements are estimated principally based on nitrogen balance and 
not maintenance of muscle mass [96, 98, 99]. Hence, the current recommended 
dietary allowance of protein is sufficient for achieving nitrogen balance but may not 
be adequate for maintaining muscle mass in older people [96]. Consequently, daily 
consumption of 1.25g/kg has been suggested for preserving muscle mass in older 
people [96, 100, 101]. 
Older people engage in fewer outdoor activities compared to other age groups, 
limiting their opportunity for sunlight exposure, a major source of vitamin D [102]. 
Indeed vitamin D levels are significantly higher in older people who engage in more 
outdoor activities like gardening and cycling compared to those who do not [103]. 
This association is independent of age, BMI or comorbidity [103]. Observational 
studies have reported a link between low levels of vitamin-D and loss of muscle mass 
and strength [104, 105]. However, findings from randomised controlled trials (RCT) 
and meta-analyses of these trials have been inconsistent, with some showing no 
effects of vitamin-D supplementation in improving muscle mass or strength and 
others showing a benefit for muscle strength but not muscle mass [69, 106]. For 
instance, a meta-analysis of 30 trials testing the efficacy of vitamin-D 
supplementation on muscle function in older people showed that supplemental 
vitamin-D improved muscle strength but not DXA-derived lean mass [69]. A more 
recent meta-analysis reported no beneficial effect of vitamin D supplementation with 
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or without calcium supplements on muscle strength in community-dwelling older 
adults [106]. Conflicting findings from meta-analyses could be attributed, in part, to 
methodological differences such as discrepancy in the selection and inclusion of 
RCTs in the meta-analyses resulting in different patient populations, study quality, 
and heterogeneity between studies. The expression of vitamin D receptor in human 
skeletal muscle, a mediator of 25(OH)D on muscle contractility, has been shown to 
decline with age and it has been linked to reduced muscle mass and function in older 
people [107, 108]. These findings highlight that vitamin D may play a role in age-
related loss of skeletal muscle mass and function. Nevertheless, there are no published 
studies examining whether variability in vitamin D over time within the same 
individual relates to muscle changes. The association of within-person and between-
person variability in vitamin D with muscle mass, strength and muscle quality in 
community-dwelling older people is described in Chapter 4 of the thesis. 
1.3.3 Chronic diseases and age-related muscle changes 
Chronic conditions such as diabetes, stroke, hypertension and rheumatological 
diseases are more prevalent in older people and could substantially induce accelerated 
loss of skeletal muscle [22, 23, 109]. Pro-inflammatory cytokines such as interleukin-
1 (IL–1), IL–6 and C-reactive protein which is increased in the normal ageing process 
are elevated in older people with chronic conditions [71, 91, 110]. These pro-
inflammatory cytokines are known contributory factors to muscle loss and the greater 
production of these inflammatory markers in older people with chronic conditions 
accelerates the loss of muscle mass and function [22, 91]. For example, older people 
with respiratory and cardiovascular diseases such as chronic obstructive pulmonary 
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diseases (COPD), chronic heart failure and peripheral arterial diseases experienced 
muscle loss of 10 – 40% higher compared to healthy age-matched controls [22]. The 
greater muscle loss in these groups of older people could be attributed in part to 
hypoxia, suppression of protein synthesis and overproduction of pro-inflammatory 
cytokines [22]. Furthermore, bed rest as a result of hospitalisation could further 
exacerbate skeletal muscle fibre atrophy and rapid loss of muscle function in an 
individual with chronic diseases [86].  
1.3.4 Pain and age-related muscle changes 
Pain is a major clinical symptom in chronic conditions such as osteoarthritis and 
rheumatoid arthritis and it is one of the main reasons for primary healthcare visit 
[111]. Knee pain could contribute to accelerated muscle loss via a reduction in 
mobility [112]. However, a direct inhibition of muscle strength by knee pain is also 
possible. For example, in a crossover study of 18 healthy adults, experimental knee 
pain induced by injecting hypertonic saline into the infrapatellar fat pad was 
associated with 5-15% reduction in knee strength compared to the control conditions 
[70]. Interestingly, there was a positive correlation between the decrease in muscle 
strength and the intensity of the experimentally induced knee pain, suggesting a 
greater reduction in muscle strength at higher pain intensities. Indeed, a history of 
pain is an important predictive parameter of accelerated muscle loss [71]. 
Nevertheless, previous studies examining the association of knee pain and muscle 
changes focused largely on the amount of muscle loss in older people with a higher 
knee pain compared to those with a lower knee pain (between-person comparison). 
There are no published studies describing the association of variability in knee pain 
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over time within the same individual (within-person) with the loss of muscle mass, 
strength and muscle quality. Pain experience varies over time within an individual, it 
is crucial to understand whether variability in pain over time is associated with 
muscle loss. Chapter 4 of the thesis described the first longitudinal study examining 
the association of within-person, in addition to the traditional between-person 
association of knee pain and dysfunction with loss of muscle mass, strength and 
muscle quality.  
1.3.5 Other factors contributing to age-related muscle decline 
Observational studies focus largely on lifestyle and behavioural factors modifying 
loss of muscle mass and strength in later life [12]. However, evidence from life course 
epidemiology suggests that early life environmental factors and biological factors 
such as low birth weight influence peak muscle mass and strength attained in 
adulthood [12, 113-116]. Furthermore, these early life circumstances may also 
determine the rate of muscle loss in later life [12, 113-116]. For instance, in the 
Herefordshire Cohort study individuals with low birth weight and lower weight at 
aged one year had significantly lower handgrip strength in later life [115]. 
Interestingly, the relationship between birth weight and reduced muscle strength in 
later life remained significant after adjusting for adult characteristics such as physical 
activity and current social class, suggesting that early life factors have an independent 
effect on muscle strength. The relationship between low birth weight and muscle 
strength in adulthood has been replicated in studies from several countries including 
Finland, Canada, Guatemala, Spain, Belgium and Australia [116].  
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In addition to early life circumstances, genetics have also been implicated in inter-
individual differences in age-related muscle loss with 45 – 90% heritability for 
muscle mass and 30 – 85% for muscle strength [117]. Recently, Lucassen and 
colleagues showed that poor sleep quality and later sleep timing were associated with 
low skeletal muscle mass [118]. Although the mechanism underlying this process is 
yet to be elucidated, this finding suggests that while physical activity is important to 
stimulate the muscle, adequate rest is vital in maintaining the body homeostasis.  
1.4 Health implication of age-related muscle loss  
Loss of skeletal muscle mass and strength with ageing has impacts on multiple health 
outcomes in older people, consistent with the focus of this thesis, this section 
summarises the relationship between age-related muscle loss and falls risk, fracture, 
mortality and health-related quality of life.  
1.4.1 Relationship between age-related muscle loss and falls and fracture  
Falls among older people are a major public health burden which can result in 
contusion, laceration and dislocation [119] to more severe injuries such as fracture 
and traumatic brain injury [120]. Falls are a leading cause of injury-related 
hospitalisation [121], and only about 50% of older adults admitted to hospital after a 
fall will survive the following year [122]. Even when falls do not result in any 
physical injury they are associated with social and psychological consequences [123]. 
These consequences may include fear of falling which further results in reduced 
mobility, social isolation, depression [124] and a subsequent increase in falls risk 
[125]. Other than the health and psychosocial impacts, the economic impact of falls is 
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also palpable. For instance, falls-related injuries was estimated to cost $604 million to 
the Australian healthcare system in 2011  [126]. By 2051 these injuries are expected 
to triple and estimated to cost the Australian health sector over $1.4 million annually 
[126]. With the growing population of older people in Australia, falls rates are likely 
to increase [2].  
Previously identified risk factors for falls among older adults include abnormalities in 
gait and balance, polypharmacy, visual and cognitive impairments [125, 127]. 
However, muscle weakness has been identified by the joint British and American 
Geriatrics association as the single biggest intrinsic risk factor for falls [128, 129]. 
Due to the discrepancy between muscle mass and strength, there has been an 
increasing interest in the independent role of muscle mass and strength with falls. 
Examining the independent impact of muscle mass and strength on falls is crucial to 
determine the focus of interventions aimed at reducing falls risk. Prior studies have 
consistently reported an association between low muscle strength and single fall, 
recurrent falls as well as injurious falls [130-132]. However, evidence for muscle 
mass has been inconsistent with some studies showing an association between low 
muscles mass and falls [38, 133] while others found no evidence for a relationship 
between low muscle mass and falls in women [134].  
Studies describing the relationship between muscle weakness and falls often measure 
muscle strength of either the upper (handgrip strength) or lower-limb [132]. Handgrip 
strength is a marker of overall muscle strength in the body and it has been shown to 
be an important predictor of multiple health outcomes [135, 136]. However, whether 
upper-limb muscle strength is a better predictor of falls is not entirely clear. In a 
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systematic review and meta-analysis of studies evaluating the association between 
muscle weakness and falls, Moreland and colleagues reported a combined odd ratio of 
1.76 (95% confidence interval (CI): 1.31 – 2.37) for lower extremity muscle 
weakness and a lower odds ratio of 1.41 (95% CI: 1.25 – 1.59) for upper-limb muscle 
weakness [132]. Notably, only four studies were included in their meta-analysis for 
upper-limb muscle weakness compared to nine studies which examined lower-limb 
muscle strength. Further research is required to assess the performance of muscle 
mass, upper and lower-limb muscle strength with falls in the same cohort of older 
people. If found to be more effective, handgrip strength is a simple and inexpensive 
test that can be easily adopted in clinical settings to identify older people at risk of 
falls over a long term.  
One of the major detrimental health impacts of falls is fracture [137]. A bone is 
fractured when the energy transmitted to it by a fall or other trauma-related activity 
exceeds bone strength [138]. Whether a fall results in a fracture is determined by four 
factors: 1) the location of the impact, determined by the direction of fall, 2) the energy 
generated by the fall, 3) the absorption of energy or protective response of soft tissue 
overlying the bone and 4) the bone strength [139]. In addition to contributing to falls, 
low muscle mass and both upper and lower limb muscle strength play major roles in 
the four factors which determine whether or not a fall would result in a fracture [138]. 
However, limited long-term prospective studies have compared the association of low 
muscle mass, upper- and lower-limb muscle strength with falls and fracture in the 
same group of community-dwelling older people. Such studies are crucial for two 
reasons. One, it would broaden our understanding of which measure of muscle loss is 
most clinically important in identifying older people at risk of falls and fracture over a 
Chapter 2 – Research questions 
52 
 
long-term. Secondly, findings from such a study may help in the design of long-term 
interventions aimed at reducing falls and fracture risk [140, 141]. The association 
between muscle mass, upper- and lower-limb muscle strength with falls risk and 
fracture over 10 years among community-dwelling older adults is examined in 
Chapter 5 of the thesis. 
1.4.2 Other risk factors for falls 
In addition to age-related muscle loss, other factors such as physical activity, vitamin 
D, and knee pain have also been identified as important risk factors for falls in 
community-dwelling older people. There is an abundance of research on between-
person differences in these risk factors for falls in older people. However, limited 
studies have examined whether variability in physical activity, vitamin D and knee 
pain over time within the same individual is associated with falls risk. Studies 
examining the association of between-person differences in physical activity, vitamin 
D, knee pain and falls risk are highlighted below. 
Falls risk has been shown to be consistently higher in older people with low levels of 
physical activity [142-145]. However, higher levels of physical activity have also 
been hypothesized to be associated with greater falls, in part because higher levels of 
physical activity increases opportunity for falls, particularly in older people with poor 
balance [146, 147]. Nonetheless, data from a large sample of community-dwelling 
older adults (N=1337) from the longitudinal Aging Study Amsterdam (LASA) 
reported no evidence of a non-linear relationship between physical activity and falls 
(P-value for PA2 >0.20) [142]. The association between physical activity and falls 
was not modified by mobility limitations and there was no evidence for an interaction 
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between physical activity and poor physical performance or functional limitations, 
suggesting that higher levels of physical activity may not have a detrimental impact 
on older people with poor physical function [142]. Older people may adapt their 
physical activity to suit their level of physical function and a higher level of physical 
activity may lead to an improvement in muscle strength and a reduction in falls. 
Nevertheless, the association of variability in physical activity over time within the 
same individual with falls risk has not been previously examined. 
Lower levels of vitamin D has been consistently shown to be associated with a higher 
falls risk in observational studies [148, 149]. However, evidence from RCTs testing 
the hypothesis of whether vitamin D supplementation reduces falls are inconclusive 
[150-152]. Recent RCTs from Australia (500,000 IU/year) and Switzerland (60,000 
IU/month) showed that high dose of vitamin D supplementation increased the risk of 
falls [150, 151]. Notably, falls were particularly higher among older people with 
sufficient vitamin D at baseline [150]. It is unclear why a high dose of vitamin D 
supplementation increases falls in older people. However, possible reasons have been 
postulated. For instance, it is possible that a high dose of vitamin D may trigger a 
short-term protective response in which the enzyme (25-hydroxyvitamin D-24-
hydroxylase [CYP24]) that catabolise 1,25(OH)D is up-regulated [153]. This may 
lead to lower availability of 1,25(OH)D in the blood and tissues (such as bone and 
muscle) potentially increasing the risk of falls [153]. Alternatively, high monthly 
doses of vitamin D may have some beneficial effects such as improved physical 
performance[154, 155], improved mood[156] and reduced pain[157] potentially 
leading to greater mobility and higher exposure to falls [154]. Other trials which 
included older people with low vitamin D at baseline found that vitamin D 
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supplementation reduced falls [158]. These findings suggest that vitamin D may be 
effective in reducing falls in older people with low vitamin D. Nonetheless, it is 
unclear whether variability in vitamin D over time within the same individual is 
associated with an increase in falls risk. 
Pain is prevalent in older people and the knee joint is one of the three most frequently 
reported painful sites [159]. There are multiple pathways through which knee pain 
could lead to falls. For instance, knee pain could increase falls through muscle 
weakness associated with mobility disability [112]. Furthermore, psychological 
factors including depression, fear and anxiety associated with knee pain also 
predispose older people to greater risk of falls [160]. For example, pain may 
contribute to loss of confidence and an increase in fear of falling [161]. Fear of falling 
could alter gait pattern and can lead to a further increase in falls [162]. Pain 
experience varies over time within the same individual and this within-person 
variability in pain has been shown to be associated with other health outcomes such as 
insomnia [163]. Less is known about the relationship between within-person 
variability in knee pain and falls risk in older people.  
The first longitudinal study describing the associations of within-person variability in 
knee pain, serum 25(OH)D and physical activity (in addition to between-person 
estimates) with falls risk in community-dwelling older adults is presented in Chapter 
6 of the thesis. 
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1.4.3 Relationship between age-related muscle loss and health-related quality 
of life 
Despite the widely documented impact of low muscle mass and function on health 
outcomes such as falls, fracture and mobility disability, there have been limited 
studies which have described the association between low muscle mass and strength 
and health-related quality of life (HRQoL). Recently, Woo et al synthesised evidence 
from 20 studies examining the relationship between low muscle mass and strength 
with HRQoL in older adults [164]. Notably, 18 of these studies were cross-sectional 
and only 2 were longitudinal studies with 3 – 6 years follow-up period. Findings from 
these studies were inconsistent with some showing an association between low 
muscle mass and strength and HRQoL while others reported no association [164-
166]. Due to the inherent limitations associated with cross-sectional study findings, 
long-term longitudinal studies are warranted to clarify the relationship of low muscle 
mass and strength with HRQoL in older adults. Furthermore, whether upper- and 
lower-limb muscle strength has differing effects on HRQoL is yet to be ascertained. 
The prospective association between low muscle mass, low upper and lower-limb 
muscle strength with HRQoL over 10 years in community-dwelling older people is 
examined in Chapter 7 of the thesis. 
1.4.4 Relationship between age-related muscle loss and mortality 
Muscle weakness contributes to de-conditioning and an increased risk of mortality 
[63, 64, 167]. Skeletal muscle mass also plays a role in survival as it serves as the 
major reservoir to replenish amino acid in vital organs and tissues like the brain, liver 
and the heart during physiological stressed state [99]. For example, strong association 
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have been consistently documented between low muscle mass and length of survival 
in patients with acetabula fracture and among those undergoing liver transplantation 
and oncologic procedure [168-170]. However, whether the relationship of muscle 
mass with mortality is independent of muscle strength has been an area of increased 
research interest. In a prospective study of 2292 older adults from the Health ABC 
study, Newman and colleagues showed that both handgrip strength and quadriceps 
muscle strength were significant predictors of mortality over 6 years whereas no 
association was observed between DXA-accessed lean mass and mortality [64]. 
Furthermore, the relationship between muscle strength and mortality remained 
significant after adjusting for muscle mass, albeit, muscle mass slightly reduced the 
magnitude of the effect of muscle strength. This finding suggests that muscle strength 
captures more important aspects of ageing that is related to mortality. Nonetheless, 
whether the superiority of muscle strength in estimating mortality persists over a 
decade is not entirely clear. Consequently, the relationship between muscle mass, 
muscle quality, upper- and lower-limb muscle strength with mortality over 10 years 
among community-dwelling older adults is examined in Chapter 3 of this thesis. 
1.5 Bone-muscle interaction and health of older people 
There is increasing research interest in how low muscle mass or function and low 
bone mass jointly influence health and health-related quality of life of older people 
[134, 171]. This is important as it would not only help identify the health risk 
associated with the co-existence of low muscle mass/function and low bone mass but 
also help in the design of interventions that target two conditions simultaneously.  
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Muscle exerts a significant mechanical force on bones, consequently, muscle 
weakness is believed to lead to low bone mass [172-174]. However, the reverse is 
also possible, for instance, in bone disease such as osteogenesis imperfecta, there is 
muscle weakness even when there is no myopathy, suggesting that the 
interconnection between muscle and bone is beyond mechanical forces [175]. The 
endocrine function of both muscle and bone has been previously documented, 
although the role of muscle as an important endocrine/secretory organ has only been 
recognised in the last decade [176-178]. The endocrine function of both muscle and 
bone has led to the hypothesis of a biochemical communications between the two 
organs [175, 179]. For instance, a decline in muscle mass is associated with abnormal 
glucose metabolism and alterations in muscle-related proteins which directly affect 
bone metabolism [180, 181]. Furthermore, both bone and muscle are infiltrated by fat 
leading to a toxic effect on cell function and survival [182, 183]. Future studies 
incorporating cellular and molecular mechanisms are warranted to better understand 
the biochemical communication between muscle and bone. Indeed, the co-existence 
of low muscle mass/function and low bone mass increased the risk of falls, impaired 
mobility and fracture [134, 180, 184]. However, current evidence is largely from 
cross-sectional studies, hence, it is unclear whether findings from these cross-
sectional studies track over time. The relationship between the simultaneous 
occurrence of low bone mineral density and low muscle mass/strength with fracture 
and mortality is examined in Chapter 8 of the thesis. 
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1.6 Summary 
Increasing life expectancy in Australia is accompanied with an increase in the 
population of older people. The number of older people in Australia is projected to 
increase from 17% in 2006 to 24% in 2036. Age-related decline in skeletal muscle 
mass and strength is a major public health concern as it is associated with functional 
declines and loss of independence among older people. This has a major impact on 
older people, and could substantially increase healthcare expenditure. While both 
muscle mass and strength decline with age, muscle strength declines at a faster rate 
and could be more important to consider in order to identify older people at a greater 
risk of poor health outcomes. Discrepancy also exists in the rate of decline in muscle 
strength of the upper and lower-limb, with strength declining at a faster rate in the 
lower-limbs potentially due to the role of lower-limbs in mobility. Limited long-term 
prospective studies have compared the association of muscle mass, upper and lower-
limb muscle strength with falls, fracture and mortality in community-dwelling older 
people. Physical activity, knee pain, and nutrition including serum 25(OH)D are 
important contributing factors to age-related muscle loss. Nonetheless, previous 
studies have only examined the association of between-person differences in physical 
activity, serum 25(OH)D and knee pain with muscle loss. There are no published 
studies describing the association of within-person variability in these risk factors and 
loss of muscle mass, strength and muscle quality. This is important to investigate 
because the inferences we make from the between-person effects may not align with 
those we would make from the within-person effects. Importantly, both estimates may 
lead to different conclusions. The research questions addressed in this thesis are 
described in the following Chapter. 
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The research questions addressed in the thesis are highlighted below. In a cohort of 
community-dwelling adults aged 50 - 80 years examined at baseline, 2.5, 5 and 10 
years later: 
1. What is the relationship between within-person and between-person variability 
in physical activity, vitamin-D, knee pain and dysfunction and muscle loss?  
2. Which measure of muscle mass and function is more strongly associated with 
falls risk, self-reported fracture and mortality over 10 years?  
3. What is the relationship between within-person and between-person variability 
in physical activity, vitamin-D, knee pain and dysfunction and falls risk over 
10 years?  
4. To what extent does low muscle mass/strength influence the health-related 
quality of life over 10 years?  
5. Does the simultaneous occurrence of osteopenia with low muscle mass or 
strength significantly increase the risk of fracture and mortality than 
osteopenia or low muscle mass/strength alone?  
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3.1 Prelude 
The study in this thesis was conducted as part of the Tasmanian Older Adult Cohort 
(TASOAC) study and a number of outcome variables, predictor variables and 
covariates have been used. This Chapter describes the study settings and participants 
of the TASOAC study. The dependent and independent variables examined in the 
subsequent chapters of the thesis are also described. Statistical analyses techniques 
are described in subsequent relevant chapters. 
It should be noted that the following chapters are presented in the form in which they 
were submitted to, or accepted by, peer-reviewed journals for publication. Thus, 
throughout these chapters there are some differences in the description of methods, 
analyses, results, and interpretations, mainly due to requests from journal reviewers. 
3.2 Study population and design 
The TASOAC study is a prospective, population-based study primarily aimed at 
examining the causes and progression of osteoarthritis. Men and women aged 50 
years and above were selected using a sex-stratified random sampling technique from 
the electoral roll in Southern Tasmania (population 229,000). A total of 1100 adults 
(response rate = 57%) consented to participate in the study. Participants were 
excluded if they had any implants that would prevent them from undergoing an MRI 
or they were living in a nursing home. Participants who consented to participate in the 
study were invited to attend a clinic at the Menzies Institute for Medical Research, 
Hobart, Tasmania between March 2002 and September, 2004. They were invited for 
follow–up clinic assessments at 2.5, 5, and 10 years after the initial clinic assessment. 
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The number of participants at each phase of the study and those loss to follow-up is 
shown in Figure 3.1 
3.3 Ethical consideration 
The TASOAC study was approved by the Tasmanian Health and Medical Research 
Ethics Committee Ethics (Approval Number: H6488). Written informed consent was 
obtained from all participants.  
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Figure 3.1 Flowchart describing number of participants and those loss to 
follow-up at each phase of TASOAC study. 
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3.4 Outcome measures 
3.4.1 Body composition 
Whole and regional body composition of the participants were measured using dual-
energy X-ray absorptiometry (DXA; Hologic Delphi, Hologic, Waltham USA). 
Appendicular lean mass (ALM), in kilograms, was calculated as the sum of lean mass 
in the upper and lower limbs. Weight was measured to the nearest 0.1 kilogram using 
electronic scales (Heine, Dover, USA) with shoes and heavy clothing removed. 
Height was measured to the nearest 0.1 centimetre using Leicester stadiometer 
(Invicta, Leicester, UK), with shoes, socks and headgear removed. Body mass index 
was calculated as weight (kg) divided by height (m) squared. 
3.4.2 Muscle strength and muscle quality 
Lower-limb muscle strength was measured to the nearest kilogram simultaneously for 
both limbs using a dynamometer (TTM Muscular Meter, Tokyo, Japan). Two trials 
were recorded and the average of the two trials was taken as previously described 
[185]. Hand grip strength in pounds per square inch (psi) was measured using a 
pneumatic handheld bulb dynamometer (North CoastTM bulb dynamometer; adult 0-
30 psi, model no. 70154). The mean of the right and left hand grip strength was 
calculated for each participant. The intra-class correlation coefficients of the first and 
second trial for lower-limb muscle strength and hand grip strength measurements 
were 0.95 (95% CI: 0.94 – 0.96) and 0.96 (95% CI: 0.92 – 0.97) respectively.  
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Upper-limb muscle quality was defined as hand grip strength divided by the sum of 
lean mass in the right and left upper limb and Lower-limb muscle quality was defined 
as lower limb muscle strength divided by the sum of lean mass in the left and right 
lower limb [63]. 
3.4.3 Falls risk 
Falls risk at was assessed at baseline, 2.5, 5 and 10 years follow-up using the short 
form Physiological Profile Assessment (PPA) (Prince of Wales Medical Research 
Institute, Sydney, Australia), a valid and reliable tool used to identify individuals who 
are at risk of falls [186]. The PPA assesses five physiological domains (visual contrast 
sensitivity, reaction time, knee extension strength, proprioception and postural sway 
on foam) and a standardized falls risk score is calculated for each individual using 
these five domains. Individuals with a falls risk score of less than zero are regarded as 
having a low risk of falls, between zero and one are at a mild risk of falls, between 
one and two are at a moderate risk of falls and those with a falls risk score of more 
than 2 are at a high risk of falls. The PPA has been shown to have 75% accuracy in 
predicting multiple falls among older people [187]. 
3.4.4 Fracture 
At each study visit participants were asked to list, by location, any fractures they had 
since their previous clinic visit. Those who experienced at least one fracture between 
the baseline and 10-year follow-up assessment were coded as ‘1’ (incident fracture) 
and those without any fracture were coded ‘0’ (no incident fracture).  
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3.4.5 Mortality 
Data on mortality was collected until August 2015. Mortality over 10 years was 
ascertained through national and state death registries.  
3.4.6 Health-related quality of life (HRQoL) 
HRQoL was assessed at baseline, 2.5, 5 and 10 years using the Assessment of Quality 
of life (AQoL-4D) questionnaire. The AQoL-4D is a validated generic questionnaire 
designed for the Australian population [188]. The questionnaire consists of 12 items 
covering four dimensions and each dimension has three items. The four dimensions 
and their corresponding items are: (1) independent living (self-care, activities of daily 
living), (2) physical senses (sight, hearing and communication), (3) social 
relationships (social isolation, relationship and family role) and (4) psychological 
wellbeing (sleep, anxiety and pain). The scores for items in each domain were 
transformed and summed to a life-death utility scale that ranges from 1.00 (full 
HRQoL) to 0.00 (death-equivalent health state) to –0.04 (health states worse than 
death) [189, 190]. The minimum important difference in AQoL score for the 
Australian population is 0.06 [190]. This score provides a measure of the smallest 
difference in AQoL score that is considered to be of a significant change in the health 
state of Australians [190].  
3.4.7 Physical activity 
Ambulatory physical activity was assessed at baseline, 2.5 and 5 years. Baseline 
assessment was measured over seven consecutive days using a pedometer (Omron 
HJ-003 & HJ-102; Omron Healthcare, Kyoto, Japan) worn on the waist band or belt 
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above their dominant leg. Participants were given a diary in which to record the 
duration of pedometer use and daily step counts. At 2.5 years follow-up Yamax 
pedometers (Yamax SW-200; Yamax USA, San Antonio, TX, USA) were given to 
the majority (98%) of the participants. A strong linear correlation (r=0.88) was found 
between the estimates of the two types of pedometer, but the Omron brand recorded 
higher mean steps. Yamax pedometers were used by all participants at 5 years. 
Baseline and 2.5 years Omron estimates were multiplied by a correction factor of 0.91 
to provide comparability between mean estimates for Omron and Yamax pedometers 
[191].  
The intensity of physical activity was assessed in a subset of 637 participants using an 
accelerometer (ActiGraph GT1M). Participants were instructed to wear the 
accelerometer for 7 consecutive days, and were provided with a daily diary to record 
when the accelerometer was worn and when it was removed (for instance, during 
swimming or showering). Data were included in the analysis if the participants wore 
the accelerometer for 5 valid days or more; with a valid day being one in which the 
accelerometer was worn for at least 10 hours. Details about accelerometer data 
cleaning and the cut-points used for intensity (sedentary, light, moderate, and 
vigorous) have been described in detail previously [68]. Vigorous physical activity 
was combined with moderate physical activity because few older adults engaged in 
vigorous physical activity. Moderate-to-vigorous physical activity (MVPA) was log-
transformed as the variable was skewed to the right. 
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3.4.8 Knee pain, stiffness and functional limitation 
Knee pain, stiffness and functional limitation were assessed by self-administered 
questionnaire using the Western Ontario and McMaster Universities osteoarthritis 
index (WOMAC) at each study visit. WOMAC is a validated and widely used 
measure of symptoms and disability in patients with osteoarthritis [192]. The three 
WOMAC sub-scales: knee pain, stiffness and functional limitation were assessed 
separately with 5, 2 and 17 questions respectively. Response to each question ranges 
from 0 (no symptom) to 9 (most severe knee pain, stiffness or functional limitation). 
Response in each sub-scale was summed to create a score for knee pain (range: 0–45), 
stiffness (range: 0–18) and functional limitation (range: 0–153). All three sub-scales 
were also summed to create a WOMAC global score (range: 0–216).  
3.4.9 Serum 25-hydroxyvitamin D [25(OH)D] 
Serum 25(OH)D was assessed at baseline, 2.5 and 10-year follow-up. Serum samples 
from blood drawn from the participants were treated initially with acetonitrile to 
rapidly extract vitamin-D and other hydroxylated metabolites. Thereafter 25(OH)D 
was assayed using a liquid-phase radioimmunoassay (Immunodiagnostics Systems 
Ltd), which detects both 25(OH)D2 and 25(OH)D3. The intra-assay and inter-assay 
coefficients of variation were 1.8% and 3.3% respectively. Participants had their 
baseline and follow-up interview at different seasons and as 25(OH)D is known to 
vary with seasons, we de-seasonalised the 25(OH)D measurement as previously 
described [15] to account for differences in the time of the year that blood was taken. 
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3.5 Covariates 
At each phase of the TASOAC study a questionnaire was mailed to study participants 
to collect information about age, sex, employment status, smoking status, medical 
history, including a previous diagnosis of diabetes, rheumatoid arthritis and 
cardiovascular disease (hypertension, bronchitis/emphysema, or heart attack). 
3.6 Study factors 
Table 3.1 shows the study factors for each research question addressed in the thesis. 
Each study is also described in their respective Chapter.  
3.7 Statistical analyses 
Description of statistical analyses performed for each study are presented in their 
respective chapters. However, a detailed description of the novel longitudinal analysis 
method used in Chapter 4 and 6 is presented below, while a shortened version is 
described in each Chapter. All statistical analyses were performed using Stata for 
Windows version 12 and 13 (StataCorp LP, Texas, US). 
 
 
 
 
Chapter 3 – Methodology  
71 
 
Table 3.1 Description of outcome variables, predictor variables, and covariates 
examined in the thesis, by Chapter. 
Chapter 
Outcome 
variable/s 
Predictor variables Covariates 
4 LLM, LMS, LMQ 
Physical activity 
25(OH)D 
Knee pain and 
dysfunction 
Age, sex, chronic 
conditions, 
employment status 
and smoking status 
5 
Falls risk 
Fracture 
Mortality 
LMQ, UMQ, 
LMS, HGS, 
ALM/HH, 
ALM/BMI, 
ALM/W, ALMR 
Age 
6 Falls risk 
 
 
Physical activity 
25(OH)D 
Knee pain and 
dysfunction 
Age, sex, chronic 
conditions, 
employment status, 
smoking status and 
appendicular lean 
mass and fat mass  
7 HRQoL 
ALM/BMI, LMS 
and HGS 
Age, sex, self-
reported pain, 
chronic conditions 
and physical 
activity 
8 
Fracture 
Mortality 
ALM/BMI, HGS, 
BMD 
Age, sex, 
25(OH)D, chronic 
conditions and 
physical activity 
LLM: Lower-limb lean mass; LMS: Lower-limb muscle strength; HGS: Handgrip 
strength; LMQ: Lower-limb muscle quality; UMQ: Upper-limb muscle quality; 
25(OH)D: Serum 25-hydroxy vitamin D; ALM/HH: Appendicular lean 
mass/height2; ALM/BMI: Appendicular lean mass/body mass index; ALM/W: 
Appendicular lean mass/weight; ALMR: Residual of appendicular lean mass on 
height and total body fat; HRQoL: Health-related quality of life; BMD: Bone 
mineral density 
 
Chapter 3 – Methodology  
72 
 
3.7.1 Description of time-varying predictor variables 
This thesis employs an advanced statistical method to examine how variability in 
physical activity, 25(OH)D, knee pain and dysfunction within the same individual 
over time is related to muscle changes and falls risk. Traditionally, research in this 
area has focused on examining how these risk factors differ between individuals 
(between-person comparison) but less well recognised is how variability within the 
same individual (within-person comparison) over time relates to muscle changes and 
falls risk. This is important to investigate because the information we get from 
between-person analysis (e.g., the magnitude and direction of effects) might be quite 
different from what a within-person analysis tells us. 
Physical activity, 25(OH)D, knee pain and dysfunction were assessed at multiple 
time-point in the TASOAC study, and the values of these variables differed for most 
participants on each measurement occasion. Hence, these variables are said to be 
‘time-varying' or ‘time-dependent covariates' [193, 194]. Time–varying predictors 
provide two sources of information in longitudinal analysis. These are within–person 
and between–person effects. The between–person component of the time-varying 
predictor is an individual’s average 25(OH)D; physical activity and WOMAC score 
across all measurement occasions. The within–person component is the deviation of 
an individual’s measurement on a particular phase of the study from his or her 
average score across all measurement occasions. Within–person (level 1) and 
between–person (level 2) effects are a ‘linked pair’ and are jointly referred to as a 
multilevel model [194]. Incorrect specification of a time–varying predictor in the 
analysis of longitudinal data will result in biased model effects [193]. For example, 
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analysing time-varying predictors without separating the variable into level 1 (within-
person) and level 2 (between-person) effects is based on the assumption that within- 
and between-cluster effects are equal [195]. This is a strong assumption and it is not 
always true for time-varying covariates [196, 197]. To ensure there is sufficient 
variance to warrant decomposing the predictor variables into between-person and 
within-person effects we calculated intra-class correlation coefficients (ICCs) for each 
predictor variable using an intercept only model [193, 198].  
Linear mixed-effect regression models were then used to estimate the between-person 
and within-person effects of 25(OH)D, physical activity, and knee pain and 
dysfunction on falls risk and muscle changes. We decomposed each time-varying 
covariate into between- and within-persons components. The statistical model 
(without adjustment for confounders), using 25(OH)D as an example of a predictor 
variable and muscle strength as outcome variable, is shown below. 
𝑀𝑢𝑠𝑐𝑙𝑒 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ𝑖𝑗
= 𝛽0 + 𝛽1(25𝑂𝐻𝐷𝑖𝑗 − 𝑀𝑒𝑎𝑛 25𝑂𝐻𝐷𝑖) + 𝛽2(𝑀𝑒𝑎𝑛 25𝑂𝐻𝐷𝑖) +∪0𝑗+ 𝑒𝑖𝑗 
Where, muscle strengthij is the muscle strength for person i at time j, β0 is the 
intercept, mean 25OHDi is individual’s average vitamin-D across all measurement 
occasions, 25OHDij is individual’s absolute vitamin-D value at each measurement 
occasion, U0j is the between–persons random components or error, and eij is the 
within–person random error. β1 and β2 are the level 1 (within–persons) and level 2 
effects (between–persons) respectively.  
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A positive beta coefficient for a level 2 predictor (between-person) suggests that an 
individual with a higher 10-year average 25(OH)D, higher 10-year average physical 
activity or lower 10-year average WOMAC score, would be estimated to have a 
higher 10-year mean muscle strength. A positive beta coefficient for the level 1 
predictor (within-person) would imply that, at a time-point when an individual has a 
higher 25(OH)D, higher physical activity or lower WOMAC score than his or her 10-
year average score, the individual would be estimated to have a higher muscle 
strength at that time-point. Model fit were accessed using likelihood ratio test, Akaike 
Information criterion and Bayesian Information Criterion [199].  
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4.1  Abstract 
Aim: To describe the associations of between-person and within-person variability in 
serum 25-hydroxyvitamin D (25(OH)D), physical activity (PA) and knee pain and 
dysfunction with muscle mass, strength and muscle quality over 10 years in 
community-dwelling older adults.  
Method: Participants (n=1033; 51% women; mean age 63±7.4 years) were measured 
at baseline, 2.5, 5, and 10 years. Lower-limb lean mass (LLM) was assessed using 
DXA, lower-limb muscle strength (LMS) using a dynamometer; and lower-limb 
muscle quality (LMQ) calculated as LMS/LLM. Knee pain and dysfunction were 
assessed using the Western Ontario and McMaster Universities Osteoarthritis 
(WOMAC) index. PA was measured using pedometers. Linear mixed effect 
regression models, with adjustment for confounders, were used to estimate the 
association of within-person and between-person variability in PA, 25(OH)D and 
WOMAC score with muscle mass, strength and muscle quality.  
Results: Both between-person and within-person increases in PA were associated 
with LLM, LMS and LMQ (all P<0.05). Within-person and between-person increases 
in knee pain and dysfunction were associated with LLS and LMQ but not LLM (all 
P<0.05). 
Between-person effects showed that higher average 25(OH)D was associated with 
higher 10-year average LLM, LMS and LMQ (all P<0.05); whereas, within person 
increases in average 25(OH)D was associated with a higher LMS, LMQ but not LLM.  
Conclusions: Variability in 25(OH)D, pain and dysfunction within an individual over 
time relate to muscle changes in that individual. Increasing one’s own physical 
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activity level further increases muscle mass, strength and quality supporting the 
clinical recommendation of promoting PA to reduce age-related muscle loss.  
4.2 Introduction:  
Age-related loss of skeletal muscle mass, strength and muscle quality is a major 
public health concern that is associated with functional disability, poor quality of life 
and mortality in older people [71, 200-202]. While loss of muscle mass and function 
increases with age, significant variability exists between individuals in the rate of loss 
of muscle mass and function [203]. Traditionally, analysis has focused on examining 
how risk factors for loss of muscle mass and function differ between individuals 
(between-person comparison). These studies showed that age-related loss of muscle 
mass and strength is more prevalent in older adults with lower levels of serum 25-
hydroxyvitamin D (25(OH)D) [104, 105, 204], physical activity [68, 71, 185] and 
higher levels of knee pain and functional limitation [71, 72]. As a result, public health 
efforts have been informed by findings from between-person comparisons but less 
well recognised is how variability within the same individual (within-person 
comparison) over time is related to muscle changes. This is important to investigate 
because the information we get from between-person analysis (for example the 
magnitude and direction of effects) might be quite different to what a within-person 
analysis tells us. Besides, neither can be inferred from the other [205]. Statistical 
methods, such as multilevel models that properly capture the within-person processes 
can be used to tell us whether changes within an individual over time relate to 
changes in muscle in that same individual [193]. Findings from within-person 
comparison are vital for formulating policies aimed at improving population health by 
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promoting good health behaviours like physical activity at the individual level. This 
could include person-centered public health messages that highlight the benefits of 
improving one’s own level of physical activity. 
To our knowledge, there are no published studies describing associations of within-
person variability in physical activity, 25(OH)D, knee pain and dysfunction with loss 
of muscle mass, strength and muscle quality in community-dwelling older people. 
Therefore, the aim of this study was to describe the associations of between-person 
and within-person variability in 25(OH)D, physical activity, knee pain and 
dysfunction with age-related loss of skeletal muscle mass, strength and muscle quality 
over 10 years in community-dwelling older adults. We hypothesized that older adults 
with a lower mean level of physical activity, 25(OH)D and higher average level of 
knee pain and dysfunction would have a lower muscle mass, strength and muscle 
quality. Furthermore, at time-points when an individual had a lower level of 
25(OH)D, physical activity and higher knee pain and dysfunction than their own 
individual average, they would also have lower muscle mass, strength and muscle 
quality. 
4.3 Data and Methods 
The Tasmanian Older Adult Cohort (TASOAC) study is a prospective, population-
based study primarily aimed at examining the causes and progression of osteoarthritis. 
Participants aged 50 years and older were selected using sex-stratified random 
sampling from the electoral roll in Southern Tasmania (population 229,000). A total 
of 1099 adults (response rate = 57%) consented to participate. Participants were 
excluded if they had any implants that would prevent them from undergoing an MRI 
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or they were living in a nursing home. Participants attended a clinic at the Menzies 
Institute for Medical Research, Hobart, Tasmania between March 2002 and 
September 2004, and follow–up clinic assessments 2.5, 5, and 10 years later. The 
study was approved by the Southern Tasmanian Health and Medical Research Ethics 
Committee and written informed consent was obtained from all participants.  
4.4 Outcome measures 
4.4.1 Body composition and anthropometrics  
Body composition was measured using dual energy X-ray absorptiometry (DXA; 
Hologic Delphi, Hologic, Waltham USA). Leg lean muscle mass (kg), was calculated 
as the sum of lean mass in both lower-limbs. Weight (kg) was measured using 
electronic scales (Heine, Dover, USA). Height (cm) was measured using the Leicester 
stadiometer (Invicta, Leicester, UK).  
4.4.2 Lower-limb muscle strength and muscle quality  
Lower-limb muscle strength (LMS) in kilograms was measured simultaneously for 
both limbs using a dynamometer (TTM Muscular Meter, Tokyo, Japan). Participants 
stood on the back of a dynamometer platform with their backs against a wall and knee 
flexed to 115°. A bar was attached to the dynamometer, and participants lifted the bar 
using their lower-limbs only to maximum contractile force, whilst maintaining proper 
head and neck posture. This test assessed the isometric strength of the whole lower-
limbs, but predominantly of the quadriceps and hip extensors. Two trials were 
recorded, with the mean score taken as the criterion value for lower-limbs muscle 
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strength [185]. The intra-class correlation coefficient (ICC) for the first and second 
trial was 0.95 (95% CI: 0.94–0.96). Leg muscle quality (LMQ), was calculated as 
LMS divided by the sum of DXA-derived lean mass of the two lower-limbs [206].  
4.5 Predictor variables 
4.5.1 Physical activity 
Habitual physical activity was assessed at baseline, 2.5 and 5 years. Baseline 
assessment was assessed over seven consecutive days using a pedometer (Omron HJ-
003 & HJ-102; Omron Healthcare, Kyoto, Japan) worn on the waist band or belt 
above their dominant lower-limb. Participants were given a diary in which to record 
the duration of pedometer use and daily step counts. At 2.5 years follow-up Yamax 
pedometers (Yamax SW-200; Yamax USA, San Antonio, TX, USA) were given to 
the majority (98%) of the participants. A strong linear correlation (r=0.88) was found 
between the estimates of the two types of pedometer, but the Omron brand recorded 
higher mean steps. Yamax pedometers were used by all participants at 5 years. 
Baseline and 2.5 year Omron estimates were multiplied by a correction factor of 0.91 
to provide comparability between mean estimates for Omron and Yamax pedometers 
[191]. Beta coefficients in the regression models were scaled to 1000 steps per day for 
ease of interpretation. 
4.5.2 Knee pain, stiffness and functional limitation 
Knee pain, stiffness and functional limitation were assessed by self-administered 
questionnaire using the Western Ontario and McMaster Universities osteoarthritis 
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index (WOMAC) at each study visit. WOMAC is a validated and widely used 
measure of symptoms and disability in patients with osteoarthritis [192]. The three 
WOMAC sub-scales: knee pain, stiffness and functional limitation were assessed 
separately with 5, 2 and 17 questions respectively. Response to each question ranges 
from 0 (no symptom) to 9 (most severe knee pain, stiffness or functional limitation). 
Response in each sub-scale was summed to create a score for knee pain (range: 0–45), 
stiffness (range: 0–18) and functional limitation (range: 0–153). All three sub-scales 
were also summed to create a WOMAC global score (range: 0–216).   
4.5.3 Serum 25-hydroxyvitamin D  
25(OH)D was assessed at baseline, 2.5 and 10-year follow-up. Serum samples from 
blood drawn from the participants were treated initially with acetonitrile to rapidly 
extract vitamin-D and other hydroxylated metabolites. Thereafter 25(OH)D was 
assayed using a liquid-phase radioimmunoassay (Immunodiagnostics Systems Ltd), 
which detects both 25(OH)D2 and 25(OH)D3. The intra-assay and inter-assay 
coefficients of variation were 1.8% and 3.3% respectively. Participants had their 
baseline and follow-up interview at different seasons and as 25(OH)D is known to 
vary with seasons, we de-seasonalised the 25(OH)D measurement as previously 
described [15] to account for differences in the time of the year that blood was taken. 
4.6 Potential confounders 
Age, sex, medical history, including a previous diagnosis of diabetes, rheumatoid 
arthritis, cardiovascular disease (hypertension, bronchitis/emphysema, or heart 
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attack), as well as employment status, and smoking history were recorded using a 
questionnaire. 
4.7 Data analysis 
Measurements for physical activity, 25(OH)D, and WOMAC scores varied across 
occasions for individuals, and were modelled as time-varying predictors [193, 194]. 
Time–varying predictors provide two sources of information in longitudinal analysis; 
consequently, we decomposed each time-varying predictor into between- person and 
within-person components. The between–person component of the time-varying 
predictor is an individual’s average 25(OH)D, physical activity and WOMAC score 
across all measurement occasions. The within–person component is the deviation of 
an individual’s measurement at a particular phase of the study from his or her average 
score across all measurement occasions. We first calculated intra-class correlation 
coefficients (ICCs) for each predictor variable to ensure there was sufficient variance 
to warrant decomposing the predictors into between-person and within-person effects 
[193, 198]. All ICC of our predictor variables were >0.3, suggesting substantial 
variability in each predictor variable[198].  
Linear mixed effect regression models were used to estimate the association of 
between-person and within-person variability in 25(OH)D, physical activity, and 
WOMAC scores over 10 years with LLM, LMS and LMQ. Models were adjusted for 
age, sex, number of chronic conditions, employment status and smoking status. 
Multiplicative interaction between age, sex and between-person and within-person 
variability in serum 25(OH)D, physical activity, knee pain and dysfunction was 
assessed for each outcome variable. All models were estimated using the maximum 
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likelihood method. The fit of models with different fixed and random effects were 
compared using the likelihood ratio test and Akaike Information Criterion [199]. Data 
was analysed using Stata version 13 (StataCorp, TX, USA). 
4.8 Results 
A total of 1033 participants with complete body composition and muscle assessments 
at baseline were included in the analysis. Of these, 853 (82%), 752 (73%) and 559 
(54%) respectively attended the 2.5, 5 and 10 years follow-up assessments. 
Participants were lost to follow-up because of reasons such as death, withdrawal of 
consent, institutionalization, moving interstate or overseas and having a joint 
replacement. Compared to those who completed the 10 year follow-up assessment, 
participants lost to follow-up were older at baseline (64.7±8.0 vs. 61.4±6.5 years, 
P<0.001), had lower lean muscle mass (23.9±5.3 vs. 24.8±5.3 kg, P=0.005), weaker 
lower-limb muscle strength (87.7±47.0 vs. 96.9±50.5 kg, P=0.003) and muscle 
quality (5.3±2.3 vs. 5.7±2.4, P=0.019) but no difference in the proportions of males 
and females was observed (P=0.524).  
Baseline characteristics of the participants are shown in Table 4.1. The mean age of 
the participants at baseline was 63±7.4 and 51% were female. The associations of 
between-person and within-person variability in 25(OH)D, physical activity, knee 
pain and dysfunction with LLM, LMS and LMQ are shown in Table 4.2.  
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4.8.1 Physical activity and LLM, LMS and LMQ 
Both between-person and within-person increases in physical activity were associated 
with muscle changes (between-person: LLM (β=0.03; 95% CI 0.02, 0.05), LMS 
(β=1.25; 95% CI 0.61, 1.88) and LMQ (β=0.10; 95% CI 0.06, 0.13)); within person: 
LLM (β=0.02; 95% CI 0.001, 0.04), LMS (β=0.56 95% CI 0.01, 1.10) and LMQ 
(β=0.04; 95% CI 0.01, 0.07)). There was an interaction between sex and between-
person variability in physical activity and LMQ, such that the positive association was 
stronger in women (β=0.14, 95% CI: 0.09, 0.19) compared to men (β=0.06, 95% CI: 
0.01, 0.11). 
4.8.2 Knee pain and dysfunction and LLM, LMS and LMQ 
Between-person increase in WOMAC global score was associated with a significantly 
lower LMS (β= –0.21; 95% CI –0.28, –0.13), LMQ (β= –0.02; 95% CI –0.02, –0.01) 
but not LLM (β=0.001; 95% CI:–0.002, 0.003). Similar associations were observed 
for the WOMAC subscales. Sex modifies the relationship between LMQ and 
between-person variability in WOMAC knee pain sub-scale (Men: β= –0.06, 95% CI: 
–0.09, –0.03; women: β= –0.10, 95% CI: –0.12, –0.07) and WOMAC knee 
dysfunction subscale (Men: β= –0.02, 95% CI: –0.03, –0.01; women: β= –0.03, 95% 
CI: –0.04, –0.02), such that the negative associations were stronger for women 
compared to men. 
Within-person increase in WOMAC global score was associated with a lower LMS 
(β= –0.09; 95% CI –0.15, –0.03), LMQ (β= –0.006 95% CI –0.01, –0.002) but not 
LLM (β= 0.002 95% CI –0.0003, 0.004). Furthermore, at time-points when WOMAC 
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knee dysfunction sub-scale scores were higher than average, LMS (β= –0.14 95% CI 
–0.22, –0.06), LMQ (β= –0.01 95% CI –0.01, –0.003) but not LLM (β= 0.002 95% CI 
–0.001, 0.005) were significantly lower. No significant within-person association was 
found between WOMAC knee pain and knee stiffness subscales and LLM, LMS and 
LMQ. The association between within-person variability in WOMAC global score 
and LMQ was modified by age such that the association was significant in 
participants aged 50-69 years (β= –0.01, 95% CI:–0.01, –0.004) but not significant in 
participants aged 70 years and older β=0.005, 95% CI:–0.001, 0.01). A similar 
relationship was observed between within-person variability in knee dysfunction 
subscale and LMS (50-69 years: β= –0.19, 95% CI:–0.28, –0.10 versus 70 years and 
older: β=0.04, 95% CI:–0.10, 0.17). 
4.8.3 Serum 25(OH)D and LLM, LMS and LMQ 
Between-person analysis showed that participants with a higher 10-year average 
25(OH)D had a significantly higher LLM (β=0.005; 95% CI: 0.001, 0.01), LMS 
(β=0.16; 95% CI: 0.05, 0.27) and LMQ (β=0.01; 95% CI: 0.01, 0.02). There was a 
significant interaction between sex and between-person increase in 25(OH)D and 
LLM (P-value for interaction=0.09), such that the association was stronger for men 
(β=0.008, 95% CI:0.003, 0.01) than women (β=0.0003, 95% CI: –0.003, 0.004). 
Within-person increase in 25(OH)D was associated with higher LMS (β=0.10; 95% 
CI: 0.03, 0.17), LMQ (β=0.01; 95% CI: 0.002, 0.01) but not LLM (β=0.002; 95% CI: 
–0.001, 0.004). 
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Table 4.1: Baseline characteristics of participants in the Tasmanian Older Adult Cohort 
(TASOAC) study (N= 1033) 
Variables Mean SD* 
Age (years)                      63.0 7.4 
Female, n (%) 525 51 
Height (cm)                    167.1 9.0 
Weight (kg)                     77.8 14.8 
Body mass index (kg/m2) 27.8 4.7 
Serum 25-hydroxyvitamin D (nmol/L) 52.6 18.7 
Appendicular lean mass, Kg 24.5 14.7 
Physical activity (steps/day) 8659 3370 
Total body fat mass, Kg 28.1 8.6 
Current smoker, n (%) 523 51 
Number of chronic conditions  1.5 1.4 
Currently employed, n (%) 416 40 
WOMAC  15.8 27.3 
     WOMAC sub-scales    
WOMAC knee pain 3.5 6.0 
Knee stiffness  1.6 2.6 
Functional limitation     10.8 19.9 
*Data are presented as mean (standard deviation (SD)) unless otherwise specified. 
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Table 4.2: Association of between-person† and within-person variability‡ in serum 25-hydroxyvitamin D, physical activity (PA), knee 
pain and dysfunction with lower-limb lean mass, lower-limb muscle strength and muscle quality (N=1033) 
     Lower-limb lean mass, Kg  Lower-limb muscle strength, Kg  Lower-limb muscle quality, Kg/Kg  
Predictor variables Between-person effect      Within-person effect      Between-person effect Within-person effect Between-person effect Within-person effect 
 β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) 
PA (per 1000 steps/day)  0.03 (0.02, 0.05)  0.02(0.001, 0.04)     1.25 (0.61, 1.88)     0.56 (0.01, 1.10) 0.10 (0.06, 0.13) 0.04 (0.01, 0.07) 
       
WOMAC global score 0.001 (–0.002, 0.003) 0.002(–0.0003, 0.004)  –0.21 (–0.28, –0.13) –0.09 (–0.15, –0.03) –0.02 (–0.02, –0.01) –0.006 (–0.01, –0.002) 
WOMAC sub-scales       
Knee pain  0.004 (–0.01, 0.01) 0.01(–0.0003, 0.02)  –0.85 (–1.20, –0.51) –0.18 (–0.42, 0.07) –0.08 (–0.10, –0.06) –0.01 (–0.03, 0.003) 
Knee stiffness 0.01 (–0.01, 0.04) 0.01(–0.01, 0.03)  –1.85 (–2.63, –1.07)   –0.29 (–0.81, 0.23) –0.19 (–0.23, –0.14) –0.02 (–0.06, 0.01) 
Knee dysfunction 0.001 (–0.002, 0.004) 0.002(–0.001, 0.005)  –0.29 (–0.39, –0.19)  –0.14 (–0.22, –0.06) –0.03 (–0.03, –0.02) –0.01 (–0.01, –0.003) 
       
Serum 25(OH)D(nmol/L) 0.005 (0.001, 0.01) 0.002(–0.001, 0.004)     0.16 (0.05, 0.27)    0.10 (0.03, 0.17) 0.01 (0.01, 0.02) 0.01 (0.002, 0.01) 
Data in bold indicate statistical significance at P < 0.05 
Models are adjusted for age, sex, number of chronic conditions (diabetes, rheumatoid arthritis, cardiovascular disease (hypertension, bronchitis/emphysema, 
or heart attack)), employment status (currently employed vs. not currently employed), smoking status, linear time and quadratic time. 
†Beta-coefficients expressed as change in 10-year average of the outcome variable per 1 unit increase in the 10-year average predictor variable (25(OH)D, 
WOMAC and PA) 
‡Beta-coefficients expressed as change in outcome variable per 1 unit deviation from the participant’s 10-year mean predictor score (25(OH)D, WOMAC 
and PA) 
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4.9 Discussion 
To our knowledge, this is the first prospective study to determine the associations 
between both within-person and between-person variability in serum 25(OH)D, 
physical activity and knee pain and dysfunction and LLM, LMS and LMQ in 
community-dwelling older adults. Consistent with between-person findings, 
fluctuations in 25(OH)D, knee pain and dysfunction and physical activity within an 
individual were related to variations in muscle in that individual. Importantly, this 
work builds on our knowledge from between-person analysis, as it demonstrates that 
within-person variability in these factors have independent effects on muscle. 
Specifically, having higher 25(OH)D and lower knee pain and dysfunction compared 
to an individual’s average was associated with greater muscle strength and quality but 
not muscle mass. Furthermore, when participants engaged in more physical activity 
than their average level, they had higher LMM, LMS and LMQ.  
Both between-person and within-person increases in physical activity were associated 
with a higher muscle mass, strength and muscle quality. The within person findings 
suggest that, irrespective of an individual’s usual level of physical activity, further 
increases in physical activity have additional beneficial effects on muscle mass, 
strength and muscle quality. For instance, at time-points when an individual (either 
with higher or lower 10-year average physical activity) increased their steps-per-day 
by 1000, that individual had a 0.56 kg increase in LMS. The effect of physical activity 
on muscle was stronger in the between-person analysis (e.g. a 1000 steps/day increase 
resulted in a 1.25 kg increase in 10-year average LMS). The discrepancy between the 
within- and between-person estimates may be because error variance associated with 
Chapter 4 – Longitudinal Associations of Serum 25-hydroxyvitamin-D, Physical 
Activity, and Knee Pain and Dysfunction with Muscle Loss 
89 
 
important individual differences are reduced in the within-person estimates compared 
to the between-person comparisons. For instance, differences such as genetic makeup, 
pain perception and motivation to engage in physical activity, which are not captured 
in the between-person comparison, are held constant in the within-person comparison. 
Nonetheless, our previous study[185] and others[68, 71] report that pedometer 
determined physical activity is associated with sarcopenia. Hence, physical activity 
has been recognised as one of the most feasible and inexpensive strategies to delay 
age-related loss of mass and function with clinical guidelines emphasizing physical 
activity to promote health including preventing incidence of sarcopenia in older 
people [97, 207]. We found that the magnitude of the associations of between-person 
increases in physical activity with LMQ was higher in women compared to men. This 
observation has been seen in some [185, 208], but not all previous studies [209]. 
Although the underlying mechanism of this sex difference is unclear, one potential 
explanation may be that because women have smaller muscles, therefore ambulatory 
activity stimulates a greater improvement in muscle quality in women than men who 
may require a greater stimulus. This present study builds on previous knowledge by 
showing that increasing one’s own physical activity above their ‘usual’ level results in 
further increases in lower-limb lean mass, muscle strength and quality.  
Within-person increase in WOMAC global score and functional limitation sub-scale 
was associated with a lower muscle strength and quality, whereas, between-person 
increase in WOMAC global score and knee pain, stiffness and functional limitation 
sub-scales were associated with lower muscle strength and quality. Muscle mass was 
not associated with WOMAC global score or the sub-scales in either between or 
within person analysis. Knee pain and dysfunction may lead to lower muscle strength 
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and muscle quality through activity limitation due to pain-related fear [210, 211] or 
via reflex muscle inhibition [70, 212]. The significant within-person association 
suggests that at time-points when the participants reported higher knee dysfunction, 
they may also have experienced greater activity limitation, thus, they had a weaker 
lower-limb muscle strength and muscle quality. It could also imply that the 
participants were less able to exert a maximal contraction due to actual or anticipated 
pain, which may explain why the decrease in muscle strength does not translate to a 
loss of muscle mass. Pain represents a major clinical symptom in older people and it 
is a predictor of transition towards sarcopenia [71, 213]. Yet, it is under-assessed and 
undertreated potentially due to the perception that pain is an unavoidable consequence 
of ageing [214]. The within-person analysis emphasizes the importance of adequate 
pain management in older people, particularly on occasions when their pain is higher 
than their ‘usual’ pain level, in order to prevent further loss of muscle strength and 
quality. Interestingly, the between-person association between knee pain and 
dysfunction and muscle parameters was stronger in women compared to men. This 
finding is consistent with our previous study [72] and may be due to the fact women 
are less capable of generating force in the presence of pain during strength testing 
compared to men [215]. Furthermore, the within-person association between pain and 
muscle measures was modified by age such that an increase in knee pain was 
associated with a higher loss of muscle strength and quality in the younger (50-69 
years) compared to the older age category (70 years and above). The reason for this is 
unclear. Notably, the association of between-person and within-person variability in 
knee pain and dysfunction with muscle strength and quality are mostly independent of 
physical activity (Table 4.3). This demonstrates that there are multiple pathways 
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including direct inhibition of muscle function through which knee pain and 
dysfunction contributes to loss of muscle function [70, 212].  
The between-person findings between 25(OH)D and muscle mass, strength and 
quality suggest that long-term maintenance of 25(OH)D is beneficial for muscle. 
These findings are supported by our previous work [105]. Notably, the magnitude of 
the association of between-person difference in 25(OH)D and LLM was higher in 
men compared to women, potentially due to higher physical activity in men. 
Furthermore, there was evidence for a dynamic within-person relationship between 
25(OH)D and muscle strength and quality but not muscle mass. This suggests that, 
irrespective of their ‘usual’ level of 25(OH)D, variability in 25(OH)D around an 
individual’s mean value results in further improvements in muscle strength and 
quality but not muscle mass. Indeed, improvement in muscle strength do not 
necessarily overlap with an increase in mass as the two processes may be the results 
of different pathophysiological mechanisms [216].The within-person increase in 
muscle strength and quality but not muscle mass may be related to the role of vitamin 
D in muscle fibre neuromuscular junction [217]. These findings highlight that vitamin 
D plays a role in age-related skeletal muscle changes and that further increases in 
25(OH)D above an individual’s average has additional benefit to muscle strength and 
muscle quality.  
This study has a number of strengths including the use of a person-mean centering 
analysis approach, allowing us to disentangle the within-person and between-person 
effects of the predictor variables. This is particularly useful as we were able to show 
both between-person and within-person variability in 25(OH)D, physical activity and 
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knee pain and dysfunction were independently contributing to muscle mass, strength 
and muscle quality. Another strength of this study is the use of objective measures of 
physical activity which likely increases the accuracy of our estimates. However, this 
study also has a number of limitations. Firstly, 47% of participants recruited at 
baseline were lost to follow-up over 10 years. Such missing data is not unexpected in 
a long-term prospective study involving older people. The missing data were 
accommodated by using maximum likelihood estimation which uses available data 
for model estimation, rather than casewise deletion. Secondly, although we 
hypothesised that higher knee pain and dysfunction would result in lower muscle 
mass, strength and muscle quality, reverse causality is also possible where muscle 
weakness could lead to an increase in knee pain. Our study focused on the association 
of between-person and within-person variability in serum 25(OH)D, physical activity 
with LLM. However, it is possible that serum 25(OH)D and physical activity have a 
systemic effect on muscle mass and function. Unlike LLM, we found no evidence for 
an association of between-person (β= –0.04, 95% CI: 0.10, 0.02) and within-person 
(β=0.01, 95% CI: –0.02, 0.04) increase in physical activity and ALM, potentially due 
to the large role the lower-limbs play in mobility. Furthermore, we found no 
association between within-person (β=0.0002; 95% CI: –0.004, 0.004) and between-
person increase in 25(OH)D (β=–0.004, 95% CI: –0.01, 0.01) and ALM. The reason 
for this observation is unclear but it is consistent with studies showing evidence for an 
association between vitamin D and specific muscle groups [218]. 
In conclusion, our findings demonstrate that both between-person and within-person 
fluctuations in 25(OH)D, pain and dysfunction and physical activity were associated 
with muscle changes. The finding that within-person variation in physical activity 
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levels were associated with within-person variation in muscle mass, strength and 
quality is reassuring and it adds a new perspective to public health efforts aimed at 
promoting physical activity in older people. It shows that increasing one’s own 
ambulatory physical activity further increases muscle mass, strength and quality. 
Chapter 4 – Longitudinal Associations of Serum 25-hydroxyvitamin-D, Physical Activity, and Knee Pain and Dysfunction with Muscle Loss 
94 
 
 
Table 4.3 (supplementary Table): Association of between-person† and within-person‡ variability in serum 25-hydroxyvitamin D, knee pain and 
dysfunction with lower-limb lean mass, lower-limb muscle strength and muscle quality (N=1033) 
     Lower-limb lean mass, Kg  Lower-limb muscle strength, Kg  Lower-limb muscle quality, Kg/Kg  
Predictor variables Between-person effect      Within-person effect      Between-person effect Within-person effect Between-person effect Within-person effect 
 β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) β (95% CI) 
WOMAC global score 0.001 (–0.002, 0.003) 0.001(–0.001, 0.004)  –0.20 (–0.28, –0.12) –0.08 (–0.15, –0.01) –0.02 (–0.02, –0.01) –0.004 (–0.01, 
0.00002) 
PA (per 1000 steps/day)  0.04 (0.02, 0.06)  0.02(0.002, 0.04)     0.99 (0.35, 1.63)     0.50 (–0.04, 1.05) 0.07 (0.04, 0.11) 0.04 (0.002, 0.07) 
WOMAC sub-scales       
Knee pain  0.004 (–0.01, 0.01) 0.01(–0.01, 0.02)  –0.83 (–1.19, –0.47) –0.13 (–0.42, 0.15) –0.08 (–0.10, –0.06) –0.01 (–0.03, 0.01) 
PA (per 1000 steps/day)  0.04 (0.02, 0.05)  0.02(0.002, 0.04)     1.07 (0.43, 1.71)     0.53 (–0.01, 1.07) 0.08 (0.04, 0.12) 0.04 (0.003, 0.07) 
Knee stiffness 0.01 (–0.01, 0.04) 0.01(–0.02, 0.03)  –1.84 (–2.65, –1.03)   –0.17 (–0.80, 0.46) –0.19 (–0.24, –0.14) –0.01 (–0.05, 0.03) 
PA (per 1000 steps/day)  0.04 (0.02, 0.06)  0.02(0.001, 0.04)     1.07 (0.44, 1.71)     0.54 (–0.003, 1.08) 0.08 (0.04, 0.12) 0.04 (0.003, 0.07) 
Knee dysfunction 0.001 (–0.002, 0.004) 0.001(–0.002, 0.005)  –0.28 (–0.39, –0.17)  –0.13 (–0.23, –0.04) –0.03 (–0.03, –0.02) –0.01 (–0.01, –0.001) 
PA (per 1000 steps/day)  0.04 (0.02, 0.06)  0.02(0.003, 0.05)     0.98 (0.34, 1.62)     0.50 (–0.05, 1.04) 0.07 (0.03, 0.11) 0.04 (0.001, 0.07) 
Serum 25(OH)D(nmol/L) 0.005 (0.002, 0.01) 0.00001(–0.004, 0.004)     0.13 (0.02, 0.25)    0.10 (–0.02, 0.21) 0.01 (0.003, 0.02) 0.01 (–0.001, 0.01) 
PA (per 1000 steps/day)  0.03 (0.01, 0.05)  0.02(–0.002, 0.05)     1.08 (0.41, 1.75)     0.42 (–0.27, 1.11) 0.09 (0.05, 0.12) 0.03 (–0.01, 0.07) 
Data in bold indicate statistical significance at P < 0.05 
Models are adjusted for age, sex, number of chronic conditions (diabetes, rheumatoid arthritis, cardiovascular disease (hypertension, bronchitis/emphysema, or 
heart attack)), employment status (currently employed vs not currently employed), smoking status, linear time and quadratic time. 
†Beta-coefficients expressed as change in 10-year average of the outcome variable per 1 unit increase in the 10-year average predictor variable (25(OH)D, 
WOMAC and PA). ‡Beta-coefficients expressed as change in outcome variable per 1 unit deviation from the participant’s 10-year mean predictor score 
(25(OH)D, WOMAC and PA) 
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5.1 Abstract 
Purpose: To compare the performance of low muscle mass and function with falls 
risk, incident fracture and mortality over 10 years. 
Methods: 1041 participants (50% women; mean age 63±7.5 years) were 
prospectively followed for 10 years. Falls risk was measured using the Physiological 
Profile Assessment, fractures were self-reported and mortality was ascertained from 
the death registry. Appendicular lean mass (ALM) was assessed using dual energy X-
ray absorptiometry. Four anthropometric: (ALM/height2, ALM/body mass index, 
ALM/weight×100, a residuals method of ALM on height and total body fat) and four 
performance-based measures: (handgrip strength, lower-limb muscle strength, upper 
and lower-limb muscle quality) were examined. Participants in the lowest 20% of the 
sex-specific distribution for each anthropometric and performance-based measure 
were classified has having low muscle mass or function. Regression analyses were 
used to estimate associations between each anthropometric and performance-based 
measure at baseline and 10-year falls risk, incident fractures and mortality.  
Results: Mean falls risk z-score at 10 years was 0.64 (SD 1.12), incident fractures 
and mortality over 10 years were 16% and 14% respectively. All baseline 
performance-based measures were significantly associated with higher falls risk score 
at 10 years. Low handgrip (RR 1.55, 95% CI: 1.09, 2.20) and ALM/body mass index 
(RR 1.54, 95% CI: 1.14, 2.08) were the only significant predictors of fracture and 
mortality respectively.  
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Conclusions: Low handgrip strength, a simple and inexpensive test could be 
considered in clinical settings for identifying future falls and fractures. ALM/ body 
mass index could be most suitable in estimating 10-year mortality risk, but requires 
specialised equipment. 
5.2 Introduction 
Ageing is associated with changes in body composition including a decline in muscle 
mass and function [57]. These changes are associated with an increased risk of falls 
[219], fracture [28, 220], reduced quality of life and death in older people [64]. Age-
related decline in muscle strength has been directly attributed to loss of muscle mass 
[221]. However, recent evidence suggests that age-associated decline in muscle mass 
and strength occur at different rates and muscle mass may account for as little as 5% 
of the decrease in muscle strength [61]. Besides, maintaining or improving muscle 
mass does not prevent age-related decline in muscle strength [57]. Given these 
potential differences, variations may also exist in the associations between low 
muscle mass and strength and long-term health outcomes among older people. For 
example, low muscle strength, but not muscle mass, has been shown to be associated 
with poor mobility, physical disability [63] and mortality over 6 years [64]. However, 
few long-term prospective studies have compared the association of muscle mass, 
strength and muscle quality in predicting health outcomes such as falls, fracture and 
mortality in community-dwelling older people. Finding the most valid predictor of 
important clinical endpoints such as falls risk and fracture is crucial in identifying 
older people at risk. Furthermore, it could also help in the design of intervention 
trials.  
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This prospective study aims to describe the association of low muscle mass and 
function with falls risk, incident fracture and all-cause mortality over 10 years in 
community-dwelling older adults. We hypothesized that low muscle function may be 
more relevant in predicting 10-year falls risk, incident fracture and all-cause 
mortality.  
5.3 Data and Methods  
5.3.1 Sample and Study Setting  
The Tasmanian Older Adult Cohort (TASOAC) study is a prospective, population-
based study primarily aimed at examining the causes and progression of osteoarthritis. 
Participants aged 50 years and above were selected using a sex-stratified random 
sampling technique from the electoral roll in Southern Tasmania (population 
229,000). A total of 1099 adults (response rate = 57%) consented to participate in the 
study. Participants were excluded if they had any implants that would prevent them 
from undergoing an MRI or they were living in a nursing home. Participants who 
consented to participate in the study were invited to attend a clinic at the Menzies 
Institute for Medical Research, Hobart, Tasmania between March 2002 and 
September, 2004. They were invited for follow–up clinic assessments at 2.5, 5, and 10 
years after the initial clinic assessment. The study was approved by the Tasmanian 
Health and Medical Research Ethics Committee and written informed consent was 
obtained from all participants. 
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5.4 Outcome measures 
5.4.1 10 year falls risk 
Falls risk at 10 years was assessed using the short form Physiological Profile 
Assessment (PPA) (Prince of Wales Medical Research Institute, Sydney, Australia), a 
valid and reliable tool used to identify individuals who are at risk of falls [186]. The 
PPA assesses five physiological domains (visual contrast sensitivity, reaction time, 
knee extension strength, proprioception and postural sway on foam) and a 
standardized falls risk score is calculated for each individual using these five 
domains.  
5.4.2 Fracture  
At each study visit participants were asked to list, by location, any fractures they had 
since their previous visit. Those who experienced at least one fracture between the 
baseline and 10-year follow-up assessment were coded as ‘1’ (incident fracture.) and 
those without any fracture were coded ‘0’ (no incident fracture).  
5.4.3 Mortality 
Mortality over 10 years was ascertained through national and state death registries. 
Data on mortality was collected until August 2015. 
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5.5 Baseline measures  
5.5.1 Muscle strength measures  
Lower-limb muscle strength (kg) was measured simultaneously for both limbs using a 
dynamometer (TTM Muscular Meter, Tokyo, Japan). Participants stood on the back 
of a dynamometer platform with their backs against a wall and knee flexed to 115°. A 
bar was attached to the dynamometer, and participants were instructed to lift the bar 
using their lower-limbs only to maximum contractile force, whilst maintaining proper 
head and neck posture. This test assessed the isometric strength of the whole lower-
limbs, but predominantly of the quadriceps and hip extensors. Two trials were 
recorded, with the mean score taken as the criterion value for lower-limbs muscle 
strength [185]. The intra-class correlation coefficient (ICC) for the first and second 
trial was 0.95 (95% CI: 0.94–0.96). Handgrip strength (psi) was measured using a 
pneumatic handheld bulb dynamometer (North CoastTM bulb dynamometer; adult 0-
30 psi, model no. 70154). Participants were required to grip the bulb and squeeze as 
hard as possible. Two trials were recorded for the right and left hand and the mean of 
grip strength both hands was calculated. 
5.5.2 Body composition 
Body composition was measured using dual energy X-ray absorptiometry (DXA; 
Hologic Delphi, Hologic, Waltham USA). Appendicular lean mass (ALM), in 
kilograms, was calculated as the sum of lean mass in the upper and lower limbs. 
Weight (kg) was measured using electronic scales (Heine, Dover, USA). Height (cm) 
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was measured using the Leicester stadiometer (Invicta, Leicester, UK). Body mass 
index was calculated as weight (kg) divided by height (m) squared.    
5.5.3 Measures of low muscle mass and function  
Four measures of low muscle mass (anthropometric measures) and four measures of 
low muscle function (performance-based measures) were considered. Anthropometric 
measures were ALM/height2 (ALMHHLOW) [28], ALM /body mass index [BMI] 
(ALMBMILOW) [41], ALM/weight multiplied by 100 (ALMLOW) [44] and the 
residuals of the linear regression of ALM on height and DXA derived total body fat 
(ALMRLOW) [36]. Performance-based measures were handgrip strength (HGSLOW), 
lower-limb muscle strength (LMSLOW) [64] , upper-limb muscle quality (UMQLOW), 
and lower-limb muscle quality (LMQLOW). UMQLOW was defined as handgrip 
strength divided by the sum of lean mass in the right and left upper limb and 
LMQLOW was defined as lower limb muscle strength divided by the sum of lean mass 
in the left and right lower limb [63]. Participants in the lowest 20% of the sex-specific 
distribution for each anthropometric or performance-based measure were classified as 
having low muscle mass or function [36, 63].  
5.6 Data analysis 
Linear regression analyses with adjustment for age at baseline were used to estimate 
the association of low muscle mass and function with 10-year falls risk. Poisson 
regression was used to estimate incident rate ratios for fracture and mortality over 10 
years. Statistical interaction between sex and each measure of muscle mass and 
Chapter 5 – Prospective Associations of Low Muscle Mass and Function with 10-year 
Falls Risk, Incident Fracture and Mortality 
102 
 
function was assessed by a test of significance of a product term. Data was analysed 
using Stata version 12. 
5.7 Results 
One thousand and ninety-nine participants attended the baseline clinics. Of these, 
1041 (63 ± 7.5 years; 50% female) completed all anthropometric and muscle function 
assessments and were included in our analyses. From baseline to 10-year clinic 
assessments, 489 (47%) participants were lost to follow-up. Compared to participants 
retained at the 10-year follow-up assessment, participants lost to follow-up were older 
(64.5±8.0 [range: 51 – 80.9 years] vs. 61.4±6.6 [range: 51.1 – 79.9 years], P<0.001), 
had greater number of chronic conditions (1.7±1.5 vs. 1.2±1.2, P<0.001), poorer 
baseline ALM (24.1±5.3 vs. 24.9±5.3, P=0.025), HGS (11.7±3.0 vs. 12.4±3.0, 
P<0.001) and LMS (87.8±45.0 vs. 96.8±50.5, P=0.003) than those who completed 
the 10 year follow-up, but no sex differences were observed (P= 0.586). Baseline 
characteristics of the participants are shown in Table 5.1. The mean age of the 
participants at baseline was 63±7.5 (range: 51 – 81 years) and the mean fall risk score 
was 0.16 ± 0.82, indicating a mild increase in risk of falls. At 10 year follow-up 
assessment, the mean age was 72.1±6.4 (range: 61.9 – 81.9 years) and 52% were 
female. The prevalence of low muscle mass or function is shown in  Table 5.2. In 
men, the prevalence ranged from 8% to 19%, 17% to 23%, and 23% to 46% in 50-59 
year olds, 60-69 year olds and those aged 70 years and above age, respectively. In 
women, the prevalence ranged from 13% to 23% in 50-59 year olds, 16% to 21% in 
60-69 year olds and from 15% to 44% in those aged 70 years and above.  Table 5.3 
shows the associations between each anthropometric and performance-based 
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measures assessed at baseline and 10-year falls risk scores, fracture incidence and 
mortality over 10 years.  
5.7.1 Falls risk  
The mean falls risk score at 10 year follow up assessment was 0.64 ± 1.12. There was 
evidence for positive associations between each of the four performance-based 
measures at baseline and falls risk score at 10 years. The strongest association was 
found between baseline LMSLOW and 10-year falls risk score (β=0.60, 95% CI: 0.39-
0.81, P<0.001). No associations were found for anthropometric measures, or for any 
interaction between sex and each measures of muscle mass or function. 
5.7.2 Fracture  
The incidence of fracture over 10 years was 16.8% (n =147). Evidence for an 
increased risk of 10-year fracture incidence was found only for HGSLOW. The risk of 
10-year fracture incidence associated with HGSLOW was modified by sex (P=0.091): 
where the association was stronger for women (RR 1.63 95% CI: 1.09-2.42, P=0.017) 
than men (RR 1.46 95% CI: 0.78-2.71, P=0.234). 
5.7.3 Mortality  
Over the follow-up period, 14% of the participants (94 men and 51 women) died. 
Increased risk of 10-year mortality was associated with ALMBMILOW (RR 1.52 95% 
CI: 1.13 - 2.06, P=0.006). There was no evidence for an association with any other 
measures of muscle mass or function or for an interaction between sex and other 
measures of muscle mass or function. 
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Table 5.1: Baseline characteristics of participants in the Tasmanian Older Adult 
Cohort (TASOAC) study (N=1041) 
 
 
 
 
Variables Mean SD 
Age (years) (range: 51 – 81)                     63.0 7.5 
Female, n (%) 525 50.4 
Height (cm) (range: 141 – 192)                    167.1 9.0 
Weight (kg) (range: 41.6 – 119.6)                      77.8 14.6 
 BMI (kg/m2) (range: 17.8 – 52.9)                    27.8 4.6 
BMI category   
   Underweight/Normal, n (%)  319 29.0 
   Overweight, n (%) 477 43.4 
   Obese, n (%) 303 27.6 
Appendicular lean mass (kg) (range: 14.7 – 39.2)        24.5 5.3 
Total body fat (%) (range: 4.4 – 54.5)                33.8 8.0 
Handgrip strength (psi†) (range: 3.9 –24.3 )            12.1 3.0 
Lower-limb muscle strength (kg) (range: 7– 256.5)                 92.5 49.1 
Falls risk z-score, (range: -2.3– 3.6)                 0.17 0.82 
Total hip BMD (g/cm2) (0.97 – 1.70)          0.97 0.15 
Values are mean (SD) unless stated otherwise 
†psi: pounds per square inch, BMD bone mineral density, SD standard deviation 
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 Table 5.2: Prevalence of low muscle mass and function at baseline stratified by sex and age (N = 1041) 
 Men  Women 
Low muscle mass / 
function 
50-59 years 
(n=204) 
60-69 years 
(n=200) 
≥70 years 
(n=112)  
50-59 years 
(n=252) 
60-69 years 
(n=173) 
≥ 70 years 
(n=100) 
 
   
N (%)    N %    N %     n %    n %    n % 
Performance-based measures 
LMQLOW    25 (12)   46 (23)   33 (30)    40 (16)    32 (19)   34 (34) 
UMQLOW    26 (12)   39 (19)   42 (36)    45 (17)    30 (16)   37 (34) 
LMSLOW     16 (8)   41 (20)   55 (46)    34 (13)    33 (17)   48 (44) 
HGSLOW    25 (12)   42 (21)   37 (33)    39 (16)    31 (18)   37 (37) 
Anthropometric measures  
ALMHHLOW    25 (12)   43 (21)   39 (33)    50 (19)    39 (21)   23 (21) 
ALMBMILOW    39 (19)   38 (19)   30 (25)    51 (20)    36 (19)   25 (23) 
ALMWLOW    34 (16)   35 (17)   38 (32)    36 (14)    38 (20)   38 (34) 
ALMRLOW    35 (17)   45 (22)   27 (23)    59 (23)    36 (19)   17 (15) 
UMQ: upper-limb muscle quality (kg/kg) LMQ: lower-limb muscle quality; (kg/kg) LMS: lower-limb muscle strength (kg) HGS: 
handgrip strength (psi) ALMHH: appendicular lean mass (ALM)/height2 (kg/m2),) ALMBMI: low ALM/body mass index(kg/ kg/m2) 
ALMW: ALM / weight * 100 (kg/kg) ALMR: residual of ALM on height and total body fats (kg)   
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 Table 5.3: Associations between low muscle mass and function at baseline and falls risk at 10-year, incident fractures and mortality 
over 10 years 
Low muscle mass/ 
function 
Cut-point for low muscle 
mass and function* 
Falls risk z-score Fracture Mortality 
(n=551) (n=841) (n=1041) 
Male Female  β (95% CI)  RR (95% CI)  RR (95% CI) 
Performance-based measures 
LMQLOW 3.85 1.85 0.41 (0.19, 0.62) 0.95 (0.63, 1.43) 1.21 (0.89, 1.64) 
UMQLOW 1.08 1.15 0.29 (0.07, 0.51) 1.13 (0.78, 1.65) 0.82 (0.59, 1.14) 
LMSLOW 69.18 26.40 0.60 (0.39, 0.81) 0.93 (0.62, 1.40) 1.03 (0.75, 1.42) 
HGSLOW 10.68 7.54 0.50 (0.27, 0.73) 1.55 (1.09, 2.20) 0.82 (0.60, 1.12) 
Anthropometric measures 
ALMHHLOW 8.32 6.64 0.03 (–0.19, 0.25) 0.94 (0.63, 1.41) 1.17 (0.85, 1.66) 
ALMBMILOW 0.88 0.60 0.08 (–0.15, 0.32) 1.01 (0.67, 1.53) 1.54 (1.14, 2.08) 
ALMWLOW 29.96 24.36 0.13 (–0.10, 0.35) 1.13 (0.77, 1.67) 1.25 (0.91, 1.72) 
ALMRLOW –0.87 –1.82 0.13 (–0.80, 0.34) 1.07 (0.73, 1.57) 1.04 (0.73, 1.48) 
*: lowest 20%, Data in bold indicate statistical significance at p<0.05, All analyses are adjusted for age.  
 UMQ: upper-limb muscle quality (kg/kg) LMQ: lower-limb muscle quality; (kg/kg) LMS: lower-limb muscle strength (kg) HGS: handgrip 
strength (psi) ALMHH: appendicular lean mass (ALM)/height2 (kg/m2),) ALMBMI: low ALM/body mass index(kg/ kg/m2) ALMW: ALM / 
weight * 100 (kg/kg) ALMR: residual of ALM on height and total body fats (kg)   
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5.8 Discussion  
This is the first prospective study, to our knowledge, investigating the association 
between multiple measures of muscle mass and function and falls risk, incident 
fracture and mortality over 10 years in a large sample of community-dwelling older 
adults. We found that all performance-based measures at baseline were associated 
with increased falls risk score at 10 years, but only HGSLOW and ALMBMILOW were 
predictive of 10-year fracture incidence and mortality respectively. Importantly, 
HGSLOW was consistently associated with an increase in falls risk and fracture over 10 
years. This finding demonstrates that low handgrip strength alone, a simple and 
inexpensive procedure, could be considered in clinical settings as a useful screening 
tool for identifying older adults at risk of falls and fracture. Low muscle mass defined 
according to ALM adjusted for BMI could be most suitable in estimating 10-year 
mortality risk in older people, but requires access to specialised equipment. 
 
Increased falls risk score at 10-years was associated with muscle function but not 
muscle mass. These results are consistent with previous studies [219, 222] and 
confirm the importance of muscle strength even a decade earlier for predicting falls-
risk. Prior studies have also showed that absolute decline in muscle strength and 
quality, but not muscle mass, are associated with functional limitations and disability 
– risk factor for falls [63]. Muscle strength decreases at a faster rate than muscle mass 
[61]. Even when muscle mass appears preserved, there is evidence of a decline in 
muscle strength [65], which may be attributable to age-related changes in 
neuromuscular contributors to strength including decreased motor unit recruitment 
and increased fatty infiltration of muscle. This rapid age-associated decline in strength 
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may lead to functional limitations at an earlier stage than mass potentially explaining 
why performance-based measures are superior to anthropometric measures in 
identifying older adult with higher falls risk over 10 years. 
HGSLOW was the only measure that provided evidence for an association with 10-year 
fracture incidence, and this is consistent with a prior study [135]. Women had a 
higher prevalence of fracture (21% vs. 11.8% in men) potentially due to higher 
prevalence of osteoporosis. Therefore, the stronger associations in women could be 
explained by low muscle strength and low bone density in women leading to falls 
related fractures. Contrary to our findings, previous studies have established an 
association between ALMHHLOW and fracture [223-225]. However, these studies 
were cross-sectional and were conducted among older people admitted to a clinic 
facility [223-225]. The strongest mechanical loads applied to bones are created by 
muscle contraction [220]. Hence, low handgrip strength, a reflection of global muscle 
weakness of the body [135], could be a better indicator of 10-year fracture risk than 
other measures of low muscle mass or function. Interestingly, despite strong 
correlation (r= 0.77, P < 0.001) between handgrip strength and lower-limb muscle 
strength in our sample, LMSLOW was not significantly associated with fracture over 
10 years. The reason for this observation is not clear.  
ALMBMILOW was the only measure that provided evidence for an association with 
mortality. Several studies have reported associations between a decline in muscle 
strength and mortality [43, 64, 226], but conflicting evidence for a decline in muscle 
mass, with some studies reporting an association [227] and others no association with 
mortality [64]. Lean muscle mass alone may not be predictive of health outcomes, but 
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a combination with other anthropometric indices such as BMI may increase 
sensitivity. BMI is an established risk factor for diseases including cardiovascular 
disease, cancer, stroke, and is in itself a strong predictor of all-cause mortality [228]. 
Low BMI is also a strong determinant of transition to sarcopenia [71]. It is possible 
that low muscle mass defined by combining ALM and BMI was the strongest 
predictor of mortality because BMI conferred additional risk besides consequences of 
decline in ALM. Furthermore, low ALM relative to BMI is an indication of high body 
fat percentage [42], hence, the effect of ALMBMILOW on mortality may potentially be 
related to obesity rather than sarcopenia. 
HGSLOW was the most consistent predictor, being associated with both falls risk and 
fracture. The predictive validity of handgrip strength as an important marker of health 
in older people has previously been established [229]. The mechanisms underlying 
why this is the case is not entirely certain [229]. Low handgrip strength is potentially 
a result of chronic conditions such as osteoarthritis, frailty or diabetic neuropathy 
which are causal risk factors for functional limitation [229]. However, recent findings 
from a sample of over 130, 000 adults from the Prospective Urban Rural 
Epidemiology study showed that the association between handgrip strength and 
cardiovascular diseases, cardiovascular death and all-cause mortality was independent 
of hypertension, diabetes, prior stroke and other co-morbidities [230]. This suggests 
that the mechanism may be independent of chronic health conditions, or alternatively 
may represent sub-clinical disease and/or, lower levels of social, physical or 
occupational activity, which increase the risk of clinical disease and disability. 
Further clinical studies incorporating genetics and environmental factors are 
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warranted to explore why handgrip strength is such a powerful marker of health 
outcomes [231]. 
This study has a number of strengths including the 10-year follow-up period, 
measurement of multiple measures of muscle mass and function and the use of a 
population-based sample increasing generalizability. A major step in designing an 
effective intervention is identifying individuals at risk. This prospective population-
based study provides evidence for the most appropriate measures of muscle mass and 
function to identify older people with higher 10-year falls risk, fracture and mortality. 
However, this study also has a number of limitations. Firstly, there was 19.2% and 
47% missing data for incident fracture and falls risk score respectively. This is a 
major limitation that could lead to bias in our results. Such missing data is not 
unexpected in a long-term prospective study involving older people. We performed 
sensitivity analysis for missing data using multiple imputations to assess the 
robustness of the falls risk and fracture models assuming the data are missing at 
random. The results of the analyses were similar to the complete case analyses ( Table 
5.4). Secondly, the incidence of fracture was self-reported and may be subject to 
recall bias. However, fractures are a major life event and inaccuracy of recall is 
unlikely [232]. Thirdly, data on the specific cause of death was not available for all 
the participants, hence, we were unable to perform cause-specific analysis for 
mortality. Fourthly, grip strength was measured using a pneumatic bulb dynamometer 
rather than a hydraulic dynamometers (e.g. Jamar), hence cut-points for increased risk 
of falls and fracture observed in this study may be different for assessments using 
hydraulic dynamometers. However, previous studies have found high reliability 
between the two methods [233]. Fifthly, physiological assessment of falls risk rather 
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than prospective data on actual falls was used in this study and therefore we cannot be 
certain whether our findings on associations with falls risk score are representative of 
incident falls. Nevertheless, the physiological approach to the assessment of falls risk 
used in the study is not subjected to recall bias [234] and the PPA has been shown to 
have 75% accuracy in predicting multiple falls among older people [187]. On 
average, our sample was young and overweight. The prevalence of fracture and 
mortality may have been higher in an ‘older’ and less overweight population. Lastly, 
we did not use definitions established for sarcopenia due to our middle-aged and 
relatively healthy older adult population. For example, previously established cut-
points for ALHMHHLOW
 and ALMBMILOW, proposed by Baumgartner et al [28] and 
the Foundation for National Institute of Health (FNIH) sarcopenia project would have 
only classified 4 (men=4; women=0) and 12 (men=10; women=2) participants 
respectively as having sarcopenia. In contrast we defined cut-points in the lowest 20% 
of the sex-specific distribution of each anthropometric and performance-based 
measure which has previously been used as a diagnostic measure for sarcopenia [36, 
63]. Despite this we still found important associations using this method. 
In conclusion, findings from this study suggest that low muscle function defined 
according to low handgrip strength is associated with increased falls risk and 
incidence of fracture over 10 years. Diagnostic criteria of low muscle mass and 
function relevant to clinical settings should be readily available, low cost and 
predictive of future health outcomes [235]. In this respect, defining low muscle 
function according to low handgrip strength appears to be a promising approach in 
identifying older people with higher falls and fracture risk over 10 years. Low muscle 
mass defined according to ALM adjusted for BMI could be most suitable in 
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estimating 10-year mortality risk in older people, but requires access to specialised 
equipment. 
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5.9 Appendix 1: Multiple imputations to account for missing data 
At the 10-year clinic assessments, 489 (47%) participants were lost to follow-up. 
Compared to participants retained at the 10-year follow-up assessment, participants 
lost to follow-up were older (P < 0.001), had more morbidity (P < 0.001), and higher 
baseline falls risk score (P < 0.001). Multiple imputations by chained equation was 
used in the estimation of missing data. Using the known participants’ characteristics 
multiple imputations replaces missing values with plausible values in a way that 
minimises bias, and helps preserve the sample size [236]. The ability to perform 
analysis on multiple imputed datasets helps to minimise bias in the parameter 
estimates. Both the outcomes (excluding mortality) and exposure variables used for 
analyses in this paper were included in the multiple imputation models. Other 
variables such as co-morbidity, physical activity, knee pain and dysfunction which 
were not used in the substantive analysis were also included in the multiple 
imputation models. Although 3 to 5 imputations are considered adequate to obtain 
excellent results [237], higher numbers of imputations have been proposed by 
Graham et. al in order to prevent loss of statistical power [238]. As suggested by 
Horton and Lipsitz [239], we performed a number of imputations (5, 10, 20 and 50 
imputations) and we explored the results using different numbers of imputations. We 
found consistency in the parameter estimates and results using 50 imputations, as is 
presented in this paper.  
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 Table 5.4: (supplementary Table) Associations between low muscle mass and function at baseline and falls risk at 10-year, incident 
fractures and mortality over 10 years (imputed data) 
 
Cut-point for low muscle mass and 
function* 
Falls risk z-score Fracture 
Low muscle mass/ function  (n=1041) (n=1041) 
 Male Female  β (95% CI)  RR (95% CI) 
Performance-based definitions 
LMQLOW 3.85 1.85 0.44 (0.23, 0.65) 0.90 (0.54, 1.48) 
UMQLOW 1.08 1.15 0.33 (0.13, 0.53) 1.16 (0.73, 1.86) 
LMSLOW 69.18 26.40 0.64 (0.44, 0.83) 0.82 (0.50, 1.38) 
HGSLOW 10.68 7.54 0.44 (0.23, 0.66) 1.72 (1.08, 2.71) 
Anthropometric definitions 
ALMHHLOW 8.32 6.64 0.02 (-0.19, 0.23) 0.91 (0.53, 1.55) 
ALMBMILOW 0.88 0.60 0.19 (-0.03, 0.41) 1.12 (0.68, 1.84) 
ALMWLOW 29.96 24.36 0.08 (-0.15, 0.32) 1.28 (0.80, 2.05) 
ALMRLOW – 0.87 – 1.82 0.07 (-0.14, 0.28) 1.08 (0.67, 1.75) 
*Lowest 20%, Data in bold indicate statistical significance at p < 0.05, All analyses are adjusted for age. 
 UMQ: upper-limb muscle quality (kg/kg) LMQ: leg muscle quality; (kg/kg) LMS: leg muscle strength (kg) HGS: handgrip strength 
(psi) ALMHH: appendicular lean mass (ALM)/height2 (kg/m2),) ALMBMI: low ALM/body mass index(kg/ kg/m2) ALMW: ALM / 
weight * 100 (kg/kg) ALMR: residual of ALM on height and total body fats (kg)   
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6.1 Abstract 
Aims: To describe the longitudinal associations between physiological falls risk, and 
between-person and within-person variability in 25-hydroxyvitamin D (25OHD), 
physical activity (PA), knee pain and dysfunction in community-dwelling older 
people. 
Methods: Data for 1053 participants (51% women; mean age 63±7.4 years) studied 
at baseline, 2.5, 5, and 10 years were analysed. Falls risk (Z-score) was measured 
using the Physiological Profile Assessment. Knee pain and dysfunction were assessed 
using the Western Ontario and McMaster Universities Osteoarthritis index 
(WOMAC). Moderate-to-vigorous PA (MVPA) was measured using accelerometer. 
Linear mixed-effect regression models, with adjustment for confounders, were used to 
estimate the association between physiological falls risk and between-person and 
within-person variability in PA, 25OHD and WOMAC score.  
Results: Between-person effects showed that 10-year average physiological falls risk 
was lower in participants who had a higher 10-year average 25OHD (β= -0.005 per 
nmol/l, 95% CI: -0.008, -0.002), log-MVPA (β= -0.16 per minute, 95% CI: -0.22, -
0.10) and lower mean WOMAC score (β=0.005 per-unit score, 95% CI: 0.003, 0.01). 
Within-person effects showed that a higher physiological falls risk at any time-point 
was associated with higher than average WOMAC score (β=0.002 per-unit score, 
95% CI: 0.0003, 0.004) and lower than average log-MVPA (β= -0.15 per minute, 
95% CI: -0.24, -0.06), but not 25OHD, at the same time-point. 
Conclusion: Having knee pain and dysfunction above an individual’s average 
increases the risk of falling, whereas, increasing one’s own MVPA level further 
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reduces their risk of falling. The presence of between-person but not within-person 
associations for 25OHD suggests the former may be confounded by other factors.  
6.2 Introduction 
Falls among older people are a leading cause of injury-related hospitalization, and 
account for a substantial amount of preventable healthcare costs [240, 241]. 
Therefore, reducing falls risk in older people is an important public health concern. 
Numerous studies have been conducted on falls and their associated risk factors. 
These studies identified low physical activity levels [145, 242], high knee pain and 
dysfunction [72, 243], and low serum 25-hydroxyvitamin D (25(OH)D) [149, 244, 
245]. However, there is controversy on whether 25(OH)D supplementation reduces 
falls in community-dwelling older people [152].  
 
Traditionally, analysis has focused on examining how risk factors for falls differ 
between individuals (between-person comparison). As a result, public health efforts 
have been informed by findings from between-person comparisons but less well 
recognized is how variability in physical activity, 25(OH)D, knee pain and dysfunction 
over time within the same individual (within-person comparison) is associated with 
falls risk. Examining both the between-person and within-person effects is important 
as the inferences we make from the between-person effects (for example the 
magnitude and direction of effects) may not align with those we would make from the 
within-person effects [73]. Besides, neither can be inferred from the other [205]. 
Statistical methods, such as multilevel models that properly capture the within-person 
processes can be used to tell us whether changes within an individual over time relate 
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to changes in physiological falls risk in that same individual [193]. To our knowledge, 
there are no published studies that have described the association of within-person 
variability in physical activity, 25(OH)D, knee pain and dysfunction with physiological 
falls risk in community-dwelling older people. Therefore, the aim of this study was to 
describe the association between physiological falls risk and between-person and 
within-person variability in physical activity, 25(OH)D, knee pain and dysfunction 
over 10 years in community-dwelling older people. 
6.3 Data and Methods 
6.3.1 Study population 
The Tasmanian Older Adult Cohort (TASOAC) study is a prospective, population-
based study primarily aimed at examining the causes and progression of osteoarthritis. 
Participants aged 50 years and older were selected using sex-stratified random 
sampling from the electoral roll in Southern Tasmania (population 229,000). A total 
of 1099 adults (response rate=57%) consented to participate. Participants were 
excluded if they had any implants that would prevent them from undergoing an MRI 
or they were living in a nursing home. Participants who consented were invited to 
attend a clinic at the Menzies Institute for Medical Research, Hobart, Tasmania 
between March 2002 and September 2004 and follow-up clinic assessments 2.5, 5, 
and 10 years later. The study was approved by the Southern Tasmanian Health and 
Medical Research Ethics Committee and written informed consent was obtained from 
all participants.   
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6.4 Outcome measure: Physiological falls risk score 
Physiological falls risk at baseline, 2.5, 5, and 10 years was assessed using the short 
form Physiological Profile Assessment (PPA) (Prince of Wales Medical Research 
Institute, Sydney, Australia), a valid and reliable tool used to identify individuals who 
are at risk of falls [186]. The PPA assesses five physiological domains (visual contrast 
sensitivity, reaction time, knee extension strength, proprioception and postural sway 
on foam) and a standardized falls risk score is calculated for each individual using 
these five domains.  
6.5 Predictor variables 
6.5.1 Physical activity 
Ambulatory physical activity was assessed at baseline, 2.5 and 5 years. Baseline 
assessment was measured over seven consecutive days using a pedometer (Omron 
HJ-003 & HJ-102; Omron Healthcare, Kyoto, Japan) worn on the waist band or belt 
above their dominant leg. Participants were given a diary in which to record the 
duration of pedometer use and daily step counts. At 2.5 years follow-up Yamax 
pedometers (Yamax SW-200; Yamax USA, San Antonio, TX, USA) were given to 
the majority (98%) of the participants. A strong linear correlation (r=0.88) was found 
between the estimates of the two types of pedometer, but the Omron brand recorded 
higher mean steps. Yamax pedometers were used by all participants at 5 years. 
Baseline and 2.5 years Omron estimates were multiplied by a correction factor of 0.91 
to provide comparability between mean estimates for Omron and Yamax pedometers 
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[191]. Beta coefficients in the regression models were scaled to 1000 steps per day for 
ease of interpretation. 
The intensity of physical activity was assessed in a subset of 637 participants using an 
accelerometer (ActiGraph GT1M). Participants were instructed to wear the 
accelerometer for 7 consecutive days, and were provided with a daily diary to record 
when the accelerometer was worn and when it was removed (for instance, during 
swimming or showering). Data were included in the analysis if the participants wore 
the accelerometer for 5 valid days or more; with a valid day being one in which the 
accelerometer was worn for at least 10 hours. Details about accelerometer data 
cleaning and the cut-points used for intensity (sedentary, light, moderate, and 
vigorous) have been described in detail previously [68]. Vigorous physical activity 
was combined with moderate physical activity because few older adults engaged in 
vigorous physical activity. Moderate-to-vigorous physical activity (MVPA) was log-
transformed as the variable was skewed to the right.  
6.5.2 Serum 25-hydroxyvitamin D 
Serum 25(OH)D was assessed at baseline, 2.5 and 10-year follow-up. Serum 
samples from blood drawn from the participants were treated initially with 
acetonitrile to rapidly extract vitamin-D and other hydroxylated metabolites. 
Thereafter serum 25(OH)D was assayed using a liquid-phase radioimmunoassay 
(Immunodiagnostics Systems Ltd), which detects both 25(OH)D2 and 25(OH)D3. 
The intra-assay and inter-assay coefficients of variations were 1.8% and 3.3% 
respectively. Participants had their baseline and follow-up interview at different 
seasons and as serum 25(OH)D is known to vary with seasons, we de-seasonalised 
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the 25(OH)D measurement as previously described [246] to account for differences 
in the time of the year that blood was taken. 
6.5.3 Knee pain, stiffness and functional limitation 
Knee pain, stiffness and functional limitation were assessed by self-administered 
questionnaire using the Western Ontario and McMaster Universities osteoarthritis 
index (WOMAC) at each study visit. WOMAC is a validated and widely used 
measure of symptoms and disability in patients with osteoarthritis [192]. The three 
WOMAC sub-scales: knee pain, stiffness and functional limitation were assessed 
separately with 5, 2 and 17 questions respectively.  
6.6 Potential confounders 
Age, sex, medical history, including a previous diagnosis of diabetes, rheumatoid 
arthritis, cardiovascular disease (hypertension, bronchitis/emphysema, or heart 
attack), as well as smoking history and level of education, was recorded using a 
questionnaire. Whole and regional body composition of the participants were 
measured using dual energy X-ray absorptiometry (DXA; Hologic Delphi, Hologic, 
Waltham USA). Appendicular lean mass and fat mass (sum of lean mass/fat mass in 
the upper-limbs and lower-limbs) were derived from the DXA scans.  
6.7 Data analysis 
Measurements for physical activity, 25(OH)D, and knee pain and dysfunction varied 
across occasions for individuals, and were modelled as time-varying predictors [193, 
194]. Time-varying predictors provide two sources of information in longitudinal 
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analysis; consequently, we decomposed each time-varying predictor into between-
person and within-person components. The between-person component of the time-
varying predictor is an individual’s average 25(OH)D, physical activity and WOMAC 
score across all measurement occasions. The within-person component is the 
deviation of an individual’s measurement at a particular phase of the study from his or 
her average score across all measurement occasions. As recommended, we first 
calculated intra-class correlation coefficients (ICCs) for each predictor variable to 
ensure there was sufficient variance to warrant decomposing the predictors into 
between-person and within-person effects [193, 198]. The ICC for each predictor 
variable was calculated using an intercept only model [193, 198]. When ICCs are 
below 0.05 models can result in biased estimates and convergence difficulties [198]. 
All ICC of our predictor variables (except for sedentary activity where the ICC was 
<0.001) were >0.3, suggesting substantial variability in each predictor variable 
permitting within-person analysis. Due to the low ICC for sedentary activity, we did 
not model within-person association for sedentary activity and physiological falls 
risk.  
Linear mixed-effect regression models were used to estimate the association between 
physiological falls risk and between-person and within-person variability in physical 
activity, 25(OH)D and WOMAC score. The models included a random intercept for 
individuals and a random coefficient for time to allow for differences in individual 
trajectories over time. Furthermore, an unstructured covariance matrix with serially 
correlated residuals was specified to allow for possible correlation between the 
random intercept and slope. The regression models were adjusted for age at baseline, 
sex, number of chronic conditions, education, smoking status, time to follow-up, 
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appendicular lean mass and fat mass. All models were estimated using the maximum 
likelihood method. Models were selected by comparing the fit of different random 
and fixed effects of simpler nested models against more complex models  using the 
likelihood ratio test and Akaike Information Criterion [199]. Because different 
metrics of time can result in different outcomes and interpretation of the results [247], 
we decided to use, a priori, follow-up time in the regression models with age at 
baseline since we are interested in modelling intra– and inter-individual variation in 
falls risk score for every additional year at which the participant entered into the 
study. Missing data were accommodated in the regression models by using maximum 
likelihood estimation which estimates means and intercept based on all available data. 
Data was analysed using Stata version 13 (StataCorp, TX, USA). 
6.8 Results 
A total of 1053 participants with complete 25(OH)D, WOMAC score and physical 
activity assessments at baseline were included in the analysis. Of these, 859(82%), 
757(72%) and 559(53%) respectively attended the 2.5, 5 and 10 years follow-up 
assessments. Participants were lost to follow-up because of reasons such as death, 
institutionalization, withdrawal of consent, joint replacement, and moving interstate 
or overseas. Participants lost to follow-up were older at baseline (64.7±8.0 vs. 
61.4±6.6 years, P<0.001), had a higher total WOMAC score (21.2±33.9 vs. 
13.5±24.6, P<0.001), lower level of pedometer-determined physical activity 
(7992±3352 vs. 9171±3261 steps/day, P<0.001), lower 25(OH)D (50.3±18.0 vs. 
54.4±19.1 nmol/L, P<0.001), higher baseline physiological falls risk score (median= 
0.21, interquartile range (IQR):  –0.25, 0.79 vs. median= –0.01, IQR: –0.52, 0.48; 
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P<0.001), greater number of chronic conditions (median=1, IQR: 1, 3 vs. median=1 
IQR: 0, 1, P<0.001) than those who completed the 10 year follow-up, but no sex 
difference was observed (P=0.473).    
Baseline characteristics of the participants stratified by the median 10-year average 
physiological fall risk score are shown in Table 6.1. Participants with a physiological 
falls risk score above the median value (i.e. higher risk of falls) were mostly women 
(55% vs. 45% in men, P=0.010) and were older (64.3±7.7 vs. 61.4±6.7, P<0.001), 
shorter (166.5±9.0 vs. 167.7±8.9, P=0.026), weighed less (76.7±15.0 vs. 78.9±14.6, 
P=0.020), had lower 25(OH)D (50.7±17.0 vs. 54.4±17.0, P<0.001) and lower level of 
physical activity (8246±3393 vs. 9075±3274, P<0.001). There was no difference in 
WOMAC scores between participants in the higher and lower median physiological 
falls risk score. The distribution of physiological falls risk score at each time-points is 
provided in Figure 6.1. 
6.8.1 Disaggregating within- and between-person effects 
The estimated between-person and within-person effects of the predictor variables on 
physiological falls risk score are shown in Table 6.2.  
6.8.1.1 Serum 25-hydroxyvitamin-D 
Participants with a higher 25(OH)D, on average, had a significantly lower mean 
physiological falls risk score (β= –0.005; 95% CI –0.008, –0.002). There was no 
evidence for a within-person 25(OH)D effect on physiological falls risks score 
(β=0.0001; 95% CI: -0.002, 0.003). However, when the analysis was stratified by 10-
year mean level of serum 25(OH)D (i.e. optimal [≥50nmol/L] vs. sub-optimal 
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[<50nmol/L]), within-person increase in 25(OH)D was associated with a lower 
physiological falls risk score in participants with insufficient 25(OH)D but not in 
those with sufficient 25(OH)D (P-value for interaction=0.025) (Figure 6.2).  
6.8.1.2 Knee pain and dysfunction 
Participants with a higher 10-year average WOMAC global score had a significantly 
higher 10-year mean physiological falls risk score (β=0.005; 95% CI: 0.003, 0.01) as 
did those with higher 10-year average WOMAC pain score (β=0.02; 95% CI 0.01, 
0.03), knee stiffness (β=0.04; 95% CI 0.02, 0.06), and functional limitation score 
(β=0.01; 95% CI 0.005, 0.01). Within-person increases in WOMAC global score 
(β=0.002; 95% CI 0.0003, 0.004), and functional limitation scores (β=0.003; 95% CI 
0.001, 0.01) were associated with occasion-specific increases in physiological falls 
risk score. There was no evidence for a within-person knee pain (β=0.005; 95% CI: –
0.003, 0.013) or knee stiffness effect (β=0.004; 95% CI: -0.01, 0.02).  
6.8.1.3 Physical activity 
Physiological falls risk score was lower in participants with a higher average 
pedometer-determined steps-per-day (β= –0.02; 95% CI: –0.04, –0.01), higher mean 
log-MVPA (β=-0.16; 95% CI: -0.22, -0.10) but not sedentary (β= 0.003; 95% CI:-
0.004, 0.010) or light physical activity (β= 0.02; 95% CI: -0.05, 0.09). Physiological 
falls risk was estimated to be lower for individuals when their log-MVPA (β= -0.15; 
95% CI: -0.24, -0.06) was higher than their average level of log-MVPA. There was no 
evidence of an association between within-person variability in light physical activity 
and pedometer-determined steps-per-day and physiological falls risk score. 
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Table 6.1: Baseline characteristics of participants in the Tasmanian Older Adult Cohort study, 
stratified by 10-year median§ physiological fall risk score (N= 1053) 
 < Median physiological 
falls risk score 
 ≥ Median physiological 
falls risk score 
 P-value 
Mean SD  Mean SD   
Age (years)                      61.4 6.7  64.3 7.7  <0.001 
Female, n (%)a 224 47  315 55  0.010 
Height (cm)                    167.7 8.9  166.5 9.0  0.026 
Weight (kg)                     78.9 14.6  76.7 15.0  0.020 
25-hydroxyvitamin D (nmol/L) 54.4 17.0  50.7 17.0  <0.001 
Appendicular lean mass, Kg 25.0 5.5  23.9 5.2  <0.001 
Physical activity (steps/day) 9075 3274  8246 3393  <0.001 
Appendicular fat mass, Kg 14.3 4.6  14.7 4.7  0.124 
Current smoker, n (%)a 224 47  315 55  <0.001 
Number of chronic conditions  1.2 1.2  1.7 1.5  <0.001 
Currently employed, n (%)a 229 55  189 45  <0.001 
WOMAC (0 – 216) 14.8 25.1  17.7 29.8  0.092 
     WOMAC sub-scales         
WOMAC knee pain (0 – 45)  3.4 5.6  3.8 6.5  0.236 
Knee stiffness (0 – 18)  1.6 2.5  1.7 2.8  0.533 
Functional limitation (0–153)      9.8 17.8  12.2 21.9  0.060 
§Median physiological falls risk score=0.04 
 a Expressed as percentages  
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Table 6.2: Linear mixed model estimates of between-person and within-person fixed 
effects for vitamin-D, physical activity (PA), knee pain and dysfunction and physiological 
falls risk score (N=1053) 
 †Between–person effects  ‡Within–person effects 
 β (95% CI)  β (95% CI) 
Vitamin-D (nmol/L) –0.005 (–0.008, –0.002)  0.0001 (–0.002, 0.003) 
    
WOMAC total score (unit) 0.005 (0.003, 0.01)  0.002 (0.0003, 0.004) 
WOMAC sub-scales     
WOMAC knee pain  0.02 (0.01, 0.03)  0.005 (–0.003, 0.013) 
Knee stiffness  0.04 (0.02, 0.06)  0.004 (–0.01, 0.02) 
Functional limitation      0.01 (0.005, 0.01)  0.003 (0.001, 0.01) 
    
PA (per 1000 steps/day)  –0.02 (–0.04, –0.01)  0.001 (–0.01, 0.02) 
Intensity of Physical activity (per minutes/day) (N=632) 
Sedentary activity  –0.0002 (–0.001, 0.0003)  – 
Light activity  0.002 (–0.005, 0.01)   –0.001 (–0.01, 0.01) 
Log moderate/vigorous activity –0.16 (–0.22, –0.10)  –0.15 (–0.24, –0.06) 
Data in bold indicate statistical significance at P<0.05 
Models are adjusted for age at baseline, sex, number of chronic conditions , employment 
status, appendicular lean mass, fat mass, time to follow-up and smoking status 
 
†: Beta-coefficients expressed as higher/lower 10-year mean physiological falls risk score 
per 1 unit increase in the 10-year average predictor variable. 
‡: Beta-coefficients expressed as higher/lower physiological falls risk score per 1 unit 
deviation from the participant’s 10-year mean predictor score. 
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Figure 6.1: Distribution of physiological falls risk score at each time-point 
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Figure 6.2: Within-person increase in serum 25OHD and falls risk score in 
older adults with sub-optimal 25OHD (<50 nmol/L) and optimal 25OHD 
(≥50nmol/L) 
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6.9 Discussion 
To our knowledge, this is the first prospective study to disaggregate within-person 
and between-person effects of serum 25(OH)D, physical activity, and knee pain and 
dysfunction on physiological falls risk in community-dwelling older adults. Between-
person differences in 25(OH)D, physical activity, and knee pain and dysfunction were 
associated with physiological falls risk score, such that, average physiological falls 
risk score was lower in participants who had a higher average 25(OH)D, physical 
activity and lower mean WOMAC score. Furthermore, within-person variability in 
WOMAC score was associated with physiological falls risk score, such that 
physiological falls risk was higher on occasions when WOMAC scores were also 
higher. This finding has an important clinical implication suggesting that having more 
knee pain and dysfunction above an individual’s average may warrant more attention 
as falls risk is likely to be higher at this time. In addition, higher than average MVPA 
also has a protective effect on falls risk. 
Between-person but not within-person variability in 25(OH)D was associated with 
physiological falls risk, suggesting that the between-person associations may be 
confounded by factors that are held constant in a within-person analysis. However, we 
did find that a within-person increase in 25(OH)D was associated with a lower 
physiological falls risk in individuals with sub-optimal (<50nmol/L) but not those 
with optimal 25(OH)D (≥50nmol/L). The reason for this observation is unclear but 
may be due to the fact that 25(OH)D was associated with better balance in older 
adults with sub-optimal, but not in those with optimal 25(OH)D (data not shown). 
Observational studies have reported a link between low levels of vitamin-D and falls 
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in older people [148, 149]. However, findings from randomised controlled trials 
(RCT) and meta-analyses of these trials have been inconsistent, with some showing a 
benefit and others showing no effects of vitamin-D supplementation in reducing falls 
in older people [245, 248]. For instance, a meta-analysis of 8 trials testing the efficacy 
of vitamin-D supplementation on falls in older people showed that supplemental 
vitamin-D in a dose of 700-1000 IU per day reduced falls risk by 19% [245]. 
Conversely, supplemental vitamin-D less than 700IU did not reduce the risk of falls, 
suggesting that low doses of vitamin-D may partly explain why some trials did not 
find a significant association between vitamin-D supplementation and falls [245]. 
However, a more recent meta-analysis of 20 trials showed that vitamin D 
supplementation, with or without calcium does not reduce falls by 15% or more 
[248]. The differences in the findings from the meta-analyses could be due to the 
harmful or neutral effects of vitamin-D supplementation reported in more recent trials 
[248]. An increase in vitamin-D may not help to improve muscle function or physical 
performance in older adults who are vitamin-D replete [249, 250]. For instance, a 4-
year prospective study of 714 adults aged 65 years and older with optimal vitamin-D 
at baseline revealed no significant association between vitamin-D and physical 
performance [249]. Our within-person analysis is consistent with studies showing no 
beneficial effect of 25(OH)D among older people with sufficient vitamin-D.  
Interestingly, within-person variability in WOMAC global score and WOMAC 
functional limitation subscale were associated with physiological falls risk score, such 
that physiological falls risk was higher on occasions when WOMAC scores were also 
higher. The effect sizes were smaller than the between-person effect suggesting a less 
substantive impact. This finding expands upon previous studies by showing that, not 
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only was falls risk higher in older adults with pain, but that falls risk was also higher 
on occasions when the older adults had more pain than their ‘usual’ level of pain. This 
finding emphasises the importance of within-person analysis in order to understand 
the impact of intra-individual variability in knee pain and dysfunction on falls risk in 
community-dwelling older adults. Pain represents a major clinical symptom and there 
are indications that pain may be undertreated in older people [251]. Clinicians and 
carers should be more concerned about pain in older adults particularly on occasion 
when the pain is higher than their ‘usual’ pain level, as the risk of falling may be 
higher at this time. Previously we have shown that, in a cross-sectional and 
prospective study over 5 years, higher knee pain and dysfunction were associated 
with a higher falls risk [72, 243]. Other studies have also reported a similar 
association between pain and falls in older adults [252]. Older adults who have knee 
pain and dysfunction may reduce their mobility in order to avoid discomforts, as a 
result, they may experience a decline in leg muscle strength and consequently a 
higher risk of falling. Alternatively, knee pain may also lead to weaker leg muscle 
strength via reflex muscle inhibition [212], as such, weaker leg muscle strength may 
lead to poorer balance and a higher falls risk [243]. The significant within-person 
effect may suggest that on occasion when the participants reported higher knee pain 
and dysfunction, they also had a greater activity limitation, consequently, they had a 
weaker leg muscle, poorer balance and a higher falls risk score, or they were perhaps 
less able to provide a maximal contraction due to actual pain or anticipated pain. 
Strategies to minimize knee pain and dysfunction may be beneficial for reducing falls 
in older adults. 
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Participants with higher average pedometer-determined steps per day and higher 
MVPA have a significantly lower average physiological falls risk score. Consistent 
with our findings, several studies have reported a link between a high level of 
physical activity and lower falls in older people [145, 242]. Although Gill et al [253] 
reported no beneficial effect of physical activity in the prevention of serious fall 
injuries others have suggested a U-shaped relationship between physical activity and 
falls, such that both high and low level of physical activity increased fall risk 
depending on the older adults’ functional status [254]. However, in the Longitudinal 
Aging Study Amsterdam, Peeters et al [142] found no evidence of a non-linear 
relationship between physical activity and falls. This finding may be reflected in our 
own results, suggesting that older adults who engaged in more physical activity, on 
average, have a lower mean physiological falls risk. Within-person MVPA but not 
light physical activity or pedometer-determined steps per day was significantly 
associated with physiological falls risk, indicating that physiological falls risk was 
lower on occasions when physical activity characterised by a greater level of intensity 
was also higher. This finding may be related to the additional benefit of MVPA in 
improving muscle strength, balance and gait parameters in older people [68, 255]. For 
instance, in a study of people aged 65 years and above, Pau et el showed that although 
both light and vigorous physical activity help improved static balance, only vigorous 
physical activity was associated with an improvement in dynamic posture and all the 
gait patterns considered [255].  
This study has a number of strengths including the 10-year follow-up period and the 
use of objective measures of physical activity which likely increases the accuracy of 
our estimates. Another key strength of the study was the use of a person-mean 
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centering analysis approach, allowing us to disentangle the within-person and 
between-person effects of the predictor variables. This is particularly useful as we 
observed important differences in the between-person and within-person relationships 
between 25(OH)D, physical activity and knee pain and dysfunction and physiological 
falls risk. However, this study also has a number of limitations. Firstly, 48.3% of 
participants recruited at baseline were lost to follow-up over 10 years. Such missing 
data is not unexpected in a long-term prospective study involving older people. The 
missing data were accommodated by using maximum likelihood estimation which 
uses available data for model estimation, rather than casewise deletion. This is 
recommended for multilevel data analysis. Secondly, the intensity of physical activity 
was accessed in a subset of the participants. These participants were found to have 
fewer chronic conditions and lower knee pain and dysfunction, hence, our findings 
may be generalisable to healthy older adults’ populations. Thirdly, physiological 
assessment of falls risk rather than prospective data on actual falls was used in this 
study because actual falls were not collected as part of this study. We cannot be 
certain whether our findings on associations with falls risk score would be similar for 
incident falls. However, the physiological approach to the assessment of falls risk is 
not subject to recall bias [234] and the PPA has been shown to have 75% accuracy in 
predicting multiple falls among older people [256].  Lastly, to assess potential 
endogeneity bias we performed a sensitivity analysis by considering time lags 
between serum 25(OH)D, physical activity, knee pain and dysfunction and falls risk 
score. There was a consistent relationship between lagged independent variables and 
physiological falls risk score, suggesting no cause for endogeneity bias. 
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In conclusion, our findings demonstrate that 10-year average falls risk score was 
lower in participants who had a higher 10-year mean vitamin-D, physical activity and 
lower mean WOMAC score. At time-points when the participants had a higher 
WOMAC score, they also had a higher falls risk. The presence of between-person but 
not overall within-person associations for 25(OH)D suggests the former may be 
confounded by other factors. Our finding that within-person variability in MVPA was 
associated with falls risk supports the clinical recommendation of physical activity for 
reducing falls risk in older people [257], but it also highlights the additional benefit of 
increasing one’s own MVPA to further reduce falls risk. 
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7.1 Abstract 
Aims: This study aims to describe the associations of low muscle mass, handgrip 
(HGS) and lower-limb muscle strength (LMS) with health-related quality of life 
(HRQoL) over 10 years in community-dwelling older adults. 
Methods: Participants (N=1002; 51% women; mean age 63±7.4 years) were 
prospectively followed for 10 years. HRQoL was measured using the validated 
assessment of quality of life (AQoL) instrument. Appendicular lean mass (ALM) was 
assessed using dual energy X-ray absorptiometry and normalised to body mass index 
(BMI). HGS and LMS were assessed using dynamometers. Low ALM/BMI 
(ALM/BMILOW), LMS (LMSLOW) and HGS (HGSLOW) at baseline were defined as the 
lowest 20% of the sex-specific distribution for each measure. Linear mixed effect 
regression models, adjusting for confounders, were used to estimate the association 
between ALM/BMILOW, LMSLOW, and HGSLOW at baseline and HRQoL over 10 
years. 
Results: Participants with LMSLOW (β= –0.061, 95% CI: –0.089, –0.033) and women 
(β= –0.089, 95% CI: –0.129, –0.049) but not men (β= –0.023, 95% CI: –0.064, 0.019) 
with HGSLOW had clinically meaningful reductions in HRQoL over 10 years 
compared to those with normal strength. There was a weaker but statistically 
significant association between ALM/BMILOW and 10-year HRQoL (β= –0.038, 95% 
CI: –0.068, –0.008). 
Conclusions: Lower-limb muscle strength and handgrip strength (in women only), 
which can be easily measured in clinical practice, appear more important than muscle 
mass for HRQoL. Interventions aimed at reducing the impact of age-related muscle 
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loss on HRQoL should focus on improving muscle strength rather than just increasing 
muscle mass. 
7.2 Introduction 
Age-related decline in skeletal muscle mass and function is associated with health 
outcomes such as falls risk, fracture, poor mobility and physical disability that could 
impact older adults’ independence and quality of life [63, 200, 201]. However, studies 
examining the relationship between muscle mass and function and health related 
quality of life (HRQoL) are sparse and largely cross-sectional [164]. These studies 
showed that HRQoL, particularly the physical health domain, is lower among older 
people with low muscle mass and strength [165, 258-261]. However, it is unclear 
whether cross-sectional associations track over time.  
While both muscle mass and strength decrease with age, the two processes do not 
occur at the same rate and may be the result of dissimilar pathophysiological 
processes [57, 61, 216]. Prior studies suggest that low muscle mass and strength may 
have different impacts on health outcomes in older people [63, 167, 201]. Despite 
these differences, few long-term prospective studies have compared the associations 
of low muscle mass and strength with HRQoL in community-dwelling older adults. 
Indeed, clarification of the relationship between low muscle mass and strength and 
HRQoL of older people may be important in the design of interventions to improve 
QoL. Therefore, this prospective study aims to describe the association of low muscle 
mass, handgrip and lower-limb muscle strength assessed at baseline with HRQoL 
over 10 years in community-dwelling older adults. We hypothesized that low muscle 
strength may be more closely related to HRQoL than muscle mass.  
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7.3 Data and Methods 
7.3.1 Sample and Study Setting 
The Tasmanian Older Adult Cohort (TASOAC) study is a prospective, population-
based study primarily aimed at examining the causes and progression of osteoarthritis. 
Participants aged 50 years and above were selected using a sex-stratified random 
sampling technique from the electoral roll in Southern Tasmania (population 
229,000). A total of 1099 adults (response rate = 57%) consented to participate in the 
study. Participants were excluded if they had any implants that would prevent them 
from undergoing an MRI or they were living in a nursing home. Participants who 
consented to participate in the study were invited to attend a clinic at the Menzies 
Institute for Medical Research, Hobart, Tasmania between March 2002 and 
September, 2004. They were invited for follow–up clinic assessments at 2.5, 5, and 10 
years after the initial clinic assessment. The study was approved by the Southern 
Tasmanian Health and Medical Research Ethics Committee and written informed 
consent was obtained from all participants.  
7.4 Outcome measure: Health-related quality of life over 10 years 
HRQoL was assessed at baseline, 2.5, 5 and 10 years using the Assessment of Quality 
of life (AQoL-4D) questionnaire. The AQoL-4D is a validated generic questionnaire 
designed for the Australian population [188]. The questionnaire consists of 12 items 
covering four dimensions and each dimension has three items. The four dimensions 
and their corresponding items are: (1) independent living (self-care, activities of daily 
living), (2) physical senses (sight, hearing and communication), (3) social 
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relationships (social isolation, relationship and family role) and (4) psychological 
wellbeing (sleep, anxiety and pain). The scores for items in each domain were 
transformed and summed to a life-death utility scale that ranges from 1.00 (full 
HRQoL) to 0.00 (death-equivalent health state) to –0.04 (health states worse than 
death) [189, 190]. The minimum important difference in AQoL score for the 
Australian population is 0.06 [190]. This score provides a measure of the smallest 
difference in AQoL score that is considered to be of a significant change in the health 
state of Australians [190].  
7.5 Predictor variables 
7.5.1 Assessments of low muscle mass and strength at baseline 
Lower-limb muscle strength (LMS) was measured to the nearest kilogram 
simultaneously for both limbs using a dynamometer (TTM Muscular Meter, Tokyo, 
Japan). Two trials were recorded and the average of the two trials was taken as 
previously described [185]. The intra-class correlation coefficients of the first and 
second trial for lower-limb muscle strength assessments was 0.95 (95% CI: 0.94 – 
0.96). Hand grip strength (HGS) in pounds per square inch (psi) was measured using 
a pneumatic handheld bulb dynamometer (North CoastTM bulb dynamometer; adult 0-
30 psi, model no. 70154). The mean of the right and left-hand grip strength was 
calculated for each participant. The intra-class correlation coefficients of the first and 
second trial for the hand grip strength measurements was 0.96 (95% CI: 0.92 – 0.97). 
Participants in the lowest 20% of the sex-specific distribution for LMS and HGS at 
baseline were classified as having low LMS (LMSLOW) and low HGS (HGSLOW) [36, 
63].  
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7.5.2 Body composition assessments at baseline 
Whole and regional body composition of the participants were measured using dual 
energy X-ray absorptiometry (DXA; Hologic Delphi, Hologic, Waltham USA). 
Appendicular lean mass (ALM), in kilograms, was calculated as the sum of lean mass 
in the upper and lower limbs. Weight was measured to the nearest 0.1 kilogram using 
electronic scales (Heine, Dover, USA) with shoes and heavy clothing removed. 
Height was measured to the nearest 0.1 centimetre using Leicester stadiometer 
(Invicta, Leicester, UK), with shoes, socks and headgear removed. Body mass index 
(BMI) was calculated as weight (kg) divided by height (m) squared. ALM was 
normalized to BMI as ALM-to-BMI ratio has been shown to be a potential criteria for 
identifying older adults with clinically relevant weakness [25]. Participants in the 
lowest 20% of the sex-specific distribution for ALM/BMI at baseline were classified 
as having low muscle mass (ALM/BMILOW) [36, 63].  
7.6 Potential confounders 
Age, sex, medical history, including a previous diagnosis of stroke, diabetes, 
rheumatoid arthritis, asthma, osteoporosis, cardiovascular disease (hypertension, 
thrombosis, bronchitis/emphysema, or heart attack) was recorded using a 
questionnaire. Physical activity was measured over seven consecutive days using a 
pedometer (Omron HJ-003 & HJ-102; Omron Healthcare, Kyoto, Japan) as 
previously described [185]. 
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7.7 Data analysis 
Means with standard deviations were used to summarize continuous variables, and 
percentages with participant numbers to describe categorical variables. Linear mixed 
effect regression analyses with adjustment for age at baseline, sex, self-reported pain 
and number of chronic conditions were used to estimate the association between low 
ALM/BMI, HGS and LMS assessed at baseline and AQoL scores over 10 years. 
Statistical interaction between sex and each muscle parameter was assessed by a test 
of significance of a (sex × muscle mass or function) product term. Data were analysed 
using Stata version 12.  
7.8 Results 
A total of 1002 participants with complete body composition, muscle strength and 
quality of life assessments at baseline were included in the analysis. Of these, 818 
(82%), 722 (72%) and 539 (54%) respectively attended the 2.5, 5 and 10 years 
follow-up assessments. Participants were lost to follow-up due to death, withdrawal 
of consent, institutionalization, moving interstate or overseas and having a joint 
replacement. Participants lost to follow-up were older at baseline (64.5±8.0 vs. 
62.5±7.3, P=0.001), more commonly female (57% vs. 43% in men, P= 0.020), had 
poorer baseline ALM (23.3±5.3kg vs. 24.7±5.3kg, P<0.001), HGS (11.3±2.9psi vs. 
12.2±3.1psi, P<0.001) and LMS (82.6±45.6kg vs. 95.3±49.7kg, P=0.001) than those 
who completed the 10-year follow-up. No difference in baseline HRQoL (P= 0.323) 
was observed between participants loss to follow-up (0.76±0.19) and those retained in 
the study (0.77±0.18). Table 7.1 shows the baseline characteristics of the participants 
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stratified by low muscle mass and strength. Participants with ALM/BMILOW, HGSLOW 
and LMSLOW were older, shorter, had higher levels of knee and foot pain, lower levels 
of physical activity and greater number of chronic conditions compared to 
participants with normal muscle mass and strength. Body weight was significantly 
lower in participants with low HGS and LMS whereas it was higher in those with 
ALM/BMILOW. Total body fat was significantly higher only in participants with 
ALM/BMILOW. Participants with ALM/BMILOW had higher hip pain and lower serum 
25-hydroxyvitamin D compared to those with normal ALM/BMI, whereas no 
significant difference in hip pain and serum 25-hydroxyvitamin D was observed 
between participants with normal and low LMS or HGS. There were no statistical 
differences in sex and smoking status between participants with low and normal 
ALM/BMI, LMS and HGS. Figure 7.1 shows the mean predicted HRQoL scores 
(predictive margin) over time for participants with low and normal ALM/BMI, LMS 
and HGS. Participants with ALM/BMILOW, HGSLOW and LMSLOW consistently had a 
lower HRQoL over time compared to those with normal muscle mass and strength.  
The associations between low muscle mass and strength at baseline and HRQoL over 
10 years are shown in Table 7.2. Of note, the minimal important difference in the 
HRQoL score (overall health state utility) is 0.06 for the Australian population [190]. 
ALM/BMILOW at baseline was associated with lower HRQoL over 10years (β= –
0.038, 95% CI: –0.068, –0.008) with no evidence of an interaction between sex and 
ALM/BMILOW (P= 0.680). Furthermore, ALM/BMILOW was associated with a lower 
independent living (β= –0.018, 95% CI: –0.032, –0.003) and psychological wellbeing 
(β= –0.026, 95% CI: –0.041, –0.011) component of HRQoL but not with social 
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relationship (β= –0.012, 95% CI: –0.031, 0.007) or physical senses components (β= –
0.004, 95% CI: –0.017, 0.009) of HRQoL. 
Participants with LMSLOW at baseline had a clinically meaningful and significantly 
lower HRQoL over 10 years (β= –0.061, 95% CI: –0.089, –0.033). The association 
between LMSLOW (β= –0.059, 95% CI: –0.087, –0.032) and HRQoL remained 
substantially lower after further adjustment for ALM/BMILOW (β= –0.035, 95% CI: –
0.064, –0.006) Table 7.3. There was no evidence for an interaction between sex and 
LMSLOW (P= 0.418) for HRQoL. Furthermore, all four components of HRQoL were 
significantly lower in participants with LMSLOW: independent living (β= –0.024, 95% 
CI: –0.038, –0.010), social relationships (β= –0.018, 95% CI: –0.036, –0.0003), 
physical senses (β= –0.016, 95% CI: –0.028, –0.003) and psychological wellbeing 
(β= –0.029, 95% CI: –0.044, –0.015). 
The association between HGSLOW at baseline and HRQoL over 10 years was modified 
by sex (P=0.008), hence, the results are presented separately for men and women. For 
men, there was no significant relationship between HGSLOW at baseline and HRQoL 
or any of the four components of HRQoL (all P>0.05). However, among women, 
HGSLOW at baseline was significantly associated with a clinically meaningful lower 
level of HRQoL over 10 years (β= –0.089, 95% CI: –0.129, –0.049). Furthermore, 
women with HGSLOW also had lower scores for the independent living (β= –0.037, 
95% CI: –0.058, –0.015), physical senses (β= –0.021, 95% CI: –0.037, –0.005), 
psychological wellbeing (β= –0.038, 95% CI: –0.060, –0.017) but not social 
relationships components of HRQoL (β= –0.020, 95% CI: –0.045, 0.005). The 
association between baseline HGSLOW (β= –0.087, 95% CI: –0.128, –0.047) and 
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HRQoL over 10 years remained significant after further adjustment for 
ALM/BMILOW, whereas the association with ALM/BMILOW was not (β= –0.015, 95% 
CI: –0.056, 0.026) Table 7.3. 
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Table 7.1: Baseline characteristics of the participants stratified by ALM/BMI, lower-limb muscle strength, and handgrip strength categories 
(N=1002) 
Variables ALM/BMI, kg/kg/m2  Lower-limb muscle strength, kg  Handgrip strength, psi 
 Normal (N=816) Low (N=186)  Normal (N=803) Low (N=199)  Normal (N=802) Low (N=200) 
Age (years) 62.3±7.3 65.3±7.7 62.1±7.2 65.6±7.8 61.6±6.9 67.6±7.7 
Female n (%) 416(51%) 95(52%) 407(51%) 104(52%) 409(51%) 102 (51%) 
Weight (kilogram) 76.0±14.0 84.8±14.6 78.3±14.8 74.9±12.9 78.2±14.7 75.4±13.4 
Height (centimetre) 168.2±8.6 162.1±8.8 167.6±9.0 165.0±8.6 167.5±8.9 165.3±9.0 
Total body fat (kilogram) 26.5±7.7 34.9±9.1 28.1±8.7 28.2±8.7 28.0±8.7 28.4±8.6 
Energy intake (Kilo Joules/day) 7784.4±2870.1 7269.3±2681.8 7769.8±2794.4 7361.4±3010.5 7754.2±2594.1 7721.6±2770.6 
Physical activity (steps/day) 9087.3±3301.6 7043.1±3177.0 8915.3±3329.5 7870.8±3423.0 8941.9±3366.5 7769.3±3237.7 
Smoking n (% yes) 404 (50%) 99 (53%) 405(51%) 98(49%) 411(51%) 92(46%) 
Serum 25(OH)D (nmol/L) 54.1±18.7 47.2±16.9 53.0±18.4 52.1±19.1 52.9±18.7 52.5±18.0 
Hip pain (%) 311(38%) 89(48%) 315(40%) 85(43%) 313(39%) 87(44%) 
Knee pain (%) 344(43%) 102(55%) 337(42%) 109(55%) 338(43%) 108(54%) 
Foot pain (%) 278(34%) 92(49%) 271(34%) 99(50%) 275(35%) 95(48%) 
Number of chronic condition 1.3±1.3 2.0±1.6 1.3±1.2 1.9±1.6 1.3±1.3 1.8±1.5 
Data are expressed as mean ± standard deviation unless otherwise indicated;  
ALM/BMI: Appendicular lean mass/body mass index; 25(OH)D: 25-hydroxy vitamin D3; psi: pounds per square inch. To convert psi to kilograms 
(kg) per centimetre squared multiply by 0.07031. 
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Table 7.2: Associations between baseline ALM/BMI, HGS, LMS status and health-related quality of life (HRQoL) over 10 years (N=818) 
 HRQoL score  Component dimensions of HRQoL 
 (Overall health state 
utility) 
 Independent living Social relationships Physical senses Psychological 
wellbeing 
ALM/BMILOW –0.038(–0.068, –0.008) –0.018(–0.032, –0.003) –0.012(–0.031, 0.007) –0.004(–0.017, 0.009) –0.026(–0.041, –0.011) 
LMSLOW –0.061(–0.089, –0.033) –0.024(–0.038, –0.010) –0.018(–0.036, –0.0003) –0.016(–0.028, –0.003) –0.029(–0.044, –0.015) 
HGSLOW (Men)
* –0.023(–0.064, 0.019) –0.009(–0.027, 0.009) –0.021(–0.049, 0.007) –0.007(–0.028, 0.013) –0.006(–0.026, 0.014) 
HGSLOW (Women)
* –0.089(–0.129, –0.049) –0.037(–0.058, –0.015) –0.020(–0.045, 0.005) –0.021(–0.037, –0.005) –0.038(–0.060, –0.017) 
Negative scores indicate poorer health. *Sex interaction existed for HGS, therefore, the results is presented separately for men and women. 
Analyses are adjusted for age, sex, physical activity, time to follow-up and number of chronic conditions. Data in bold indicates P<0.05. 
Note: The HRQoL score ranges from 1.00 (full HRQoL) to 0.00 (death-equivalent health state) to –0.04 (health states worse than death). The minimal important 
difference in HRQoL score (overall health state utility) for the Australian population is 0.06 [190].  
ALM/BMILOW: Sex specific lowest 20% of appendicular lean mass (ALM)/body mass index [BMI] (kg/ kg/m2);  LMSLOW: Sex specific lowest 20% of lower-
limb muscle strength (kg); HGSLOW: Sex specific lowest 20% of handgrip strength (psi) 
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Figure 7.1: Mean HRQoL over time for each ALM/BMI (A), lower-limb muscle 
strength (B) and handgrip strength (C) categories. 
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7.9 Discussion  
This is the first long-term prospective study, to our knowledge, investigating the 
association between muscle mass, upper- and lower-limb muscle strength and 
HRQoL among community-dwelling older adults. Participants with LMSLOW and 
women with HGSLOW had a clinically meaningful and significantly lower HRQoL 
over 10 years compared to those with normal strength. The association between 
ALM/BMILOW and HRQoL over 10 years was weaker and ALM/BMILOW did not 
affect the association between handgrip or lower-limb muscle strength and HRQoL. 
This demonstrates that muscle strength, which is closely related to physical 
performance and easy to measure in clinical practice, is a more important predictor of 
long-term quality of life in community-dwelling older adults than muscle mass, 
suggesting that interventions aimed at reducing the impact of age-related muscle loss 
on HRQoL might be better focused on improving muscle strength rather than just 
increasing muscle mass.  
In older adults, both men and women with lower muscle mass, lower-limb muscle 
strength and women but not men with lower handgrip strength at baseline had lower 
HRQoL over 10 years. Interestingly, a greater and more clinically meaningful 
difference (approaching or exceeding 0.06) in HRQoL [190] was observed for older 
adults with LMSLOW and women with HGSLOW than in those with low muscle mass, 
the latter effect being around 40 – 60% the magnitude of the former two. One reason 
for this could be that age-associated loss of muscle strength occurs at a faster rate than 
loss of muscle mass [57]. A rapid loss of muscle strength can result in early onset of 
functional impairments, physical inactivity and poor social engagement that could 
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have a larger impact on HRQoL. Contrary to our findings, a recent 3-year prospective 
study suggested that muscle mass, not muscle strength, was significantly associated 
HRQoL [262]. However, this study was limited by its very small sample size (n=26) 
and because QoL was assessed using only the physical components of 36 item short-
form survey (SF-36) rather than the combined physical and mental components. 
Indeed, physical components of SF-36 correlates poorly with muscle strength and this 
measure alone may not be a suitable outcome measure in musculoskeletal studies 
[260]. Consistent with our findings, several studies have documented the clinical 
utility of muscle strength as a better predictor of health and HRQoL in older adults 
[62, 260]. This, combined with the fact that low muscle mass did not affect the 
clinically meaningful decrease in HRQoL in individuals with low muscle strength, 
suggest that interventions aimed at reducing the impact of age-related muscle loss on 
HRQoL should focus on improving muscle strength rather than just increasing muscle 
mass.  
Women with HGSLOW had a lower HRQoL over 10 years, while no significant 
association was found in men. The reason for this observation is unclear, nonetheless, 
this finding is consistent with prior studies which suggest that maintenance of HGS 
appears to be more important in reducing detrimental health outcomes in women 
compared to men [263]. One possible explanation is that women generally have a 
lower upper-limb muscle strength than men, hence, any loss of upper-limb strength in 
women is more likely to result in difficulty performing tasks required to maintain 
function [34]. Potentially this contributes to an increased likelihood of loss of 
independence and poorer HRQoL in women. 
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Participants with ALM/BMILOW, LMSLOW, and women with HGSLOW had lower 
scores on the independent living component of HRQoL. This demonstrates the 
importance of preserving muscle mass and strength in order to perform tasks 
associated with maintaining independent living over a decade. A requirement for 
independent living in old age is the ability to perform (instrumental) activities of daily 
living (ADL/IADL) with no difficulty [264]. In several studies, older adults with 
advanced muscle loss have had a reduced capacity to perform ADLs as well as an 
increased need for health support services and subsequent institutionalisation [63, 
200, 264]. Public health initiatives that help older adults maintain muscle mass and 
strength will be important to decrease dependency in later life. 
Social relationship component of HRQoL was significantly lower only in individuals 
with LMSLOW, suggesting that lower extremity muscle strength could be important in 
maintaining an interpersonal relationship with friends and family over the long-term. 
Contrary to our findings in this community-dwelling population, previous cross-
sectional studies among pre-frail and frail older adults have reported no significant 
association between muscle strength and social participation [265, 266]. It may be 
that poor lower extremity muscle strength in independent living older adults could 
result in greater social isolation than in frailer adults with complex medical conditions 
and are likely to receive to health supports. This could occur via impairment in 
mobility, as a reduction in mobility is associated with a decline in physical function 
[267]. Interestingly, physical senses domain of HRQoL was lower in older adults with 
LMSLOW and women with HGSLOW whereas no associations was observed for 
ALM/BMILOW. Low muscle strength is not likely to be a direct cause of poorer 
physical senses, rather it could lead to the development of some chronic diseases 
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which affect physical senses. Furthermore, low muscle strength may also be a marker 
of pre-existing or current chronic conditions (such as diabetes) affecting physical 
senses like visual function. 
Interestingly, the psychological wellbeing component of HRQoL was lower in older 
adults with ALM/BMILOW, LMSLOW, and women with HGSLOW. This is consistent 
with prior studies reporting poorer psychological health in older adults with low 
muscle mass and strength, although the mechanism underlying the association 
between age-related muscle loss and psychological wellbeing is not entirely clear 
[261, 268-271]. Potentially loss of independent living skills associated with low 
muscle mass and strength could have physical and emotional impacts on older adults, 
and could contribute to poorer psychological wellbeing. For instance, a recent 
systematic review and meta-analysis of 15 observational studies reported a 
significantly higher odds of depression in older adults with sarcopenia [270]. Muscle 
function may be related to psychological wellbeing because they both have a central 
nervous system involvement and muscle weakness may be an early indicator of age-
related decline in central nervous system that is manifested in poor mental health 
[268]. Indeed, resistance exercises have been shown to lead to an improvement of, 
and prevention of decline in mental health, in addition to improvement in muscle 
strength suggesting a link between the two processes [272, 273]. Further clinical 
studies incorporating brain morphology and neuroplasticity are warranted to 
determine the physiological mechanisms through which low muscle mass and 
strength may be related to poorer psychological wellbeing [274].  
Chapter 7 – Prospective Associations of Low Muscle Mass and Strength with Health-
Related Quality of Life over 10 years 
153 
 
The strengths of this study includes the 10-year follow-up period and the use of a 
population-based sample which increases its generalizability. In addition, muscle 
mass was assessed using DXA, a valid and accurate tool for assessing muscle mass. 
However, this study has a number of limitations. Forty-six percent of the participants 
were lost to follow-up over 10 years. Such missing data is not unexpected in a long-
term prospective study involving older people. The missing data were accommodated 
in the linear mixed effect models by using maximum likelihood estimation which 
estimates means and intercepts based on all available data. This minimize bias and 
increase power as participants with missing follow-up data were retained in the 
analysis. HRQoL was assessed using a generic questionnaire rather than a disease-
specific HRQoL measure such as the sarcopenia and quality of Life (SARQoL) 
questionnaire. Unlike SARQoL, AQoL was not originally designed to assess the 
impact of age-related loss of muscle mass and function, nonetheless, some of the 
items (for instance, difficulty with ADL, mobility and pain) assessed in SarQoL are 
also captured in AQoL. AQoL is a commonly used tool specifically designed for the 
Australian population demonstrating both validity and reproducibility [190]. 
In conclusion, lower-limb muscle strength and handgrip strength (in women only) 
were a better predictor of HRQoL over 10 years compared to muscle mass. In this 
respect, measuring muscle strength in clinical practice appears to be a promising 
approach to identify older adults who are at risk of having a considerable decline in 
HRQoL as they age. As age-related decline in muscle strength is amenable to 
interventions, resistance exercise training aimed at improving muscle strength may 
have a beneficial impact on long-term HRQoL. Interventions aimed at reducing the 
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impact of age-related muscle loss on HRQoL should focus on improving muscle 
strength rather than just increasing muscle mass. 
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Table 7.3: Supplementary Table: Associations of baseline LMS status and HGS (women only) with health-related quality of life (HRQoL) over 10 years, 
with additional adjustment for baseline ALM/BMI (N=818) 
 HRQoL score  Component dimensions of HRQoL 
 (Overall health state utility)  Independent living Social relationships Physical senses Psychological wellbeing 
LMSLOW –0.059(–0.087, –0.032) –0.023(–0.037, –0.010) –0.018(–0.037, 0.0002) –0.016(–0.028, –0.003) –0.028(–0.042, –0.014) 
ALM/BMILOW –0.035(–0.064, –0.006) –0.016(–0.031, –0.002) –0.011(–0.030, 0.008) –0.003(–0.016, 0.010) –0.024(–0.040, –0.009) 
HGSLOW (Women) –0.087(–0.128, –0.047) –0.036(–0.057, –0.014) –0.020(–0.045, 0.006) –0.021(–0.038, –0.005) –0.036(–0.058, –0.014) 
ALM/BMILOW –0.015(–0.056, 0.026) –0.007(–0.029, 0.014) –0.004(–0.030, 0.022) –0.002(–0.014, 0.018) –0.018(–0.040, 0.004) 
Negative scores indicate poorer health.  Analyses are adjusted for age, sex, physical activity, time to follow-up and number of chronic conditions. Data in bold 
indicates P<0.05. 
Note: The HRQoL score ranges from 1.00 (full HRQoL) to 0.00 (death-equivalent health state) to –0.04 (health states worse than death). The minimal important 
difference in HRQoL score (overall health state utility) for the Australian population is 0.06 [190].  
ALM/BMILOW: Sex specific lowest 20% of appendicular lean mass (ALM)/body mass index [BMI] (kg/ kg/m2);  LMSLOW: Sex specific lowest 20% of lower-limb 
muscle strength (kg); HGSLOW: Sex specific lowest 20% of handgrip strength (psi) 
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8.1 Abstract 
Aim: To determine whether older adults with low muscle mass (sarcopenia) and 
strength (dynapenia), in the presence of osteoporosis/osteopenia, have an increased 
risk of fracture and mortality over 10 years, compared to those with low muscle or 
low bone mass alone or with neither condition. 
Methods: 1032 participants (52% women; mean age 62.9±7.4 years) were studied at 
baseline, 2.5, 5 and 10 years. Mortality was ascertained from the death registry and 
fractures were self-reported. Baseline appendicular lean mass (ALM) was assessed 
using dual-energy X-ray absorptiometry and normalised to body mass index (BMI). 
Hand grip strength (HGS) was assessed by dynamometer. Osteosarcopenia and 
osteodynapenia were defined as having T-scores of the total hip and/or lumbar spine 
bone mineral density (BMD) < –1 combined with being in the lowest 20% of the sex-
specific distribution for ALM/BMI or HGS respectively.  
Results: Incident fracture risk was significanlty higher in participants who were 
osteodynapenic (RR=2.07, 95% CI: 1.26–3.39), dynapenic alone (RR=1.74, 95% CI: 
1.05–2.87), and osteopenic alone (RR=1.63, 95% CI: 1.15–2.31), compared to those 
without dynapenia or osteopenia. Mortality risk was significantly higher only in 
participants with osteosarcopenia (RR=1.49, 95% CI: 1.01–2.21) compared to those 
without sarcopenia or osteopenia. However, osteosarcopenia and osteodynapenia did 
not lead to a significantly greater fracture or mortality risk compared to having these 
conditions on their own. 
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Conclusion: Osteopenia combined with low muscle mass or strength does not 
significantly increase the risk of fracture or mortality compared to having osteopenia 
or sarcopenia/dynapenia alone, suggesting that combined assessments may not add 
additional risk for fracture and mortality. 
8.2 Introduction 
Ageing is associated with changes in body composition including decreases in muscle 
mass, strength and bone mass, with declines in each occurring at a different rate [275, 
276]. Loss of muscle mass and loss of bone mass (osteopenia/osteoporosis) are 
closely interconnected, however, both have been considered independently as risk 
factors for falls, fracture and mortality in older people [175]. Historically, the 
interconnection between muscle and bone mass has been thought to be through the 
mechanostat model which postulates that a decrease in muscle function would result 
in a decline in mechanical loading on bone and consequently results in a decrease in 
bone mass [277]. However, recent evidence suggests that, beyond the mechanostat 
model, there is a biochemical and metabolic interconnection between muscle and 
bone [180]. Indeed, a significant proportion of older people with low muscle function 
also experience osteopenia/osteoporosis [180, 278]. Due to the close interconnection 
between bone and muscle tissue, the simultaneous occurrence of 
osteopenia/osteoporosis and low muscle mass/strength could significantly increase the 
risk of fracture and mortality compared to low muscle mass/strength or 
osteopenia/osteoporosis alone.  
Previous cross-sectional studies showed that older adults with combined low muscle 
and bone mass experienced higher falls, fracture and poorer quality of life compared 
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to those without low muscle or low bone mass [278]. However, limited long-term 
prospective studies have described the association between the combination of low 
muscle and bone mass with fracture and mortality in older people [134]. It is also 
unclear whether low bone mass when combined with low muscle mass has a different 
impact on fracture and mortality than when combined with low muscle strength. This 
is particularly important to investigate because muscle strength is associated with 
functional declines in older people independent of muscle mass [279]. The aim of the 
present study was to determine whether older adults with low muscle mass 
(sarcopenia) and strength (dynapenia), in the presence of osteoporosis/osteopenia, 
have an increased risk of fracture and mortality over 10 years, compared to those with 
low muscle or low bone mass alone or with neither condition. We hypothesised that 
fracture and mortality risk over 10 years will be significantly higher in older people 
with combined low muscle and bone quality compared to individuals with low muscle 
or low bone mass alone and those with neither condition. 
8.3 Data and Methods 
8.3.1 Sample and Study Setting 
 The Tasmanian Older Adult Cohort (TASOAC) study is a prospective, population-
based study primarily aimed at examining the causes and progression of osteoarthritis. 
Participants aged 50 years and above were selected using sex-stratified random 
sampling from the electoral roll in Southern Tasmania (population 229,000). A total 
of 1099 adults (response rate = 57%) consented to participate in the study and were 
invited to attend a clinic at the Menzies Institute for Medical Research, Hobart, 
Tasmania between March 2002 and September, 2004. They were invited for follow–
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up clinic assessments at 2.5, 5, and 10 years after the initial clinic assessment. The 
study was approved by the Tasmanian Health and Medical Research Ethics 
Committee and written informed consent was obtained from all participants.  
8.4 Outcome measures 
8.4.1 Fracture 
At each study visit participants were asked to list, by site, any fractures they had since 
their previous visit. Those who experienced at least one fracture between the baseline 
and 10-year follow-up assessment were coded as ‘1’ (incident fracture.) and those 
without any fracture were coded ‘0’ (no incident fracture).  
8.4.2 Mortality  
Mortality over 10 years was ascertained through national and state death registries.  
8.5 Baseline measures  
8.5.1 Anthropometrics 
Weight was measured to the nearest 0.1 kilogram (kg) using electronic scales (Heine, 
Dover, USA) with shoes and heavy clothing removed. Height was measured to the 
nearest 0.1 centimetre using Leicester stadiometer (Invicta, Leicester, UK), with 
shoes, socks and headgear removed. Body mass index (BMI) was calculated as 
weight (kg) divided by height (metre) squared.  
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8.5.2 Body composition and BMD measures 
Lean mass, fat mass, right hip and lumbar spine bone mineral density (BMD) were 
measured using dual-energy X-ray absorptiometry (DXA; Hologic Delphi, Hologic, 
Waltham USA). Appendicular lean mass (ALM) calculated as the sum of lean mass in 
the upper and lower limbs was normalised to body mass index [BMI] (ALM/BMI) 
[41].  
8.5.3 Muscle strength 
Handgrip strength in pounds per square inch (psi) was measured using a pneumatic 
handheld bulb dynamometer (North CoastTM bulb dynamometer; adult 0-30 psi, 
model no. 70154). The mean of the right and left handgrip strength was calculated for 
each participant. The intra-class correlation coefficients of the first and second trial 
for handgrip strength measurements was 0.96 (95% CI: 0.92 – 0.97).  
8.5.4 Operational definitions of osteosarcopenia and osteodynapenia 
Osteopenia was defined as a T-scores of the total hip and/or lumbar spine of less than 
–1 [184, 280, 281]. Sarcopenia and dynapenia were defined as being in the lowest 
20% of the sex-specific distribution of muscle mass and strength respectively of our 
study sample at baseline [36, 63]. Participants were classified into one of the 
following four categories based on osteopenic and sarcopenic status: (1) non-
sarcopenic, non-osteopenic; (2) sarcopenic non-osteopenic; (3) osteopenic non-
sarcopenic; (4) osteosarcopenic. A similar classification was made based on 
osteopenic and dynapenic status: (1) non-osteopenic, non-dynapenic; (2) dynapenic 
non-osteopenic; (3) osteopenic non-dynapenic; (4) osteodynapenic.  
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8.6 Potential confounders  
Physical activity was measured over seven consecutive days using a pedometer 
(Omron HJ-003 & HJ-102; Omron Healthcare, Kyoto, Japan) as previously described 
[185]. Serum 25-hydroxyvitamin D [25(OH)D] was assayed using a liquid-phase 
radioimmunoassay (Immunodiagnostics Systems Ltd), which detects both 25(OH)D2 
and 25(OH)D3. The intra-assay and inter-assay coefficients of variation were 1.8% 
and 3.3% respectively. Serum 25(OH)D was de-seasonalised as previously described 
[15] to account for differences in the time of the year that blood was taken. Age, sex, 
medical history, including a previous diagnosis of diabetes, rheumatoid arthritis, 
cardiovascular disease (hypertension, bronchitis/emphysema, or heart attack) were 
recorded using a questionnaire. Falls risk was assessed using the short form 
Physiological Profile Assessment (PPA) (Prince of Wales Medical Research Institute, 
Sydney, Australia), a valid and reliable tool used to identify individuals who are at 
risk of falls [186].  
8.7 Data analysis 
Categorical and continuous variables were compared across categories of 
osteopenia/sarcopenia and osteopenia/dynapenia using Chi-square tests and one-way 
ANOVA, respectively. Poisson regression was used to estimate the relative risk (RR) 
for fracture and mortality over 10 years in unadjusted and adjusted analysis. The 
fracture models were adjusted for age, sex, physical activity (steps/day) and 25-
hydroxyvitamin-D. The mortality models were adjusted for age, sex, physical activity 
(steps/day) and number of chronic conditions. We assessed statistical interaction 
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between sex and osteopenic/sarcopenic and osteopenic/dynapenic status. 
Additionally, we modelled fracture and mortality using continuous (hip BMD) and 
muscle measures (muscle mass (ALM/BMI) and strength (HGS)) in both univariable 
and multivariable models. Hip BMD, HGS and ALM/BMI were standardised for 
comparison and the relative risk of fracture and mortality were reported as per 
standard deviation (SD) decrease in hip BMD and per SD increase in HGS or 
ALM/BMI. We assessed the robustness of our models to missing data using inverse 
probability weighting. Data were analyzed using Stata version 13 (StataCorp, TX, 
USA). 
8.8 Results 
A total of 1032 participants (63 ± 7.4 years; 52% female) with complete body 
composition and muscle strength assessments at baseline were included in the 
analysis. Table 8.1 presents the baseline characteristics of the participants stratified 
according to osteopenic, sarcopenic and dynapenic status. Both osteosarcopenic and 
osteodynapenic participants were older, shorter, had lower ALM, and engaged in 
lower levels of physical activity compared to non-sarcopenic non-osteopenic and non-
dynapenic non-osteopenic participants. There were a higher proportion of women in 
the osteodynapenic group compared to non-dynapenic non-osteopenic participants. 
The proportion of women in the osteopenic non-sarcopenic group was significantly 
higher than those in the non-sarcopenic non-osteopenic category. BMI and total body 
fat mass were significantly higher in participants with osteosarcopenia compared to 
those who were non-sarcopenic non-osteopenic. BMI but not total body fat mass was 
significantly lower in participants with osteodynapenia compared to those who were 
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non-dynapenic non-osteopenic. Smoking status did not differ across sarcopenic, 
osteopenic and dynapenic categories. Participants with osteosarcopenia had a greater 
number of chronic conditions and lower levels of serum 25(OH)D compared to non-
sarcopenic non-osteopenic participants whereas no significant differences in serum 
25(OH)D or number of chronic conditions was observed between osteodynapenic and 
non-dynapenic non-osteopenic participants. Falls risk score did not differ across 
sarcopenic/osteopenic categories whereas it was significantly higher among 
participants with osteodynapenia compared to those who were non-dynapenic non-
osteopenic.  
Incident fracture and mortality over 10 years were 17% and 15% respectively. Figure 
8.1 shows the incidence of fracture over 10 years stratified according to osteopenic, 
sarcopenic and dynapenic status. Incident fractures were more common in 
participants who were osteosarcopenic (21%) and osteopenic non-sarcopenic (21.5%) 
compared to those who were sarcopenic non-osteopenic (13%) and non-sarcopenic 
non-osteopenic (13.5%). Fracture was also more common among participants who 
were osteodynapenic (25.4%), osteopenic non-dynapenic (20.4%) and dynapenic non-
osteopenic (19.5%) compared to those who were non-dynapenic non-osteopenic 
(12%). The interaction between osteopenia and sarcopenia (P=0.666) or dynapenia 
(P=0.763) was not statistically significant.  
Figure 8.2 shows the incidence of mortality over 10 years stratified according to 
osteopenic, sarcopenic and dynapenic status. Mortality was higher in participants who 
were osteosarcopenic (27.9%), and sarcopenic non-osteopenic (23.2%) compared to 
those who were osteopenic non-sarcopenic (15.3%) and non-sarcopenic non-
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osteopenic (11.3%). Mortality was also higher in participants who were 
osteodynapenic (22%) and dynapenic non-osteopenic (21.6%) compared to those who 
were osteopenic non-dynapenic (16.4%) and non-dynapenic non-osteopenic (11.5%). 
The interaction between osteopenia and sarcopenia (P=0.002) was statistically 
significant whereas no statistical interaction was observed between osteopenia and 
dynapenia (P=0.550) 
8.8.1 Associations of Osteosarcopenia and Osteodynapenia with Incident 
Fracture 
Table 8.2 shows the risk ratios for self-reported fracture over 10 years according to 
osteopenic, sarcopenic, and dynapenic categories. Fracture risk was significantly 
higher among participants who were osteopenic non-sarcopenic (RR=1.50, 95% CI: 
1.07, 2.10) but not among those who were osteosarcopenic (RR=1.48, 95% CI: 0.83, 
2.64) or sarcopenic non-osteopenic (RR=0.97, 95% CI: 0.52, 1.81), compared to non-
sarcopenic non-osteopenic participants. Osteosarcopenia did not lead to a 
significantly greater risk of fracture compared to those with sarcopenia alone (P= 
0.255) or osteopenia alone (P=0.964).  
Fracture risk was significantly higher in participants who were osteodynapenic 
(RR=2.07, 95% CI: 1.26–3.39), dynapenic non-osteopenic (RR=1.74, 95% CI: 1.05, 
2.87), and osteopenic non-dynapenic (RR=1.63, 95% CI: 1.15, 2.31), compared to 
those without dynapenia or osteopenia. Osteodynapenia did not lead to a significantly 
greater risk of fracture compared to those with dynapenia alone (P= 0.561) or 
osteopenia alone (P= 0.311).  
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There was no significant sex interaction with regards to the association between 
fracture risk and sarcopenic/osteopenic categories (P=0.889) or dynapenic/osteopenic 
categories (P=0.749). Table 8.3 shows the RR for fracture with muscle mass 
(ALM/BMI), strength (HGS) and hip BMD used as continuous variables. Every 1 SD 
decrease in hip BMD resulted in a 32% increase in fracture risk (RR=1.32, 95% CI: 
1.09, 1.61), whereas no significant association was observed between ALM/BMI and 
fracture (RR=0.96 per 1 SD increase, 95% CI: 0.73, 1.27). Furthermore, there was no 
evidence for an association between HGS (RR=0.81 per 1 SD increase, 95% CI: 0.63, 
1.03) and fracture risk; whereas, every 1 SD decrease in hip BMD resulted in a 31% 
increase in fracture risk (RR=1.31, 95% CI: 1.08, 1.58).  
8.8.2 Associations of Osteosarcopenia and Osteodynapenia with Mortality 
Table 8.4 shows the incident rate ratios for mortality over 10 years according to 
osteopenic, sarcopenic, and dynapenic categories. Mortality risk was significantly 
higher among participants who were osteosarcopenic (RR=1.49, 95% CI: 1.01, 2.21) 
but not among those who were osteopenic non-sarcopenic (RR=1.27, 95% CI: 0.92, 
1.76) or sarcopenic non-osteopenic participants (RR=1.30, 95% CI: 0.88, 1.91), 
compared to those participants who were non-sarcopenic non-osteopenic. The 
combination of osteosarcopenia did not lead to a significantly greater risk of fracture 
compared to those with sarcopenia alone (P=0.529) or osteopenia alone (P=0.418). 
There was no evidence for increased risk of mortality for participants who were 
osteodynapenic (RR=1.03, 95% CI: 0.68, 1.57), dynapenic non-osteopenic (RR=0.91, 
95% CI: 0.62, 1.34) or osteopenic non-dynapenic (RR=1.27, 95% CI: 0.93, 1.72) 
compared to those who were non-dynapenic non-osteopenic. The combination of 
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osteodynapenia did not lead to a significantly greater risk of fracture compared to 
those with dynapenia alone (P=0.602) or osteopenia alone (P=0.318).  
There was no significant sex interaction with regards to the association between 
mortality risk and sarcopenic and osteopenic categories (P=0.555) or dynapenic and 
osteopenic status (P= 0.514). Table 8.5 shows the relative risk for mortality with 
muscle mass (ALM/BMI), strength (HGS) and hip BMD used as continous variables. 
As a continuous variable, there was no evidence for an association among hip BMD, 
ALM/BMI, HGS and mortality in the multivariable models.
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Table 8.1: Baseline descriptive characteristics according to categories of sarcopenia, dynapenia and osteopenia 
Variables 
Non-
sarcopenic, 
Non-
osteopenic 
N = 471 
Osteopenic 
non-sarcopenic 
N =367 
Sarcopenic 
non-
osteopenic 
N =108 
Osteosarcope
nic 
  
N =86 
 Non-
dynapenic, 
Non-
osteopenic 
N =468 
Osteopenic 
non-
dynapenic 
N =353 
Dynapenic 
non-osteopenic 
N =111 
Osteodynapeni
c 
 
 N =100 
Age (years) 61.3 ± 6.9 63.7 ± 7.6a 64.5 ± 7.8a 66.5 ± 7.3a  60.9 ± 6.6 62.9 ± 7.2b 66.3 ± 7.9b 68.8 ± 7.0b 
Female, (%)* 219 (47%) 213 (58%)a 50 (46%) 50 (58%) 225 (48%) 200 (57%) 44 (40%)  63 (63%)b 
Weight (Kg) 80.1 ± 13.7 70.5 ± 12.4a 88.2 ± 14.3a 80.1 ± 14.6 81.9 ± 14.5 72.8 ± 13.6b 80.2 ± 12.8b 70.7 ± 12.5b 
Height (cm) 169.5 ± 8.5 166.4 ± 8.5a 164.1 ± 8.4a 159.6 ± 8.7a 168.8 ± 8.8 165.7 ± 8.9b 167.6 ± 8.4 163.1 ± 9.2b 
BMI (kg/m2) 27.8 ± 3.9 25.4 ± 3.4a 32.7 ± 4.6a 31.4 ± 4.7a 28.7 ± 4.6 26.5 ± 4.4b 28.6 ± 4.3 26.6 ± 4.4b 
Total body fat mass kg) 27.8 ± 8.0 24.9 ± 7.3a 35.8 ± 9.3a 33.9 ± 8.6a 29.3 ± 8.8 26.4 ± 8.4b 29.6 ± 9.1 27.6 ± 8.0 
Appendicular lean mass  25.8 ± 5.4 23.1 ± 5.1a 24.3 ± 4.7a 22.2 ± 4.8a 25.7 ± 5.5 23.3 ± 5.1b 24.7 ± 4.5 21.5 ± 4.5a 
Physical activity (steps/day) 9159 ± 3301 8861 ± 3271 7029 ± 3156a 6872 ± 3070a 8949 ± 3404 8769 ± 3295 7974 ± 3147b 7476 ± 3244b 
Current smoker (%)* 234 (50%) 182 (50%) 55 (51%) 47 (55%) 233 (50%) 188 (53%) 56 (50%) 41 (41%) 
Number of chronic 
conditions 
1.03 ± 1.09 1.00 ± 1.06 1.43 ± 1.31a 1.51 ± 1.28a 1.04 ± 1.10 1.03 ± 1.10 1.40 ± 1.27b 1.21 ± 1.20 
25-hydroxyvitamin D 54.8 ± 17.2 52.2 ± 16.6 46.8 ± 16.2a 47.6 ± 14.4a  53.3 ± 17.5 51.5 ± 16.3 53.3 ± 16.4 50.5 ± 16.0 
Falls risk Z-score 0.08 ± 0.82 0.23 ± 0.81 0.20 ± 0.74 0.28 ± 0.90  0.03 ± 0.76 0.15 ± 0.75 0.40 ± 0.94b 0.56 ± 0.98b 
±Standard deviation; all tests are one-way ANOVA except * (Chi-square test) 
a Significant difference to non-sarcopenic non-osteopenic 
b Significant difference to non-dynapenic non-osteopenic  
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Figure 8.1: Incident fracture over 10 years stratified according to sarcopenic/osteopenic (A) and dynapenic/osteopenic (B) status. 
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Figure 8.2: Mortality over 10 years stratified according to sarcopenic/osteopenic (A) and dynapenic/osteopenic (B) status. 
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Table 8.2: Relative risk (95% CI) for self-reported fracture over 10 years according to sarcopenic, 
dynapenic, and osteopenic categories. 
 Non-sarcopenic, 
Non-osteopenic 
N = 401 
Osteopenic 
non-sarcopenic 
N =288 
Sarcopenic 
non-osteopenic 
N =85 
Osteosarcopenic 
 
N =62 
Unadjusted REF 1.60 (1.15, 2.23) 0.96 (0.52, 1.76) 1.56 (0.90, 2.68) 
Adjusted‡ REF 1.50 (1.07, 2.10) 0.97 (0.52, 1.81) 1.48 (0.83, 2.64) 
 
 Non-dynapenic, 
Non-osteopenic 
N = 399 
Osteopenic 
non-dynapenic 
N =279 
Dynapenic 
non-osteopenic 
N =87 
Osteodynapenic 
 
N =71 
Unadjusted REF 1.70 (1.19, 2.42) 1.62 (0.98, 2.68) 2.11 (1.30, 3.40) 
Adjusted‡ REF 1.63 (1.15, 2.31) 1.74 (1.05, 2.87) 2.07 (1.26, 3.39) 
Relative risk represents the increased risk compared to the REF (reference) group.  
‡Adjusted for age, sex, physical activity (steps/day) and 25-hydroxyvitamin-D.  
Bold text indicates significant at P <0.05 
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Appendicular lean mass normalised to BMI (ALM/BMI) 
 ALM/BMI (/ 1 SD 
increase) 
BMD (/1 SD decrease) 
Univariable model 0.78 (0.66, 0.92) 1.43 (1.21, 1.68) 
Multivariable model ‡ 0.96 (0.73, 1.27) 1.32 (1.09, 1.61) 
Handgrip strength (HGS) 
 HGS (/ 1 SD increase) BMD (/1 SD decrease) 
Univariable model 0.72 (0.61, 0.86) 1.43 (1.21, 1.68) 
Multivariable model † 0.81 (0.63, 1.03) 1.31 (1.08, 1.58) 
Relative risk represents an increase in 1 SD of ALM/BMI, HGS and 1 SD decrease 
in hip BMD.  
‡Both ALM/BMI and hip BMD in the model with further adjustment for age, sex, 
physical activity (steps/day) and 25-hydroxyvitamin-D.  
†Both handgrip strength and hip BMD in the model with further adjustment for age, 
sex, physical activity (steps/day) and 25-hydroxyvitamin-D. 
 
Bold text indicates significant at P <0.05 
Table 8.3: Relative risk (95% CI) for self-reported fracture over 10 years (muscle mass, 
strength and hip BMD as continuous variables) 
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Table 8.4: Relative risk (95% CI) for mortality over 10 years according to sarcopenic, 
dynapenic, and osteopenic categories. 
 
 
 
 
 
 
 
 Non-sarcopenic, 
Non-osteopenic 
N = 471 
Osteopenic 
non-sarcopenic 
N =367 
Sarcopenic 
non-osteopenic 
N =108 
Osteosarcopenic 
 
N =86 
Unadjusted REF 1.36 (0.96, 1.92) 2.06 (1.34, 3.15) 2.48 (1.62, 3.79) 
Adjusted‡ REF 1.27 (0.92, 1.76) 1.30 (0.88, 1.91) 1.49 (1.01, 2.21) 
 
 Non-dynapenic, 
Non-osteopenic 
N = 468 
Osteopenic 
non-dynapenic 
N =353 
Dynapenic 
non-osteopenic 
N =111 
Osteodynapenic 
 
N =100 
Unadjusted REF 1.42 (1.01, 2.01) 1.87 (1.21, 2.89) 1.91 (1.22, 2.98) 
Adjusted‡ REF 1.27 (0.93, 1.72) 0.91 (0.62, 1.34) 1.03 (0.68, 1.57) 
Relative risk represents the increased risk compared to the REF (reference) group.  
‡Adjusted for age, sex, physical activity (steps/day) and number of chronic conditions.  
Bold text indicates significant at P <0.05 
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Table 8.5: Relative risk (95% CI) for mortality over 10 years (muscle mass, strength 
and hip BMD as continuous variables) 
Appendicular lean mass normalised to BMI (ALM/BMI) 
 ALM/BMI (/ 1 SD increase) BMD (/1 SD decrease) 
Univariable model 1.12 (0.97, 1.28) 1.14 (0.97, 1.35) 
Multivariable model ‡ 1.01 (0.79, 1.28) 1.15 (0.98, 1.36) 
Handgrip strength 
 HGS (/ 1 SD increase) BMD (/1 SD decrease) 
Univariable model 0.94 (0.82, 1.07) 1.14 (0.97, 1.35) 
Multivariable model † 1.00 (0.83, 1.21) 1.16 (0.98, 1.36) 
Relative risk represents an increase in 1 SD of ALM/BMI, HGS and 1 SD decrease in hip 
BMD.  
‡Both ALM/BMI and hip BMD in the model with further adjustment for age, sex, physical 
activity (steps/day) and number of chronic conditions.  
†Both handgrip strength and hip BMD in the model with further adjustment for age, sex, 
physical activity (steps/day) and number of chronic conditions. 
 
Bold text indicates significant at P <0.05 
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8.9 Discussion 
This long-term prospective study investigates the association of sarcopenia and dynapenia in 
the presence of osteopenia with fracture and mortality over 10 years in a large sample of 
community-dwelling older adults. Incident fracture over 10 years was significantly higher 
among older adults who were osteodynapenic, dynapenic alone and osteopenic alone 
compared to those without dynapenia or osteopenia. Furthermore, mortality over 10 years 
was significantly higher in participants with osteosarcopenia compared to those without 
sarcopenia or osteopenia. Notably, the combination of osteopenia with sarcopenia or 
dynapenia did not lead to a significantly greater mortality or fracture risk compared to having 
these conditions on their own. These findings suggest that the combined effect of osteopenia 
and sarcopenia or dynapenia on fracture and mortality risk, respectively, may not be greater 
than that of each individual condition. 
The coexistence of low BMD and low muscle strength (osteodynapenia), but not low BMD 
and low muscle mass (osteosarcopenia), significantly increased the risk of fracture over 10 
years. Low BMD is an established risk factor for fracture [282, 283] and muscle strength 
exerts significant force on the bone, contributing to the maintenance of bone strength [284]. 
Hence, both low muscle strength and low BMD in older adults may not adequately stimulate 
osteogenesis thereby increasing fracture risk in the event of a fall. Furthermore, prior studies 
have suggested that low muscle strength (but not muscle mass) significantly increases falls 
risk in older people, potentially due to accelerated age-related decline in muscle strength 
compared to muscle mass [61, 201]. This may explain why the coexistence of low BMD and 
low muscle strength appears to impact more on fracture risk than low muscle mass. It has 
been suggested that the combined assessment of low muscle and bone mass may improve 
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fracture risk assessment compared to low muscle or low BMD alone [285]. We found that, 
although fracture risk was higher in older adults with osteodynapenia compared to those with 
neither condition, the risk of fracture was not significantly greater compared to having 
osteopenia or dynapenia alone. This finding is consistent with previous studies which suggest 
that combining low muscle and bone mass assessment may not improve prediction of fracture 
risk in individuals with either condition [286].The fact that the risk of fracture with 
osteodynapenia was not significantly greater compared to having osteopenia or dynapenia 
alone suggests that combining these assessments may not improve prediction of fracture risk. 
When BMD, muscle mass and strength were considered as continuous variables, increasing 
BMD but not muscle mass or strength was associated with a lower risk of fracture. There 
have been several attempts to identify HGS thresholds for the identification of clinically 
relevant weakness [135, 136]. The lowest 20% of the sex-specific distribution of HGS, as 
used in this study, has been shown to be predictive of fracture and poorer health outcomes in 
older people [63, 201].  
The coexistence of low BMD and low muscle mass (osteosarcopenia), but not low BMD and 
low muscle strength (osteodynapenia), significantly increased the risk of mortality over 10 
years. While osteosarcopenia was associated with increased mortality risk, the risk was not 
significantly greater compared to having osteopenia or sarcopenia alone. Contrary to the risk 
of fracture it was muscle mass (not strength) that was important for mortality. Low 
ALM/BMI is indicative of high body fat percentage which has been shown to be associated 
with mortality risk [287]. A prior study also showed that low BMD is predictive of mortality 
over 6 years, independent of comorbidities, physical activity and previous history of fractures 
[288]. Therefore, it is plausible that older adults with both low BMD and low ALM/BMI had 
an additional risk of mortality compared to individuals with neither condition. Low muscle 
Chapter 8 – Prospective Associations of Osteosarcopenia and Osteodynapenia with Incident 
Fracture and Mortality 
177 
 
mass (as opposed to low strength) combined with low BMD may increase mortality risk 
because muscle mass serves as a reliable protein reserve and plays a key role in recovery 
from illness or trauma, including fracture healing [289]. Indeed, survival following fracture is 
lower in older adults with low muscle mass compared to those with normal muscle mass 
[169]. For instance, in a sample of 192 older adults admitted to the hospital following 
acetabular fracture, mortality over one year was 28.6% in those with low muscle mass 
compared with 12.3% in those with normal muscle mass [169]. Interestingly, no significant 
relationships were observed bewteen muscle strength or mass and BMD as continuous 
variables, and mortality after adjusting for covariates. This finding is consistent with prior 
studies providing evidence for a non-linear relationship between muscle mass, BMD and 
mortality [25, 288].  
The strength of this study includes the 10-year follow-up period and the use of a population-
based sample which increases its generalizability. In addition, body composition was assessed 
using DXA, a gold standard for diagnosing osteopenia/osteoporosis and a valid instrument for 
measuring muscle mass. However, this study has a number of limitations. Firstly, there was 
19% missing data for incident fracture due to loss to follow-up. Such missing data is not 
unexpected in a long-term prospective study involving older people. However, the results of 
sensitivity analysis for missing data using inverse probability weighting were similar to the 
complete case analyses (Table 8.6 and Table 8.7). Secondly, incidence of fracture was self-
reported and may be subject to recall bias. However, inaccuracy of fracture recall is unlikely 
as fractures are a major life event [232]. Thirdly, we were unable to perform cause-specific 
analysis for mortality as data on the specific cause of death was not available for all the 
participants. Lastly, established definitions for sarcopenia were not used in this study as only 
4 participants (men=4; women=0) were classified has having sarcopenia according to the 
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established cut-points for ALM/BMI by the Foundation for National Institute of Health 
(FNIH) sarcopenia project. In contrast we defined cut-points in the lowest 20% of the sex-
specific distribution of muscle mass and strength, which has previously been used as a 
diagnostic measure for sarcopenia (8, 12). Despite this we were able to find important 
associations using this diagnostic measure for low muscle mass and strength. 
In conclusion, low BMD combined with low muscle mass or strength does not significantly 
increase the risk of fracture or mortality compared to having low BMD or low muscle 
mass/strength alone, suggesting that combined assessments may not add additional risk for 
fracture and mortality. 
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Table 8.6: Relative risk (95% CI) for self-reported fracture over 10 years according to sarcopenic, 
dynapenic and osteopenic categories. (Inverse probability weighting) 
 Non-sarcopenic, 
Non-osteopenic 
N = 401 
Osteopenic 
non-sarcopenic 
N =288 
Sarcopenic 
non-osteopenic 
N =85 
Osteosarcopenic 
 
N =62 
Unadjusted REF 1.68 (1.19, 2.38) 1.01 (0.54, 1.90) 1.85 (1.07, 3.21) 
Adjusted‡ REF 1.59 (1.11, 2.27) 0.99 (0.51, 1.92) 1.73 (0.95, 3.14) 
 
 Non-dynapenic, 
Non-osteopenic 
N = 399 
Osteopenic 
non-dynapenic 
N =279 
Dynapenic 
non-osteopenic 
N =87 
Osteodynapenic 
 
N =71 
Unadjusted REF 1.80 (1.25, 2.60) 1.57 (0.93, 2.64) 2.09 (1.26, 3.46) 
Adjusted‡ REF 1.72 (1.19, 2.49) 1.60 (0.95, 2.71) 2.02 (1.19, 3.44) 
Relative risk represents the increased risk compared to the REF (reference) group.  
‡Adjusted for age, sex, physical activity (steps/day) and 25-hydroxyvitamin-D.  
Bold text indicates significant at P <0.05 
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Appendicular lean mass normalised to BMI (ALM/BMI) 
 ALM/BMI (/ 1 SD increase) BMD (/1 SD decrease) 
Univariable model 0.80 (0.67, 0.95) 1.48 (1.24, 1.76) 
Multivariable model ‡ 1.00 (0.75, 1.33) 1.37 (1.12, 1.68) 
 
Handgrip strength (HGS) 
 HGS (/ 1 SD increase) BMD (/1 SD decrease) 
Univariable model 0.75 (0.63, 0.91) 1.48 (1.24, 1.76) 
Multivariable model † 0.88 (0.68, 1.15) 1.37 (1.11, 1.67) 
Relative risk represents an increase in 1 SD of ALM/BMI, HGS and 1 SD decrease in hip 
BMD.  
‡Both ALM/BMI and hip BMD in the model with further adjustment for age, sex, physical 
activity (steps/day) and 25-hydroxyvitamin-D.  
†Both handgrip strength and hip BMD in the model with further adjustment for age, sex, 
physical activity (steps/day) and 25-hydroxyvitamin-D. 
 
Bold text indicates significant at P <0.05 
Table 8.7: Relative risk (95% CI) for self-reported fracture over 10 years (muscle mass, 
strength and hip BMD as continuous variables) (Inverse probability weighting) 
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9.1 Prelude 
Age-related decline in skeletal muscle mass and strength is a major public health 
problem that is associated with functional decline and loss of independence in older 
people. With the ageing population in Australia, the absolute number of older people 
is expected to increase, contributing to substantial increase in direct and indirect costs 
attributed to age-related muscle loss and its sequelae. Prior studies suggest that 
modifiable lifestyle factors such as physical activity may be related to muscle loss. 
However, limited long-term prospective studies have examined these associations. 
Longer term prospective studies are crucial in the design of long-term interventions to 
reduce age-related muscle loss and its associated health consequences. This thesis 
examined the risk factors for age-related muscle loss over a decade and the impact 
that muscle loss has on important clinical outcomes like falls risk, fracture, HRQoL 
and mortality. 
9.2 Summary of findings 
Chapter 4 describes the first longitudinal study to examine the associations of within-
person variability in physical activity, 25(OH)D, knee pain and dysfunction with 
muscle loss over a long-term, in addition to traditional between-person comparisons. 
Participants with a higher physical activity and 25(OH)D, on average, had a higher 
lower-limb muscle mass, strength and muscle quality. Furthermore, participants with 
a higher WOMAC global score, on average, had significantly lower muscle strength, 
muscle quality but not muscle mass. Interestingly, at time-points when an individual 
had a higher physical activity, 25(OH)D and lower WOMAC global score than their 
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average level, they also had a higher muscle strength and muscle quality. Generally, 
within-person estimates were smaller in magnitude compared to the between-person 
estimates potentially because error variance is reduced when individual are compared 
to themselves. This study builds on our knowledge from the between-person analysis, 
as it demonstrates that within-person variability in physical activity, 25(OH)D, knee 
pain and dysfunction have independent effects on the muscle. Chapter 6 uses a similar 
analysis method to examine the associations of between-person and within-person 
variability in physical activity, 25(OH)D, knee pain and dysfunction with falls risk. A 
novel finding of this study was that falls risk score was lower at time-point when an 
individual had a lower WOMAC global score and a higher MVPA above their 
average level. Between-person but not within-person increases in 25(OH)D was 
associated with a lower falls risk score. The within-person findings presented in 
Chapter 4 and 6 may be an incentive to further promote physical activity in otherwise 
inactive older people.  
Chapter 5 compares the performance of low muscle mass and function with falls risk, 
incident fracture and mortality over 10 years. Discrepancy exists in the rate of decline 
in muscle mass and strength and age-related muscle loss is higher in lower-limbs 
compared to upper-limb. Identifying the most valid predictor of important health 
outcomes is vital for developing interventions to prevent older people at risk. Baseline 
low muscle strength (LMS and HGS) and muscle quality (LMQ and UMQ) but not 
the various indices of muscle mass (ALM/HH, ALM/BMI, ALMW and ALMR) were 
associated with a higher falls risk at 10 years. Low handgrip strength and low 
ALM/BMI were the only significant predictors of fracture and mortality respectively. 
Chapter 8 examined whether the prognostic ability of HGS and ALM/BMI as the only 
Chapter 9 – Summary and future directions 
184 
 
predictor of fracture and mortality respectively, would be greater when combined 
with osteopenia. Indeed, mortality risk was significantly higher in participants with 
both osteopenia and low ALM/BMI compared to those without low ALM/BMI or 
osteopenia. Similarly, incident fracture was significantly higher in participants with 
both low HGS and osteopenia, compared to those without osteopenia or low HGS. 
However, osteopenia combined with low ALM/BMI or HGS does not significantly 
increase the risk of fracture or mortality compared to having osteopenia or low HGS / 
low ALM/BMI alone, suggesting that combined assessments may not add additional 
risk for fracture and mortality.  
Chapter 5 showed that low muscle strength (HGS and LMS) but not muscle mass 
were associated with lower falls risk and that low muscle mass, particularly 
ALM/BMI was the only predictor of mortality in this cohort of older people. Chapter 
7 assessed whether ALM/BMI, LMS and HGS had a different impact on HRQoL over 
10 years. Participants (both men and women) with low LMS at baseline had a 
clinically meaningful difference in HRQoL over 10 years compared to those with 
normal strength. Sex modified the association between low HGS at baseline and 
HRQoL over 10 years such that women with low baseline HGS had a clinically 
meaning lower HRQoL over 10 years whereas no significant relationship was 
observed in men. There was a weaker but statistically significant association between 
low ALM/BMI at baseline and HRQoL over 10 years. 
In conclusion, the prospective study of community-dwelling older people presented in 
this thesis demonstrates that, in addition to traditional between-person associations, 
variability in physical activity, 25(OH)D, knee pain and dysfunction within an 
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individual over time relate to muscle changes and falls risk. Furthermore, muscle 
strength, which can be easily measured in clinical practice, appears more important 
than muscle mass for identifying individuals with a higher falls risk, fractures and 
poorer quality of life. However, muscle mass appears to be a better predictor of 
mortality risk. The predictive ability of low HGS and low ALM/BMI in identifying 
individuals with a higher fracture and mortality risk respectively, was stronger when 
these measures were combined with low BMD. Recommendations for further 
research is provided in the following section. 
9.3 Future directions 
Findings from the prospective population-based studies presented in this thesis have 
provided novel and additional information on the long-term risk factors for age-
related muscle loss and the impact that this muscle loss has on multiple health 
outcomes over a decade in community-dwelling older adults. These findings offer a 
new pathway for public health efforts and interventions aimed at minimising muscle 
loss and its sequel.  
For instance, the observation that within-person increase in physical activity was 
associated with higher muscle mass and function and a lower falls risk score could be 
relevant in personalised public health messages aimed at reducing muscle loss and 
falls risk in community-dwelling older people. This could be achieved by highlighting 
that, although maintaining a consistently higher physical activity is beneficial for 
muscle and lower falls risk (between-person effects), increases in physical activity 
(irrespective of the current level of physical activity) also has benefits on muscle 
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mass, strength and muscle quality and also helps reduce falls risk (within-person 
effects).  
The health benefit of physical activity highlighted in Chapter 4 and 6 of this thesis has 
been documented in prior studies [68, 71]. Yet, only 25 – 55% of older people in 
Australia meet or exceed the recommended physical activity guidelines [290]. 
Multimodal interventions including lifestyle counselling and personalised physical 
activity goals can increase physical activity participation at 12 months [291]. 
However, the benefit of such interventions beyond 12 months is unclear [291]. Future 
studies investigating interventions to promote physical activity participation over the 
long-term is critical to preventing muscle loss and poor musculoskeletal health 
outcomes in the older people. Such interventions may include cognitive-behavioural 
therapy that empowers older people to adopt a behaviour that would help sustain 
physical activity participation over long-term.  
Chapter 5 highlighted that low HGS was a consistent predictor of falls risk and 
fracture over a decade. This finding is consistent with studies showing that low HGS 
is associated with important clinical health outcomes, with studies suggesting HGS as 
a vital assessment tool in clinical settings [292]. Despite the available epidemiological 
data showing the relevance of handgrip strength as a non-invasive, cheap and readily 
available tool in identifying individuals with poor health outcome, studies 
demonstrating the feasibility of translating handgrip strength assessments in clinical 
settings are limited. Such studies are vital in implementing handgrip strength 
assessment in routine clinical practice. Recently, Ibrahim et al published the protocol 
of the Grip Strength Routine Implementation (GRImP) study which was aimed at 
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evaluating the acceptability and feasibility of HGS assessment in acute medical wards 
of an hospital in the UK [293]. While the completion of this study may provide 
crucial information on translating HGS assessments into routine clinical practice on 
acute medical wards, studies evaluating the feasibility of HGS assessments in other 
clinical settings including outpatients and rehabilitation wards are warranted. There is 
a wide heterogeneity in the protocol used for the assessments of HGS [294]. 
Therefore, for HGS assessments to be relevant in clinical settings, its measurements 
need to be standardised for comparisons and follow-up of patients in different health 
settings [295]. For instance, several factors including posture, the position of the 
elbow and the wrist during the assessments of HGS may influence the value of the 
grip strength [294]. Hence, variations in the protocols used for the assessments of 
HGS may result in the misclassification of different individuals as having low HGS 
[294].  
Chapter 6 highlight the significance of the relationship of dynamic within-person 
variability in physical activity, serum 25(OH)D, knee pain and dysfunction with 
physiological falls risk. Whilst the PPA is an objective falls risk measure that is not 
subjected to recall bias, this measure assessed physiological falls risk that may not 
necessarily translate to actual falls. Further studies need to confirm the relationship of 
dynamic within-person variability in physical activity, serum 25(OH)D, knee pain and 
dysfunction using actual falls data as an outcome.  
Furthermore, it is possible that within-person variability in the risks for falls follow a 
specific trajectory for different groups of older people. Future studies could adopt a 
group-based trajectory modelling approach to characterise older adults into similar 
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falls trajectories and examine the risk factors for each trajectory. Findings from such 
studies are crucial to help better select which patients would most benefit from a falls 
prevention intervention. Older people are heterogenous, hence, falls prevention 
interventions targeting older people with similar falls trajectory could be more 
effective.  
The interconnection among the multiple risk factors for falls risk and muscle loss 
examined in this thesis are likely to be complex and should be studied in detail in 
future studies. For instance, serum 25(OH)D, knee pain and dysfunction could be a 
possible pathway through which physical activity affects falls risk, muscle mass and 
function. It is also possible that physical activity mediates the association between the 
knee pain/dysfunction and loss of muscle mass and function. Hence, the complex 
mediation pathways among these variables could be studied using multivariate 
analysis technique like structural equation modelling. 
Lastly, the novel within-person analysis method used in this thesis could be used to 
examine between-person and within-person differences for other musculoskeletal 
outcomes (for example osteoarthritis) or for other populations (for instance, BMD 
loss in younger age groups). 
 
 
 
 
Bibliography 
189 
 
 
 
 
 
 
 
Bibliography  
 
 
 
 
 
 
 
 
Bibliography 
190 
 
1. United Nations Department of Economic and Social Affairs Population 
Division, World Population Ageing 2015 (ST/ESA/SER.A/390). 
2. Australian Institute of Health and Welfare, Older Australia at a glance. 4th 
ed. 2007: AIHW Canberra. 
3. Briggs, A.M., et al., Musculoskeletal health conditions represent a global 
threat to healthy aging: a report for the 2015 World Health Organization 
World Report on Ageing and Health. The Gerontologist, 2016. 56(Suppl 2): p. 
S243-S255. 
4. Rosenberg, I.H., Sarcopenia: origins and clinical relevance. The Journal of 
Nutrition, 1997. 127(5): p. 990S-991S. 
5. Janssen, I., et al., The healthcare costs of sarcopenia in the United States. 
Journal of the American Geriatrics Society, 2004. 52(1): p. 80-85. 
6. Beaudart, C., et al., Sarcopenia: burden and challenges for public health. 
Archives of Public Health, 2014. 72(45): p. 1-8. 
7. Scott, D., B. de Courten, and P.R. Ebeling, Sarcopenia: a potential cause and 
consequence of type 2 diabetes in Australia’s ageing population? Med J Aust, 
2016. 205(7): p. 329-333. 
8. Sousa, A., et al., Financial impact of sarcopenia on hospitalization costs. 
European Journal of Clinical Nutrition, 2016. 70(9): p. 1046-1051. 
9. Antunes, A.C., et al., Sarcopenia and hospitalisation costs in older adults: a 
cross‐sectional study. Nutrition & Dietetics, 2017. 74(1): p. 46-50. 
10. Rosenberg, I., Summary comments: epidemiological and methodological 
problems in determining nutritional status of older persons. American Journal 
of Clinical Nutrition, 1989. 50: p. 1231-1233. 
11. Doherty, T.J., Invited review: aging and sarcopenia. Journal of Applied 
Physiology, 2003. 95(4): p. 1717-1727. 
12. Sayer, A.A., et al., The developmental origins of sarcopenia. The Journal of 
Nutrition, Health & Aging, 2008. 12(7): p. 427-432. 
13. Lexell, J., C.C. Taylor, and M. Sjöström, What is the cause of the ageing 
atrophy?: Total number, size and proportion of different fiber types studied in 
whole vastus lateralis muscle from 15-to 83-year-old men. Journal of the 
Neurological Sciences, 1988. 84(2): p. 275-294. 
Bibliography 
191 
 
14. Nilwik, R., et al., The decline in skeletal muscle mass with aging is mainly 
attributed to a reduction in type II muscle fiber size. Experimental 
Gerontology, 2013. 48(5): p. 492-498. 
15. Goodpaster, B.H., et al., Attenuation of skeletal muscle and strength in the 
elderly: The Health ABC Study. Journal of Applied Physiology, 2001. 90(6): 
p. 2157-2165. 
16. Visser, M., et al., Muscle mass, muscle strength, and muscle fat infiltration as 
predictors of incident mobility limitations in well-functioning older persons. 
The Journals of Gerontology Series A: Biological Sciences and Medical 
Sciences, 2005. 60(3): p. 324-333. 
17. Manini, T.M., et al., Effect of dietary restriction and exercise on lower 
extremity tissue compartments in obese, older women: a pilot study. The 
Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 
2014. 69(1): p. 101-108. 
18. Anker, S.D., et al., Muscle wasting disease: a proposal for a new disease 
classification. Journal of Cachexia, Sarcopenia and Muscle, 2014. 5(1): p. 1-3. 
19. Fearon, K., W.J. Evans, and S.D. Anker, Myopenia—a new universal term for 
muscle wasting. Journal of Cachexia, Sarcopenia and Muscle, 2011. 2(1): p. 1-
3. 
20. Cruz-Jentoft, A.J., et al., Sarcopenia: European consensus on definition and 
diagnosis Report of the European Working Group on Sarcopenia in Older 
People. Age and Ageing, 2010. 39(4): p. 412-423. 
21. Santos, M.L.A.S., et al., Muscle strength, muscle balance, physical function 
and plasma interleukin-6 (IL-6) levels in elderly women with knee 
osteoarthritis (OA). Archives of Gerontology and Geriatrics, 2011. 52(3): p. 
322-326. 
22. Kalyani, R.R., M. Corriere, and L. Ferrucci, Age-related and disease-related 
muscle loss: the effect of diabetes, obesity, and other diseases. The Lancet 
Diabetes & Endocrinology, 2014. 2(10): p. 819-829. 
23. Scherbakov, N., et al., Stroke induced Sarcopenia: muscle wasting and 
disability after stroke. International Journal of Cardiology, 2013. 170(2): p. 
89-94. 
24. Cheung, C.-L., K.S. Lam, and B.M. Cheung, Evaluation of cutpoints for low 
lean mass and slow gait speed in predicting death in the National Health and 
Nutrition Examination Survey 1999–2004. The Journals of Gerontology Series 
A: Biological Sciences and Medical Sciences, 2016. 71(1): p. 90-95. 
Bibliography 
192 
 
25. Cawthon, P.M., et al., Cutpoints for low appendicular lean mass that identify 
older adults with clinically significant weakness. The Journals of Gerontology 
Series A: Biological Sciences and Medical Sciences, 2014. 69(5): p. 567-575. 
26. Santilli, V., et al., Clinical definition of sarcopenia. Clinical Cases in Mineral 
and Bone Metabolism, 2014. 11(3): p. 177. 
27. Anker, S.D., J.E. Morley, and S. Haehling, Welcome to the ICD‐10 code for 
sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 2016. 7(5): p. 512-
514. 
28. Baumgartner, R.N., et al., Epidemiology of sarcopenia among the elderly in 
New Mexico. American Journal of Epidemiology, 1998. 147(8): p. 755-763. 
29. Yu, S., et al., The impact of low muscle mass definition on the prevalence of 
sarcopenia in older Australians. BioMed Research International, 2014. 2014: 
p. 1-7. 
30. Bijlsma, A., et al., Defining sarcopenia: the impact of different diagnostic 
criteria on the prevalence of sarcopenia in a large middle aged cohort. Age, 
2013. 35(3): p. 871-881. 
31. Clynes, M., et al., Definitions of sarcopenia: associations with previous falls 
and fracture in a population sample. Calcified Tissue International, 2015. 
97(5): p. 445-452. 
32. Mitchell, W.K., et al., Sarcopenia, dynapenia, and the impact of advancing 
age on human skeletal muscle size and strength; a quantitative review. 
Physiology and Pathophysiology of Musculoskeletal Aging, 2015. 3: p. 1-18. 
33. Newman, A.B., et al., Strength and Muscle Quality in a Well‐Functioning 
Cohort of Older Adults: The Health, Aging and Body Composition Study. 
Journal of the American Geriatrics Society, 2003. 51(3): p. 323-330. 
34. Janssen, I., et al., Skeletal muscle mass and distribution in 468 men and 
women aged 18–88 yr. Journal of Applied Physiology, 2000. 89(1): p. 81-88. 
35. Woo, J., et al., Ethnic and geographic variations in muscle mass, muscle 
strength and physical performance measures. European Geriatric Medicine, 
2014. 5(3): p. 155-164. 
36. Newman, A.B., et al., Sarcopenia: alternative definitions and associations 
with lower extremity function. Journal of the American Geriatrics Society, 
2003. 51(11): p. 1602-1609. 
Bibliography 
193 
 
37. Delmonico, M.J., et al., Alternative definitions of sarcopenia, lower extremity 
performance, and functional impairment with aging in older men and women. 
Journal of the American Geriatrics Society, 2007. 55(5): p. 769-774. 
38. Scott, D., et al., Operational definitions of sarcopenia and their associations 
with 5-year changes in falls risk in community-dwelling middle-aged and 
older adults. Osteoporosis International, 2014. 25(1): p. 187-193. 
39. Sorkin, J.D., D.C. Muller, and R. Andres, Longitudinal change in height of 
men and women: implications for interpretation of the body mass index: the 
Baltimore Longitudinal Study of Aging. American Journal of Epidemiology, 
1999. 150(9): p. 969-977. 
40. Domiciano, D., et al., Discriminating sarcopenia in community-dwelling older 
women with high frequency of overweight/obesity: the Sao Paulo Ageing & 
Health Study (SPAH). Osteoporosis International, 2013. 24(2): p. 595-603. 
41. Studenski, S.A., et al., The FNIH sarcopenia project: rationale, study 
description, conference recommendations, and final estimates. The Journals of 
Gerontology Series A: Biological Sciences and Medical Sciences, 2014. 
69(5): p. 547-558. 
42. Scott, D., et al., Associations of low muscle mass and the metabolic syndrome 
in Caucasian and Asian middle-aged and older adults. The Journal of 
Nutrition, Health & Aging, 2016. 20(3): p. 248-255. 
43. McLean, R.R., et al., Criteria for clinically relevant weakness and low lean 
mass and their longitudinal association with incident mobility impairment and 
mortality: the foundation for the National Institutes of Health (FNIH) 
sarcopenia project. The Journals of Gerontology Series A: Biological 
Sciences and Medical Sciences, 2014. 69(5): p. 576-583. 
44. Janssen, I., S.B. Heymsfield, and R. Ross, Low relative skeletal muscle mass 
(sarcopenia) in older persons is associated with functional impairment and 
physical disability. Journal of the American Geriatrics Society, 2002. 50(5): p. 
889-896. 
45. Rolland, Y., et al., Sarcopenia: its assessment, etiology, pathogenesis, 
consequences and future perspectives. The Journal of Nutrition Health and 
Aging, 2008. 12(7): p. 433-450. 
46. Kim, J., et al., Intermuscular adipose tissue-free skeletal muscle mass: 
estimation by dual-energy X-ray absorptiometry in adults. Journal of Applied 
Physiology, 2004. 97(2): p. 655-660. 
Bibliography 
194 
 
47. Chen, Z., et al., Dual-energy X-ray absorptiometry is a valid tool for assessing 
skeletal muscle mass in older women. The Journal of Nutrition, 2007. 137(12): 
p. 2775-2780. 
48. Muscaritoli, M., et al., Consensus definition of sarcopenia, cachexia and pre-
cachexia: joint document elaborated by Special Interest Groups 
(SIG)“cachexia-anorexia in chronic wasting diseases” and “nutrition in 
geriatrics”. Clinical Nutrition, 2010. 29(2): p. 154-159. 
49. Fielding, R.A., et al., Sarcopenia: an undiagnosed condition in older adults. 
Current consensus definition: prevalence, etiology, and consequences. 
International working group on sarcopenia. Journal of the American Medical 
Directors Association, 2011. 12(4): p. 249-256. 
50. Morley, J.E., et al., Sarcopenia with limited mobility: an international 
consensus. Journal of the American Medical Directors Association, 2011. 
12(6): p. 403-409. 
51. Dam, T.-T., et al., An evidence-based comparison of operational criteria for 
the presence of sarcopenia. The Journals of Gerontology Series A: Biological 
Sciences and Medical Sciences, 2014. 69(5): p. 584-590. 
52. Hughes, V.A., et al., Longitudinal muscle strength changes in older adults 
influence of muscle mass, physical activity, and health. The Journals of 
Gerontology Series A: Biological Sciences and Medical Sciences, 2001. 
56(5): p. B209-B217. 
53. Munn, J., et al., Training with unilateral resistance exercise increases 
contralateral strength. Journal of Applied Physiology, 2005. 99(5): p. 1880-
1884. 
54. Hendy, A.M., M. Spittle, and D.J. Kidgell, Cross education and 
immobilisation: mechanisms and implications for injury rehabilitation. 
Journal of Science and Medicine in Sport, 2012. 15(2): p. 94-101. 
55. Farthing, J.P., J.R. Krentz, and C.R. Magnus, Strength training the free limb 
attenuates strength loss during unilateral immobilization. Journal of Applied 
Physiology, 2009. 106(3): p. 830-836. 
56. Deschenes, M.R., et al., Neural factors account for strength decrements 
observed after short-term muscle unloading. American Journal of Physiology-
Regulatory, Integrative and Comparative Physiology, 2002. 282(2): p. R578-
R583. 
57. Goodpaster, B.H., et al., The loss of skeletal muscle strength, mass, and 
quality in older adults: the health, aging and body composition study. The 
Bibliography 
195 
 
Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 
2006. 61(10): p. 1059-1064. 
58. Dey, D.K., et al., Changes in body composition and its relation to muscle 
strength in 75-year-old men and women: a 5-year prospective follow-up study 
of the NORA cohort in Göteborg, Sweden. Nutrition, 2009. 25(6): p. 613-619. 
59. Frontera, W.R., et al., Aging of skeletal muscle: a 12-yr longitudinal study. 
Journal of Applied Physiology, 2000. 88(4): p. 1321-1326. 
60. Pillen, S., I.M. Arts, and M.J. Zwarts, Muscle ultrasound in neuromuscular 
disorders. Muscle & Nerve, 2008. 37(6): p. 679-693. 
61. Clark, B.C. and T.M. Manini, Sarcopenia≠ dynapenia. The Journals of 
Gerontology Series A: Biological Sciences and Medical Sciences, 2008. 
63(8): p. 829-834. 
62. Cawthon, P.M., et al., Do muscle mass, muscle density, strength, and physical 
function similarly influence risk of hospitalization in older adults? Journal of 
the American Geriatrics Society, 2009. 57(8): p. 1411-1419. 
63. Hairi, N.N., et al., Loss of muscle strength, mass (sarcopenia), and quality 
(specific force) and its relationship with functional limitation and physical 
disability: the Concord Health and Ageing in Men Project. Journal of the 
American Geriatrics Society, 2010. 58(11): p. 2055-2062. 
64. Newman, A.B., et al., Strength, but not muscle mass, is associated with 
mortality in the health, aging and body composition study cohort. The 
Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 
2006. 61(1): p. 72-77. 
65. Barbat-Artigas, S., et al., How to assess functional status: a new muscle 
quality index. The Journal of Nutrition, Health and Aging, 2012. 16(1): p. 67-
77. 
66. McGregor, R.A., D. Cameron-Smith, and S.D. Poppitt, It is not just muscle 
mass: a review of muscle quality, composition and metabolism during ageing 
as determinants of muscle function and mobility in later life. Longevity and 
Healthspan, 2014. 3(9): p. 1-8. 
67. Komar, B., L. Schwingshackl, and G. Hoffmann, Effects of leucine-rich 
protein supplements on anthropometric parameter and muscle strength in the 
elderly: a systematic review and meta-analysis. The Journal of Nutrition, 
Health & Aging, 2015. 19(4): p. 437-446. 
Bibliography 
196 
 
68. Foong, Y.C., et al., Accelerometer‐determined physical activity, muscle 
mass, and leg strength in community‐dwelling older adults. Journal of 
Cachexia, Sarcopenia and Muscle, 2016. 7(3): p. 275-283. 
69. Beaudart, C., et al., The effects of vitamin D on skeletal muscle strength, 
muscle mass, and muscle power: a systematic review and meta-analysis of 
randomized controlled trials. The Journal of Clinical Endocrinology & 
Metabolism, 2014. 99(11): p. 4336-4345. 
70. Henriksen, M., et al., Experimental knee pain reduces muscle strength. The 
Journal of Pain, 2011. 12(4): p. 460-467. 
71. Murphy, R.A., et al., Transition to sarcopenia and determinants of transitions 
in older adults: a population-based study. The Journals of Gerontology Series 
A: Biological Sciences and Medical Sciences, 2013: p. 1-8. 
72. Scott, D., et al., Prospective study of self‐reported pain, radiographic 
osteoarthritis, sarcopenia progression, and falls risk in community‐dwelling 
older adults. Arthritis care & research, 2012. 64(1): p. 30-37. 
73. Robitaille, A., et al., Physical activity and cognitive functioning in the oldest 
old: within-and between-person cognitive activity and psychosocial mediators. 
European Journal of Ageing, 2014. 11(4): p. 333-347. 
74. Rodriguez, J.C., et al., Association Between Pain and Functional 
Independence in Older Adults During and After Admission to Rehabilitation 
After an Acute Illness or Injury. Journal of the American Geriatrics Society, 
2015. 63(11): p. 2275-2281. 
75. Ryu, M., et al., Association of physical activity with sarcopenia and 
sarcopenic obesity in community-dwelling older adults: the Fourth Korea 
National Health and Nutrition Examination Survey. Age and Ageing, 2013. 
42(6): p. 734-740. 
76. Szulc, P., et al., Hormonal and lifestyle determinants of appendicular skeletal 
muscle mass in men: the MINOS study. The American Journal of Clinical 
Nutrition, 2004. 80(2): p. 496-503. 
77. Baumgartner, R.N., et al., Predictors of skeletal muscle mass in elderly men 
and women. Mechanisms of Ageing and Development, 1999. 107(2): p. 123-
136. 
78. Lee, J.S., et al., Associated factors and health impact of sarcopenia in older 
Chinese men and women: a cross-sectional study. Gerontology, 2007. 53(6): 
p. 404-410. 
Bibliography 
197 
 
79. Park, H., et al., Yearlong physical activity and sarcopenia in older adults: the 
Nakanojo Study. European Journal of Applied Physiology, 2010. 109(5): p. 
953-961. 
80. Raguso, C.A., et al., A 3-year longitudinal study on body composition changes 
in the elderly: role of physical exercise. Clinical Nutrition, 2006. 25(4): p. 
573-580. 
81. Drummond, M.J., et al., Bed rest impairs skeletal muscle amino acid 
transporter expression, mTORC1 signaling, and protein synthesis in response 
to essential amino acids in older adults. American Journal of Physiology-
Endocrinology and Metabolism, 2012. 302(9): p. E1113-E1122. 
82. Reid, M.B., A.R. Judge, and S.C. Bodine, CrossTalk opposing view: The 
dominant mechanism causing disuse muscle atrophy is proteolysis. The 
Journal of Physiology, 2014. 592(24): p. 5345-5347. 
83. Hawley, J.A., et al., Integrative biology of exercise. Cell, 2014. 159(4): p. 738-
749. 
84. Kortebein, P., et al., Effect of 10 days of bed rest on skeletal muscle in healthy 
older adults. JAMA, 2007. 297(16): p. 1769-1774. 
85. Gillen, J.B., et al., Three minutes of all-out intermittent exercise per week 
increases skeletal muscle oxidative capacity and improves cardiometabolic 
health. PLoS One, 2014. 9(11): p. e111489. 
86. Wall, B.T., et al., Substantial skeletal muscle loss occurs during only 5 days of 
disuse. Acta Physiologica, 2014. 210(3): p. 600-611. 
87. Phillips, S.M., A brief review of critical processes in exercise-induced 
muscular hypertrophy. Sports Medicine, 2014. 44(1): p. 71-77. 
88. Glover, E.I., et al., Immobilization induces anabolic resistance in human 
myofibrillar protein synthesis with low and high dose amino acid infusion. 
The Journal of Physiology, 2008. 586(24): p. 6049-6061. 
89. Wall, B.T. and L.J. Van Loon, Nutritional strategies to attenuate muscle 
disuse atrophy. Nutrition Reviews, 2013. 71(4): p. 195-208. 
90. Wall, B.T., M.L. Dirks, and L.J. van Loon, Skeletal muscle atrophy during 
short-term disuse: implications for age-related sarcopenia. Ageing Research 
Reviews, 2013. 12(4): p. 898-906. 
Bibliography 
198 
 
91. Schaap, L.A., et al., Inflammatory markers and loss of muscle mass 
(sarcopenia) and strength. The American Journal of Medicine, 2006. 119(6): 
p. 526. e9-526. e17. 
92. Watts, A., et al., Intra-Individual Variability of Physical Activity in Older 
Adults With and Without Mild Alzheimer’s Disease. PloS One, 2016. 11(4): p. 
e0153898. 
93. Morley, J.E., Anorexia of aging: a true geriatric syndrome. The Journal of 
Nutrition, Health & Aging, 2012. 16(5): p. 422-425. 
94. Bauer, J., et al., Evidence-based recommendations for optimal dietary protein 
intake in older people: a position paper from the PROT-AGE Study Group. J 
Am Med Dir Assoc, 2013. 14(8): p. 542-59. 
95. Robinson, S., C. Cooper, and A. Aihie Sayer, Nutrition and sarcopenia: a 
review of the evidence and implications for preventive strategies. Journal of 
Aging Research, 2012. 2012: p. 1-6. 
96. Houston, D.K., et al., Dietary protein intake is associated with lean mass 
change in older, community-dwelling adults: the Health, Aging, and Body 
Composition (Health ABC) Study. The American Journal of Clinical Nutrition, 
2008. 87(1): p. 150-155. 
97. Buford, T.W., et al., Models of accelerated sarcopenia: critical pieces for 
solving the puzzle of age-related muscle atrophy. Ageing Research Reviews, 
2010. 9(4): p. 369-383. 
98. Institute of Medicine Standing Committee on the Scientific Evaluation of 
Dietary Reference Intakes, Dietary reference intakes for energy, 
carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. 
Washington, DC: National Academy Press, 2005. 
99. Wolfe, R.R., The underappreciated role of muscle in health and disease. The 
American Journal of Clinical Nutrition, 2006. 84(3): p. 475-482. 
100. Evans, W.J. and D. Cyr-Campbell, Nutrition, exercise, and healthy aging. 
Journal of the American Dietetic Association, 1997. 97(6): p. 632-638. 
101. Rizzoli, R., et al., The role of dietary protein and vitamin D in maintaining 
musculoskeletal health in postmenopausal women: a consensus statement 
from the European Society for Clinical and Economic Aspects of Osteoporosis 
and Osteoarthritis (ESCEO). Maturitas, 2014. 79(1): p. 122-132. 
102. Kerr, J., et al., The relationship between outdoor activity and health in older 
adults using GPS. International Journal of Environmental Research and Public 
Health, 2012. 9(12): p. 4615-4625. 
Bibliography 
199 
 
103. De Rui, M., et al., Vitamin D deficiency and leisure time activities in the 
elderly: are all pastimes the same? PLoS One, 2014. 9(4): p. e94805. 
104. Liu, G., et al., Poor vitamin D status is prospectively associated with greater 
muscle mass loss in middle-aged and elderly Chinese individuals. Journal of 
the Academy of Nutrition and Dietetics, 2014. 114(10): p. 1544-1551. 
105. Scott, D., et al., A prospective study of the associations between 25‐
hydroxy‐vitamin D, sarcopenia progression and physical activity in older 
adults. Clinical Endocrinology, 2010. 73(5): p. 581-587. 
106. Rosendahl‐Riise, H., et al., Vitamin D supplementation and its influence on 
muscle strength and mobility in community‐dwelling older persons: a 
systematic review and meta‐analysis. Journal of Human Nutrition and 
Dietetics, 2017. 30(1): p. 3-15. 
107. Bischoff‐Ferrari, H., et al., Vitamin D receptor expression in human muscle 
tissue decreases with age. Journal of Bone and Mineral Research, 2004. 19(2): 
p. 265-269. 
108. Roth, S.M., et al., Vitamin D receptor genotype is associated with fat-free 
mass and sarcopenia in elderly men. The Journals of Gerontology Series A: 
Biological Sciences and Medical Sciences, 2004. 59(1): p. B10-B15. 
109. Curtis, E., et al., Determinants of muscle and bone aging. Journal of Cellular 
Physiology, 2015. 230(11): p. 2618-2625. 
110. Tiainen, K., et al., Inflammatory markers and physical performance among 
nonagenarians. The Journals of Gerontology Series A: Biological Sciences 
and Medical Sciences, 2010. 65(6): p. 658-663. 
111. Mäntyselkä, P., et al., Pain as a reason to visit the doctor: a study in Finnish 
primary health care. Pain, 2001. 89(2): p. 175-180. 
112. Leveille, S.G., et al., Widespread musculoskeletal pain and the progression of 
disability in older disabled women. Annals of Internal Medicine, 2001. 
135(12): p. 1038-1046. 
113. Patel, H., et al., Developmental influences, muscle morphology, and 
sarcopenia in community-dwelling older men. The Journals of Gerontology 
Series A: Biological Sciences and Medical Sciences, 2012. 67A(1): p. 82-87. 
114. Sayer, A.A., et al., The developmental origins of sarcopenia: using peripheral 
quantitative computed tomography to assess muscle size in older people. The 
Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 
2008. 63(8): p. 835-840. 
Bibliography 
200 
 
115. Sayer, A.A., et al., Does sarcopenia originate in early life? Findings from the 
Hertfordshire cohort study. The Journals of Gerontology Series A: Biological 
Sciences and Medical Sciences, 2004. 59(9): p. M930-M934. 
116. Dodds, R., et al., Birth weight and muscle strength: a systematic review and 
meta-analysis. The journal of Nutrition, Health & Aging, 2012: p. 1-7. 
117. Tan, L.-J., et al., Molecular genetic studies of gene identification for 
sarcopenia. Human Genetics, 2012. 131(1): p. 1-31. 
118. Lucassen, E., et al., Poor sleep quality and later sleep timing are risk factors 
for osteopenia and sarcopenia in middle-aged men and women: The NEO 
study. PloS One, 2017. 12(5): p. e0176685. 
119. Stevens, J.A. and E.D. Sogolow, Gender differences for non-fatal 
unintentional fall related injuries among older adults. Injury Prevention, 
2005. 11(2): p. 115-119. 
120. Alexander, B.H., F.P. Rivara, and M.E. Wolf, The cost and frequency of 
hospitalization for fall-related injuries in older adults. American Journal of 
Public Health, 1992. 82(7): p. 1020-1023. 
121. Tovell, A., et al., Hospital separations due to injury and poisoning, Australia 
2009–10. Injury Research and Statistics Series no. 69. Cat. no. INJCAT 145. 
Canberra: AIHW. 2012. 
122. Rubenstein, L.Z., Falls in older people: epidemiology, risk factors and 
strategies for prevention. Age and Ageing, 2006. 35(suppl 2): p. ii37-ii41. 
123. Hadjistavropoulos, T., K. Delbaere, and T.D. Fitzgerald, Reconceptualizing 
the role of fear of falling and balance confidence in fall risk. Journal of Aging 
and Health, 2011. 23(1): p. 3-23. 
124. Zijlstra, G., et al., Prevalence and correlates of fear of falling, and associated 
avoidance of activity in the general population of community-living older 
people. Age and Ageing, 2007. 36(3): p. 304-309. 
125. Ambrose, A.F., G. Paul, and J.M. Hausdorff, Risk factors for falls among 
older adults: a review of the literature. Maturitas, 2013. 75(1): p. 51-61. 
126. Moller, J., Projected costs of fall related injury to older persons due to 
demographic change in Australia. Canberra: Commonwealth Department of 
Health and Ageing, 2003. 28. 
127. Ganz, D.A., et al., Will my patient fall? JAMA, 2007. 297(1): p. 77-86. 
Bibliography 
201 
 
128. American Geriatrics Society and A.A.o.O. Surgeons, Guideline for the 
prevention of falls in older persons. Journal of the American Geriatrics 
Society, 2001. 49(5): p. 664-672. 
129. Kenny, R., et al., Summary of the updated American Geriatrics Society/British 
Geriatrics Society clinical practice guideline for prevention of falls in older 
persons. Journal of the American Geriatrics Society, 2011. 59(1): p. 148-157. 
130. Ward, R.E., et al., Functional performance as a predictor of injurious falls in 
older adults. Journal of the American Geriatrics Society, 2015. 63(2): p. 315-
320. 
131. Scott, D., et al., Investigating the predictive ability of gait speed and 
quadriceps strength for incident falls in community-dwelling older women at 
high risk of fracture. Archives of Gerontology and Geriatrics, 2014. 58(3): p. 
308-313. 
132. Moreland, J.D., et al., Muscle weakness and falls in older adults: a systematic 
review and meta‐analysis. Journal of the American Geriatrics Society, 2004. 
52(7): p. 1121-1129. 
133. Bischoff-Ferrari, H., et al., Comparative performance of current definitions of 
sarcopenia against the prospective incidence of falls among community-
dwelling seniors age 65 and older. Osteoporosis International, 2015. 26(12): 
p. 2793-2802. 
134. Chalhoub, D., et al., Risk of nonspine fractures in older adults with 
sarcopenia, low bone mass, or both. Journal of the American Geriatrics 
Society, 2015. 63(9): p. 1733-1740. 
135. Cheung, C.-L., et al., Low handgrip strength is a predictor of osteoporotic 
fractures: cross-sectional and prospective evidence from the Hong Kong 
Osteoporosis Study. Age, 2012. 34(5): p. 1239-1248. 
136. Alley, D.E., et al., Grip strength cutpoints for the identification of clinically 
relevant weakness. Journals of Gerontology Series A: Biomedical Sciences 
and Medical Sciences, 2014. 69(5): p. 559-566. 
137. Peeters, G., N.M. van Schoor, and P. Lips, Fall risk: the clinical relevance of 
falls and how to integrate fall risk with fracture risk. Best Practice & Research 
Clinical Rheumatology, 2009. 23(6): p. 797-804. 
138. Benichou, O. and S.R. Lord, Rationale for strengthening muscle to prevent 
falls and fractures: a review of the evidence. Calcified Tissue International, 
2016. 98(6): p. 531-545. 
Bibliography 
202 
 
139. Norton, R., et al., Circumstances of falls resulting in hip fractures among 
older people. Journal of the American Geriatrics Society, 1997. 45(9): p. 
1108-1112. 
140. Altman, D.G., Systematic reviews in health care: Systematic reviews of 
evaluations of prognostic variables. British Medical Journal, 2001. 323(7306): 
p. 224. 
141. Stenhagen, M., et al., Falls in the general elderly population: a 3-and 6-year 
prospective study of risk factors using data from the longitudinal population 
study ‘Good ageing in Skane’. BMC Geriatrics, 2013. 13(81): p. 1-11. 
142. Peeters, G., et al., Is there a U-shaped association between physical activity 
and falling in older persons? Osteoporosis International, 2010. 21(7): p. 1189-
1195. 
143. Caban-Martinez, A.J., et al., Leisure-time physical activity, falls, and fall 
injuries in middle-aged adults. American Journal of Preventive Medicine, 
2015. 49(6): p. 888-901. 
144. Jefferis, B.J., et al., Physical activity and falls in older men: the critical role of 
mobility limitations. Med Sci Sports Exerc, 2015. 47(10): p. 2119-28. 
145. Thibaud, M., et al., Impact of physical activity and sedentary behaviour on fall 
risks in older people: a systematic review and meta-analysis of observational 
studies. European Review of Aging and Physical Activity, 2012. 9(1): p. 5-15. 
146. Friedman, S.M., et al., Falls and fear of falling: which comes first? A 
longitudinal prediction model suggests strategies for primary and secondary 
prevention. Journal of the American Geriatrics Society, 2002. 50(8): p. 1329-
1335. 
147. Graafmans, W., et al., Daily physical activity and the use of a walking aid in 
relation to falls in elderly people in a residential care setting. Zeitschrift für 
Gerontologie und Geriatrie, 2003. 36(1): p. 23-28. 
148. Menant, J., et al., Relationships between serum vitamin D levels, 
neuromuscular and neuropsychological function and falls in older men and 
women. Osteoporosis International, 2012. 23(3): p. 981-989. 
149. Shimizu, Y., et al., Serum 25-hydroxyvitamin D level and risk of falls in 
Japanese community-dwelling elderly women: a 1-year follow-up study. 
Osteoporosis International, 2015. 26(8): p. 2185-2192. 
150. Bischoff-Ferrari, H.A., et al., Monthly high-dose vitamin D treatment for the 
prevention of functional decline: a randomized clinical trial. JAMA Internal 
Medicine, 2016. 176(2). 
Bibliography 
203 
 
151. Sanders, K.M., et al., Annual high-dose oral vitamin D and falls and fractures 
in older women: a randomized controlled trial. JAMA, 2010. 303(18): p. 
1815-22. 
152. Uusi-Rasi, K., et al., Exercise and vitamin D in fall prevention among older 
women: a randomized clinical trial. JAMA Internal Medicine, 2015. 175(5): 
p. 703-711. 
153. Dawson-Hughes, B. and S.S. Harris, High-dose vitamin D supplementation: 
too much of a good thing? JAMA, 2010. 303(18): p. 1861-2. 
154. Ginde, A.A., et al., High‐Dose Monthly Vitamin D for Prevention of Acute 
Respiratory Infection in Older Long‐Term Care Residents: A Randomized 
Clinical Trial. Journal of the American Geriatrics Society, 2017. 65(3): p. 
496-503. 
155. Wicherts, I.S., et al., Vitamin D status predicts physical performance and its 
decline in older persons. The Journal of Clinical Endocrinology & 
Metabolism, 2007. 92(6): p. 2058-2065. 
156. Wilkins, C.H., et al., Vitamin D deficiency is associated with low mood and 
worse cognitive performance in older adults. The American journal of 
geriatric psychiatry, 2006. 14(12): p. 1032-1040. 
157. Atherton, K., et al., Vitamin D and chronic widespread pain in a white middle-
aged British population: evidence from a cross-sectional population survey. 
Annals of the Rheumatic Diseases, 2009. 68(6): p. 817-822. 
158. Murad, M.H., et al., The effect of vitamin D on falls: a systematic review and 
meta-analysis. The Journal of Clinical Endocrinology & Metabolism, 2011. 
96(10): p. 2997-3006. 
159. Abdulla, A., et al., Guidance on the management of pain in older people. Age 
and Ageing, 2013. 42: p. i1-57. 
160. Tinetti, M.E., M. Speechley, and S.F. Ginter, Risk factors for falls among 
elderly persons living in the community. New England Journal of Medicine, 
1988. 319(26): p. 1701-1707. 
161. Myers, A.M., et al., Psychological indicators of balance confidence: 
relationship to actual and perceived abilities. The Journals of Gerontology 
Series A: Biological Sciences and Medical Sciences, 1996. 51(1): p. M37-
M43. 
Bibliography 
204 
 
162. Landers, M.R., et al., Balance confidence and fear of falling avoidance 
behavior are most predictive of falling in older adults: prospective analysis. 
Physical Therapy, 2016. 96(4): p. 433-442. 
163. Dzierzewski, J.M., et al., Daily variations in objective nighttime sleep and 
subjective morning pain in older adults with insomnia: Evidence of 
covariation over time. Journal of the American Geriatrics Society, 2010. 
58(5): p. 925-930. 
164. Woo, T., S. Yu, and R. Visvanathan, Systematic Literature Review on the 
Relationship Between Biomarkers of Sarcopenia and Quality of Life in Older 
People. The Journal of Frailty & Aging, 2016. 5(2): p. 88-99. 
165. Beaudart, C., et al., Quality of life and physical components linked to 
sarcopenia: The SarcoPhAge study. Experimental Gerontology, 2015. 69: p. 
103-110. 
166. Neto, L.S.S., et al., Association between sarcopenia, sarcopenic obesity, 
muscle strength and quality of life variables in elderly women. Brazilian 
Journal of Physical Therapy, 2012. 16(5): p. 360-367. 
167. Schaap, L.A., A. Koster, and M. Visser, Adiposity, muscle mass, and muscle 
strength in relation to functional decline in older persons. Epidemiologic 
Reviews, 2013. 35(1): p. 51-65. 
168. Joglekar, S., P.N. Nau, and J.J. Mezhir, The impact of sarcopenia on survival 
and complications in surgical oncology: a review of the current literature. 
Journal of Surgical Oncology, 2015. 112(5): p. 503-509. 
169. Deren, M.E., et al., Increased Mortality in Elderly Patients with Sarcopenia 
and Acetabular Fractures. J Bone Joint Surg Am, 2017. 99(3): p. 200-206. 
170. Kaido, T., et al., Impact of sarcopenia on survival in patients undergoing 
living donor liver transplantation. American Journal of Transplantation, 2013. 
13(6): p. 1549-1556. 
171. Kull, M., R. Kallikorm, and M. Lember, Impact of a new sarco-osteopenia 
definition on health-related quality of life in a population-based cohort in 
Northern Europe. Journal of Clinical Densitometry, 2012. 15(1): p. 32-38. 
172. He, H., et al., Relationship of sarcopenia and body composition with 
osteoporosis. Osteoporosis International, 2016. 27(2): p. 473-482. 
173. Edwards, M.H., et al., Muscle size, strength, and physical performance and 
their associations with bone structure in the Hertfordshire Cohort Study. 
Journal of Bone and Mineral Research, 2013. 28(11): p. 2295-2304. 
Bibliography 
205 
 
174. Kim, S.W., H.A. Lee, and E.-H. Cho, Low handgrip strength is associated 
with low bone mineral density and fragility fractures in postmenopausal 
healthy Korean women. Journal of Korean medical science, 2012. 27(7): p. 
744-747. 
175. Brotto, M. and L. Bonewald, Bone and muscle: interactions beyond 
mechanical. Bone, 2015. 80: p. 109-114. 
176. Kurek, J.B., et al., The role of leukemia inhibitory factor in skeletal muscle 
regeneration. Muscle & Nerve, 1997. 20(7): p. 815-822. 
177. DiGirolamo, D.J., T.L. Clemens, and S. Kousteni, The skeleton as an 
endocrine organ. Nature Reviews Rheumatology, 2012. 8(11): p. 674-683. 
178. Pratesi, A., F. Tarantini, and M. Di Bari, Skeletal muscle: an endocrine organ. 
Clinical Cases in Mineral and Bone Metabolism, 2013. 10(1): p. 11-14. 
179. Gentry, B.A., et al., Skeletal muscle weakness in osteogeneis imperfecta mice. 
Matrix Biology, 2010. 29(7): p. 638-644. 
180. Levinger, I., S. Phu, and G. Duque, Sarcopenia and Osteoporotic Fractures. 
Clinical Reviews in Bone and Mineral Metabolism, 2016. 14(1): p. 38-44. 
181. Kawao, N. and H. Kaji, Interactions between muscle tissues and bone 
metabolism. Journal of Cellular Biochemistry, 2015. 116(5): p. 687-695. 
182. Rosen, C.J. and M.L. Bouxsein, Mechanisms of disease: is osteoporosis the 
obesity of bone? Nature Clinical Practice Rheumatology, 2006. 2(1): p. 35-43. 
183. Hamrick, M.W., M.E. McGee-Lawrence, and D.M. Frechette, Fatty 
Infiltration of Skeletal Muscle: Mechanisms and Comparisons with Bone 
Marrow Adiposity. Frontiers in Endocrinology, 2016. 7(69): p. 1-7. 
184. Huo, Y.R., et al., Phenotype of osteosarcopenia in older individuals with a 
history of falling. Journal of the American Medical Directors Association, 
2015. 16(4): p. 290-295. 
185. Scott, D., et al., Prospective associations between ambulatory activity, body 
composition and muscle function in older adults. Scandinavian Journal of 
Medicine & Science in Sports, 2011. 21(6): p. e168-e175. 
186. Lord, S.R., H.B. Menz, and A. Tiedemann, A physiological profile approach 
to falls risk assessment and prevention. Physical Therapy, 2003. 83(3): p. 237-
252. 
Bibliography 
206 
 
187. Lord, S.R., et al., Physiological factors associated with falls in older 
community-dwelling women. Journal of the American Geriatrics Society, 
1994. 42(10): p. 1110-1117. 
188. Hawthorne, G., J. Richardson, and R. Osborne, The Assessment of Quality of 
Life (AQoL) instrument: a psychometric measure of health-related quality of 
life. Quality of Life Research, 1999. 8(3): p. 209-224. 
189. Richardson, J., et al., Difficulty with Life and Death: Methodological Issues 
and Results from the Utility Scaling of the Assessment of Quality of Life 
(AQoL) Instrument. Centre for Health Program Evaluation, Melbourne. 1998: 
p. 29 pages. 
190. Hawthorne, G. and R. Osborne, Population norms and meaningful differences 
for the Assessment of Quality of Life (AQoL) measure. Australian and New 
Zealand Journal of Public Health, 2005. 29(2): p. 136-142. 
191. Schmidt, M.D., et al., Cardiometabolic risk in younger and older adults 
across an index of ambulatory activity. American Journal of Preventive 
Medicine, 2009. 37(4): p. 278-284. 
192. McConnell, S., P. Kolopack, and A.M. Davis, The Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility 
and measurement properties. Arthritis Care & Research, 2001. 45(5): p. 453-
461. 
193. Hoffman, L. and R.S. Stawski, Persons as contexts: Evaluating between-
person and within-person effects in longitudinal analysis. Research in Human 
Development, 2009. 6(2-3): p. 97-120. 
194. Singer, J.D. and J.B. Willett, Applied longitudinal data analysis: Modeling 
change and event occurrence. 2003: Oxford university press. 
195. Bartels, B., Beyond" fixed versus random effects": a framework for improving 
substantive and statistical analysis of panel, time-series cross-sectional, and 
multilevel data. The Society for Political Methodology, 2008: p. 1-43. 
196. Neuhaus, J.M. and J.D. Kalbfleisch, Between-and within-cluster covariate 
effects in the analysis of clustered data. Biometrics, 1998: p. 638-645. 
197. Bell, A. and K. Jones, Explaining fixed effects: Random effects modeling of 
time-series cross-sectional and panel data. Political Science Research and 
Methods, 2015. 3(01): p. 133-153. 
198. Preacher, K.J., M.J. Zyphur, and Z. Zhang, A general multilevel SEM 
framework for assessing multilevel mediation. Psychological Methods, 2010. 
15(3): p. 209-233. 
Bibliography 
207 
 
199. Hoffman, L., Longitudinal analysis: Modeling within-person fluctuation and 
change. 2015: Routledge. 
200. Hirani, V., et al., Sarcopenia is associated with incident disability, 
institutionalization, and mortality in community-dwelling older men: the 
Concord Health and Ageing in Men Project. Journal of the American Medical 
Directors Association, 2015. 16(7): p. 607-613. 
201. Balogun, S., et al., Prospective Associations of Low Muscle Mass and 
Function with 10-year Falls Risk, Incident Fracture and Mortality in 
Community-dwelling Older Adults. Journal of Nutrition Health & Aging, 
2017. 21(7): p. 843–848. 
202. Roshanravan, B., et al., Association of Muscle Endurance, Fatigability, and 
Strength With Functional Limitation and Mortality in the Health Aging and 
Body Composition Study. The Journals of Gerontology Series A: Biological 
Sciences and Medical Sciences, 2017. 72(2): p. 284-291. 
203. Denison, H.J., et al., Prevention and optimal management of sarcopenia: a 
review of combined exercise and nutrition interventions to improve muscle 
outcomes in older people. Clinical Interventions in Aging, 2015. 10: p. 859-
869. 
204. Hirani, V., et al., Longitudinal Associations Between Vitamin D Metabolites 
and Sarcopenia in Older Australian men: The Concord Health and Aging in 
Men Project. The Journals of Gerontology: Series A, 2017. 00(00): p. 1-8. 
205. Wang, L.P. and S.E. Maxwell, On disaggregating between-person and within-
person effects with longitudinal data using multilevel models. Psychological 
Methods, 2015. 20(1): p. 63-83. 
206. Metter, E.J., et al., Muscle quality and age: cross-sectional and longitudinal 
comparisons. The Journals of Gerontology Series A: Biological Sciences and 
Medical Sciences, 1999. 54(5): p. B207-B218. 
207. Elsawy, B. and K.E. Higgins, Physical activity guidelines for older adults. 
American Family Physician, 2010. 81(1): p. 55-9. 
208. Scott, D., et al., Ambulatory activity, body composition, and lower-limb 
muscle strength in older adults. Medicine Science in Sports Exercise, 2009. 
41(2): p. 383-389. 
209. Da Boit, M., et al., Sex differences in the response to resistance exercise 
training in older people. Physiological Reports, 2016. 4(12): p. e12834. 
210. Vlaeyen, J.W. and S.J. Linton, Fear-avoidance and its consequences in 
chronic musculoskeletal pain: a state of the art. Pain, 2000. 85(3): p. 317-332. 
Bibliography 
208 
 
211. Cruz-Almeida, Y., et al., Associations of Musculoskeletal Pain With Mobility 
in Older Adults: Potential Cerebral Mechanisms. The Journals of Gerontology 
Series A: Biological Sciences and Medical Sciences, 2017. 00(00): p. 1-7. 
212. Young, A., Current issues in arthrogenous inhibition. Annals of the 
Rheumatic Diseases, 1993. 52(11): p. 829-834. 
213. Wade, K.F., et al., Does Pain Predict Frailty in Older Men and Women? 
Findings From the English Longitudinal Study of Ageing (ELSA). The 
Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 
2016. 71(6): p. 823-830. 
214. Fransen, M., et al., A longitudinal study of knee pain in older men: Concord 
Health and Ageing in Men Project. Age and Ageing, 2013. 43(2): p. 206-212. 
215. Meints, S.M., et al., Pain-Related Rumination, But Not Magnification or 
Helplessness, Mediates Race and Sex Differences in Experimental Pain. The 
Journal of Pain, 2016. 18(3): p. 332-339. 
216. Rizzoli, R., et al., Quality of Life in Sarcopenia and Frailty. Calcified Tissue 
International, 2013. 93(2): p. 101-120. 
217. Gifondorwa, D.J., et al., Vitamin D and/or calcium deficient diets may 
differentially affect muscle fiber neuromuscular junction innervation. Muscle 
& nerve, 2016. 54(6): p. 1120-1132. 
218. Grimaldi, A.S., et al., 25 (OH) vitamin D is associated with greater muscle 
strength in healthy men and women. Medicine and Science in Sports and 
Exercise, 2013. 45(1): p. 157. 
219. Tanimoto, Y., et al., Sarcopenia and falls in community-dwelling elderly 
subjects in Japan: defining sarcopenia according to criteria of the European 
Working Group on Sarcopenia in Older People. Archives of Gerontology and 
Geriatrics, 2014. 59(2): p. 295-299. 
220. Cederholm, T., A. Cruz-Jentoft, and S. Maggi, Sarcopenia and fragility 
fractures. European Journal of Physical and Rehabilitation Medicine, 2013. 
49(1): p. 111-117. 
221. Frontera, W.R., et al., A cross-sectional study of muscle strength and mass in 
45-to 78-yr-old men and women. Journal of Applied Physiology, 1991. 71(2): 
p. 644-650. 
222. Sjöblom, S., et al., Relationship between postmenopausal osteoporosis and the 
components of clinical sarcopenia. Maturitas, 2013. 75(2): p. 175-180. 
Bibliography 
209 
 
223. Iolascon, G., et al., Sarcopenia in women with vertebral fragility fractures. 
Aging Clinical and Experimental Research, 2013. 25(1): p. 129-131. 
224. Di Monaco, M., et al., Prevalence of sarcopenia and its association with 
osteoporosis in 313 older women following a hip fracture. Archives of 
Gerontology and Geriatrics, 2011. 52(1): p. 71-74. 
225. Steihaug, O.M., et al., Identifying low muscle mass in patients with hip 
fracture: Validation of bioelectrical impedance analysis and anthropometry 
compared to dual energy X-ray absorptiometry. The Journal of Nutrition, 
Health & Aging, 2016. 20(7): p. 685-90. . 
226. Kim, J.H., et al., Sarcopenia: an independent predictor of mortality in 
community-dwelling older Korean men. The Journals of Gerontology Series 
A: Biological Sciences and Medical Sciences, 2014. 69(10): p. 1244-1252. 
227. Landi, F., et al., Midarm muscle circumference, physical performance and 
mortality: results from the aging and longevity study in the Sirente geographic 
area (ilSIRENTE study). Clinical Nutrition, 2010. 29(4): p. 441-447. 
228. di Angelantonio E., B.S., Wormser D, Gao P, Kaptoge S, Berrington de 
Gonzalez A, Cairns BJ, et al., Body-mass index and all-cause mortality: 
Individual-participant-data meta-analysis of 239 prospective studies in four 
continents. The Lancet, 2016. 388(10046): p. 776 - 786. 
229. Bohannon, R.W., Hand‐Grip Dynamometry Predicts Future Outcomes in 
Aging Adults. Journal of Geriatric Physical Therapy, 2008. 31(1): p. 3-10. 
230. Leong, D.P., et al., Prognostic value of grip strength: findings from the 
Prospective Urban Rural Epidemiology (PURE) study. The Lancet, 2015. 
386(9990): p. 266-273. 
231. Chan, J.P., et al., Genetics of hand grip strength in mid to late life. Age, 2015. 
37(1): p. 1-10. 
232. Ivers, R.Q., et al., The accuracy of self-reported fractures in older people. 
Journal of Clinical Epidemiology, 2002. 55(5): p. 452-457. 
233. Ward, C. and J. Adams, Comparative study of the test-re-test reliability of four 
instruments to measure grip strength in a healthy population. The British 
Journal of Hand Therapy, 2007. 12(2): p. 48-54. 
234. Lord, S.R., et al., Falls in older people: risk factors and strategies for 
prevention. 2007: Cambridge University Press. 
Bibliography 
210 
 
235. Pahor, M., T. Manini, and M. Cesari, Sarcopenia: clinical evaluation, 
biological markers and other evaluation tools. The Journal of Nutrition, 
Health and Aging, 2009. 13(8): p. 724-728. 
236. van der Heijden, G.J., et al., Imputation of missing values is superior to 
complete case analysis and the missing-indicator method in multivariable 
diagnostic research: a clinical example. Journal of Clinical Epidemiology, 
2006. 59(10): p. 1102-1109. 
237. Rubin, D.B., Inference and missing data. Biometrika, 1976. 63(3): p. 581-592. 
238. Graham, J.W., A.E. Olchowski, and T.D. Gilreath, How many imputations are 
really needed? Some practical clarifications of multiple imputation theory. 
Prevention Science, 2007. 8(3): p. 206-213. 
239. Horton, N.J. and S.R. Lipsitz, Multiple imputation in practice: comparison of 
software packages for regression models with missing variables. The 
American Statistician, 2001. 55(3): p. 244-254. 
240. Davis, J., et al., International comparison of cost of falls in older adults living 
in the community: a systematic review. Osteoporosis International, 2010. 
21(8): p. 1295-1306. 
241. Johnson, S., S. Kelly, and D. Rasali, Differences in fall injury hospitalization 
and related survival rates among older adults across age, sex, and areas of 
residence in Canada. Injury Epidemiology, 2015. 2(24): p. 1-10. 
242. Heesch, K.C., J.E. Byles, and W.J. Brown, Prospective association between 
physical activity and falls in community-dwelling older women. Journal of 
Epidemiology and Community Health, 2008. 62(5): p. 421-426. 
243. Foley, S., et al., Falls risk is associated with pain and dysfunction but not 
radiographic osteoarthritis in older adults: Tasmanian Older Adult Cohort 
study. Osteoarthritis and Cartilage, 2006. 14(6): p. 533-539. 
244. Dukas, L., et al., Alfacalcidol Reduces the Number of Fallers in a 
Community‐Dwelling Elderly Population with a Minimum Calcium Intake of 
More Than 500 Mg Daily. Journal of the American Geriatrics Society, 2004. 
52(2): p. 230-236. 
245. Bischoff-Ferrari, H.A., et al., Fall prevention with supplemental and active 
forms of vitamin D: a meta-analysis of randomised controlled trials. British 
Medical Journal, 2009. 339: p. b3692. 
246. Mei, I., et al., Vitamin D deficiency in Tasmania: a whole of life perspective. 
Internal Medicine Journal, 2012. 42(10): p. 1137-1144. 
Bibliography 
211 
 
247. Hoffman, L., Considering alternative metrics of time: Does anybody really 
know what "Time" is?, in Advances in Longitudinal Methods in the Social and 
Behavioral Sciences, Jeffrey Harring and Gregory Hancock, Editors. 2012: 
Charlotte, NC. p. 255 -287. 
248. Bolland, M.J., et al., Vitamin D supplementation and falls: a trial sequential 
meta-analysis. The lancet Diabetes & Endocrinology, 2014. 2(7): p. 573-580. 
249. Chan, R., et al., Not all elderly people benefit from vitamin D supplementation 
with respect to physical function: results from the Osteoporotic Fractures in 
Men Study, Hong Kong. Journal of the American Geriatrics Society, 2012. 
60(2): p. 290-295. 
250. Stockton, K., et al., Effect of vitamin D supplementation on muscle strength: a 
systematic review and meta-analysis. Osteoporosis International, 2011. 22(3): 
p. 859-871. 
251. Denny, D.L. and G.W. Guido, Undertreatment of pain in older adults: an 
application of beneficence. Nursing Ethics, 2012. 19(6): p. 800-809. 
252. Leveille, S.G., et al., Musculoskeletal pain and risk for falls in older disabled 
women living in the community. Journal of the American Geriatrics Society, 
2002. 50(4): p. 671-678. 
253. Gill, T.M., et al., Effect of structured physical activity on prevention of serious 
fall injuries in adults aged 70-89: randomized clinical trial (LIFE Study). 
BMJ, 2016. 352: p. i245. 
254. Faber, M.J., et al., Effects of exercise programs on falls and mobility in frail 
and pre-frail older adults: a multicenter randomized controlled trial. Archives 
of Physical Medicine and Rehabilitation, 2006. 87(7): p. 885-896. 
255. Pau, M., et al., Effect of light and vigorous physical activity on balance and 
gait of older adults. Archives of Gerontology and Geriatrics, 2014. 59(3): p. 
568-573. 
256. Lord, S.R., et al., Physiological Factors Associated with Falls in Older 
Community‐Dwelling Women. Journal of the American Geriatrics Society, 
1994. 42(10): p. 1110-1117. 
257. Dhanak, M. and R. Penhal, Australian and New Zealand Society for Geriatric 
Medicine: Position Statement--Exercise guidelines for older adults. 
Australasian Journal of Ageing, 2014. 33(4): p. 287-94. 
258. Sayer, A.A., et al., Is grip strength associated with health-related quality of 
life? - Findings from the Hertfordshire Cohort Study. Age and Ageing, 2006. 
35(4): p. 409-415. 
Bibliography 
212 
 
259. Go, S.W., et al., Association between sarcopenia, bone density, and health-
related quality of life in Korean men. Korean Journal of Family Medicine, 
2013. 34(4): p. 281-288. 
260. Samuel, D., et al., The relationships between muscle strength, biomechanical 
functional moments and health-related quality of life in non-elite older adults. 
Age and Ageing, 2012. 41(2): p. 224-230. 
261. Manrique-Espinoza, B., et al., Sarcopenia Is Associated With Physical and 
Mental Components of Health-Related Quality of Life in Older Adults. Journal 
of the American Medical Directors Association, 2017. 
262. Trombetti, A., et al., Age-associated declines in muscle mass, strength, power, 
and physical performance: impact on fear of falling and quality of life. 
Osteoporosis International, 2016. 27(2): p. 463-471. 
263. Arvandi, M., et al., Gender differences in the association between grip 
strength and mortality in older adults: results from the KORA-age study. 
BMC Geriatrics, 2016. 16(201): p. 1-8. 
264. Tanimoto, Y., et al., Association between muscle mass and disability in 
performing instrumental activities of daily living (IADL) in community-
dwelling elderly in Japan. Archives of gerontology and geriatrics, 2012. 
54(2): p. e230-e233. 
265. Warren, M., K.J. Ganley, and P.S. Pohl, The association between social 
participation and lower extremity muscle strength, balance, and gait speed in 
US adults. Preventive Medicine Reports, 2016. 4: p. 142-147. 
266. Haider, S., et al., Associations between daily physical activity, handgrip 
strength, muscle mass, physical performance and quality of life in prefrail and 
frail community-dwelling older adults. Quality of Life Research, 2016. 25(12): 
p. 3129-3138. 
267. Satariano, W.A., et al., Mobility and Aging : New Directions for Public Health 
Action. American Journal of Public Health, 2012. 102: p. 1508-1516. 
268. Alfaro-Acha, A., et al., Handgrip strength and cognitive decline in older 
Mexican Americans. The Journals of Gerontology Series A: Biological 
Sciences and Medical Sciences, 2006. 61(8): p. 859-865. 
269. Taekema, D.G., et al., Handgrip strength as a predictor of functional, 
psychological and social health. A prospective population-based study among 
the oldest old. Age and ageing, 2010. 39(3): p. 331-337. 
Bibliography 
213 
 
270. Chang, K.-V., et al., Is sarcopenia associated with depression? A systematic 
review and meta-analysis of observational studies. Age and Ageing, 2017: p. 
1-9. 
271. Hsu, Y.H., et al., Association of cognitive impairment, depressive symptoms 
and sarcopenia among healthy older men in the veterans retirement 
community in southern Taiwan: A cross‐sectional study. Geriatrics and 
Gerontology International, 2014. 14(S1): p. 102-108. 
272. Katula, J.A., W.J. Rejeski, and A.P. Marsh, Enhancing quality of life in older 
adults: A comparison of muscular strength and power training. Health and 
Quality of Life Outcomes, 2008. 6(45): p. 1-8. 
273. Chang, Y.-K., et al., Effect of resistance-exercise training on cognitive 
function in healthy older adults: a review. Journal of Aging and Physical 
Activity, 2012. 20(4): p. 497-517. 
274. Mavros, Y., et al., Mediation of Cognitive Function Improvements by Strength 
Gains After Resistance Training in Older Adults with Mild Cognitive 
Impairment: Outcomes of the Study of Mental and Resistance Training. 
Journal of the American Geriatrics Society, 2016. 65(3): p. 550-559. 
275. Delmonico, M.J., et al., Longitudinal study of muscle strength, quality, and 
adipose tissue infiltration. The American Journal of Clinical Nutrition, 2009. 
90(6): p. 1579-1585. 
276. Daly, R.M., et al., Gender specific age-related changes in bone density, 
muscle strength and functional performance in the elderly: a-10 year 
prospective population-based study. BMC Geriatrics, 2013. 13(1): p. 71. 
277. Pearson, O.M. and D.E. Lieberman, The aging of Wolff's “law”: ontogeny and 
responses to mechanical loading in cortical bone. American journal of 
physical anthropology, 2004. 125(S39): p. 63-99. 
278. Huo, Y., et al., Comprehensive nutritional status in sarco-osteoporotic older 
fallers. The Journal of Nutrition, Health & Aging, 2015. 19(4): p. 474-480. 
279. Visser, M. and L.A. Schaap, Consequences of sarcopenia. Clinics in Geriatric 
Medicine, 2011. 27(3): p. 387-399. 
280. Ilich, J., et al., Osteosarcopenic obesity is associated with reduced handgrip 
strength, walking abilities, and balance in postmenopausal women. 
Osteoporosis International, 2015. 26(11): p. 2587-2595. 
281. World Health Organization, Assessment of fracture risk and its application to 
screening for postmenopausal osteoporosis: report of a WHO study group 
[meeting held in Rome from 22 to 25 June 1992]. 1994. 
Bibliography 
214 
 
282. Hamdy, R.C., Bone Mineral Density and Fractures. Journal of Clinical 
Densitometry, 2016. 19(2): p. 125-126. 
283. Ensrud, K.E., Epidemiology of fracture risk with advancing age. Journals of 
Gerontology Series A: Biomedical Sciences and Medical Sciences, 2013. 
68(10): p. 1236-1242. 
284. Christen, P., et al., Bone remodelling in humans is load-driven but not lazy. 
Nature Communications, 2014. 5(4855): p. 1-5. 
285. Buehring, B., D. Krueger, and N. Binkley, Effect of including historical height 
and radius BMD measurement on sarco‐osteoporosis prevalence. Journal of 
Cachexia, Sarcopenia and Muscle, 2013. 4(1): p. 47-54. 
286. Harris, R., et al., Risk of Fracture in Women with Sarcopenia, Low Bone 
Mass, or Both. Journal of the American Geriatrics Society, 2017: p. 1-6. 
287. Padwal, R., et al., Relationship Among Body Fat Percentage, Body Mass 
Index, and All-Cause MortalityA Cohort StudyRelationship Among Body Fat 
Percentage, Body Mass Index, and Mortality. Annals of Internal Medicine, 
2016. 164(8): p. 532-541. 
288. Johansson, H., et al., Low bone mineral density is associated with increased 
mortality in elderly men: MrOS Sweden. Osteoporosis International, 2011. 
22(5): p. 1411-1418. 
289. Stini, W.A., Body composition and longevity: is there a longevous 
morphotype? Medical Anthropology, 1991. 13(3): p. 215-229. 
290. Hill, R.L. and W.J. Brown, Older Australians and physical activity levels: Do 
we know how many are meeting guidelines? Australasian Journal on Ageing, 
2012. 31(4): p. 208-217. 
291. Hobbs, N., et al., Are behavioral interventions effective in increasing physical 
activity at 12 to 36 months in adults aged 55 to 70 years? A systematic review 
and meta-analysis. BMC Medicine, 2013. 11(75): p. 1-12. 
292. Bohannon, R.W., Muscle strength: clinical and prognostic value of hand-grip 
dynamometry. Current Opinion in Clinical Nutrition & Metabolic Care, 2015. 
18(5): p. 465-470. 
293. Ibrahim, K., et al., A feasibility study of implementing grip strength 
measurement into routine hospital practice (GRImP): study protocol. Pilot 
and Feasibility Studies, 2016. 2(27): p. 1-10. 
Bibliography 
215 
 
294. Sousa-Santos, A. and T. Amaral, Differences in handgrip strength protocols to 
identify sarcopenia and frailty-a systematic review. BMC Geriatrics, 2017. 
17(238): p. 1-21. 
295. Roberts, H.C., et al., A review of the measurement of grip strength in clinical 
and epidemiological studies: towards a standardised approach. Age and 
Ageing, 2011. 40(4): p. 423-429. 
 
 
 
 
